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Abstract
Background: The kidneys play a crucial role in maintaining homeostasis of serum potassium levels (K+).
Patients with advanced chronic kidney disease (CKD) are at a higher risk of experiencing dyskalemia
events (i.e. hyper- and hypokalemia; especially the former) and thus future adverse outcomes. Currently,
there is a dearth of literature on prediction models for hyperkalemia and the effects of dyskalemia on
outcomes such as incidence of ischemic stroke and short-term hospital/emergency room (ER) utilization
in an advanced CKD population transitioning to dialysis. Objectives: Using a nationally representative
sample of US veterans with advanced CKD transitioning to dialysis, in the pre-dialysis period we studied
the following aims: Aim 1) Develop and validate a prediction model for predicting hyperkalemia in
individual patients; Aim 2) Examine the association of dyskalemias with time to first ischemic stroke; Aim
3) Examine the association of dyskalemias with time to short-term hospital/ER utilization. Methods: A
retrospective cohort analysis of the Transition of Care in Chronic Kidney Disease cohort (n=102,477), a
nationally representative sample of US veterans with advanced CKD transitioning to dialysis between
October 1, 2007 through March 31, 2015 identified from the United States Renal Data System was
conducted. Across the three study aims, we identified patients with an initial selection criterion (prior to
dialysis initiation) of two estimated glomerular filtration rate (eGFR) of /min/1.73m2 90-365 days apart
(second eGFR as index); at least one-year each of baseline period (prior to index) and follow-up period
(following index but prior to dialysis initiation); and at least one K+ measurement each in the baseline and
follow-up period. For each study aim, further inclusion criteria were used to yield a final sample size of
21,654, 21,357, and 21,366 for aim 1, aim 2, and aim 3, respectively. For Aim 1 (Chapter 2), we compared
the performance (area under the receiver operating curve [AUROC]) of different machine learning
methods including logistic regression (LR), random forest, extreme gradient boosting, and support vector
machines using geographical splitting (for creating training and test set) with 10-fold cross validation to
predict the outcome of hyperkalemia (K+ >5.5 mEq/L). The method that yielded the best performance
was used to build a reduced model with 10 predictors to develop a patient-level hyperkalemia risk score.
For Aim 2 (Chapter 3), we assessed the association of baseline time-averaged K+ levels (distant
exposure) and time-updated K+ levels (acute exposure) (both categorized as hypokalemia [K+ 5.5 mEq/L]
and referent [3.5 mEq/L ≤ K+ ≤ 5.5 mEq/L]) with time to first ischemic stroke using Cox regression
models. Finally, for Aim 3 (Chapter 4), we assessed the association of time-updated outpatient K+ levels
(categorized as hypokalemia [K+ 5.5 mEq/L] and referent [3.5 mEq/L ≤ K+ ≤ 5.5 mEq/L]) with hospital/
ER utilization (as separate events) using generalized estimating equations. Across all the three study
aims (Aim 1, 2, and 3) several different sensitivity analyses were conducted to test the robustness of the
results. Results: Across the analytic samples (Aim 1, 2, and 3), the mean age was 69 years, ~98% were
males; ~28% were African Americans, ~69% had diabetes mellitus, and the one-year baseline averaged
K+ was 4.5 mEq/L. In aim 1 (n=21,654), the LR model yielded the best performance with an average
AUROC (95% confidence interval [CI]) of 0.765 (0.756-0.774) (training set) and 0.763 (0.753-0.771) (test
set) using the geographical splitting with 10-fold cross validation. Using the LR method, the top 10
predictors identified were K+ value prior to index, age, having at least 1 K+ >5.5 mEq/L in the baseline,
index eGFR, baseline averaged SBP, baseline averaged HCO3-, number of K+ counts, thiazide use, number
of outpatient visits, and NSAIDs use in baseline. The LR parameter estimates for the above listed
predictors were used to develop a patient-level risk score for predicting hyperkalemia. In aim 2 (n=21,357),
hypokalemia (distant exposure) was associated with higher risk of ischemic stroke (hazard ratio [HR]; 95
% CI: 1.35, 1.01-1.81). Conversely, hyperkalemia (acute exposure) was associated with a lower risk of
ischemic stroke (HR; 95% CI: 0.82, 0.68-0.98). Finally, in aim 3 (n=21,366) using outpatient K+ levels, both
hyperkalemia (odds ratio [OR]; 95% CI: 2.04; 1.88-2.21) and hypokalemia (OR; 95% CI: 1.66; 1.48-1.86)
were associated with higher risk of hospital visit within 2 calendar days of outpatient K+ measurement.

Similarly, both hyperkalemia (OR; 95% CI: 1.83; 1.65-2.03) and hypokalemia (OR; 95% CI: 1.24; 1.07-1.44)
were associated with higher risk of ER visit within 2 calendar days of outpatient K+ measurement. Across
all the three study aims, the results were robust to various sensitivity analysis. Conclusion: In an advanced
CKD population transitioning to dialysis, in the pre-dialysis period, we developed an internally valid model
for predicting hyperkalemia. We observed that hypokalemia as a chronic exposure is associated with
higher risk of ischemic stroke and hyperkalemia as an acute exposure is associated with lower risk of
ischemic stroke. Finally, both hyper- and hypokalemia are associated with higher risk of short-term
hospital/ER visits. Further studies are needed to externally validate the hyperkalemia risk prediction
model; understand the mechanisms underlying the association of dyskalemias with stroke; and expand
on the association of dyskalemias with short-term hospital/ER visits by including cost as an outcome.
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Abstract

Ankur Dashputre
Predictors of Hyperkalemia and Outcomes of Dyskalemia in US
Veterans with Advanced Chronic Kidney Disease Transitioning to
Dialysis
Background. The kidneys play a crucial role in maintaining homeostasis of serum
potassium (K+ ) levels. Patients with advanced chronic kidney disease (CKD) are at a higher
risk of experiencing dyskalemia events (i.e. hypo- and hyperkalemia; especially the latter)
and thus future adverse outcomes. Currently, there is a dearth of literature on prediction
models for hyperkalemia and the effects of dyskalemia on outcomes such as incidence of
ischemic stroke and short-term hospital/emergency room (ER) utilization in an advanced
CKD population transitioning to dialysis.
Objectives. Using a nationally representative sample of US Veterans with advanced
CKD transitioning to dialysis, in the pre-dialysis period we studied the following aims:
Aim 1) Develop and validate a prediction model for predicting hyperkalemia in individual
patients; Aim 2) Examine the association of dyskalemias with time to first ischemic stroke;
Aim 3) Examine the association of dyskalemias with short-term hospital/ER utilization.
Methods. A retrospective cohort analysis of the Transition of Care in Chronic
Kidney Disease cohort (n=102,477), a nationally representative sample of US Veterans with
advanced CKD transitioning to dialysis between October 1, 2007 through March 31, 2015
identified from the United States Renal Data System was conducted. Across the three study
aims, we identified patients with an initial selection criterion (prior to dialysis initiation)
of two estimated glomerular filtration rate (eGFR) of <30 ml/min/1.73m2 90-365 days
apart (second eGFR as index); at least one-year each of baseline period (prior to index)
and follow-up period (following index but prior to dialysis initiation); and at least one
K+ measurement each in the baseline and follow-up period. For each study aim, further
inclusion criteria were used to yield a final sample size of 21,654, 21,357, and 21,366 for Aim
1, Aim 2, and Aim 3, respectively. For Aim 1 (Chapter 2), we compared the performance
(area under the receiver operating curve [AUROC]) of different machine learning methods
including logistic regression (LR), Random Forest, Extreme Gradient Boosting, and Support
Vector Machines using geographical splitting (for creating training and test set) with 10-fold
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cross validation to predict the outcome of hyperkalemia (K+ >5.5 mEq/L). The method
that yielded the best performance was used to build a reduced model with 10 predictors to
develop a patient-level hyperkalemia risk score. For Aim 2 (Chapter 3), we assessed the
association of baseline time-averaged K+ levels (distant exposure) and time-updated K+
levels (acute exposure) (both categorized as hypokalemia [K+ <3.5 mEq/L], hyperkalemia
[K+ >5.5 mEq/L] and referent [3.5 mEq/L ≤ K+ ≤5.5 mEq/L]) with time to first ischemic
stroke using Cox regression models. Finally, for Aim 3 (Chapter 4), we assessed the
association of time-updated outpatient K+ levels (categorized as hypokalemia [K+ <3.5
mEq/L], hyperkalemia [K+ >5.5 mEq/L] and referent [3.5 mEq/L ≤ K+ ≤5.5 mEq/L])
with hospital/ER utilization (as separate events) using generalized estimating equations.
Across all the three study aims (Aim 1, 2, and 3) several different sensitivity analyses were
conducted to test the robustness of the results.
Results. Across the analytic samples (Aim 1, 2, and 3), the mean age was 69 years,
98% were males; 28% were African Americans, 69% had diabetes mellitus, and the oneyear baseline averaged K+ was 4.5 mEq/L. In Aim 1 (n=21,654), the LR model yielded
the best performance with an average AUROC (95% confidence interval [CI]) of 0.765
(0.756-0.774) (training set) and 0.763 (0.753-0.771) (test set) using the geographical splitting
with 10-fold cross validation. Using the LR method, the top 10 predictors identified were
K+ value prior to index, age, having at least 1 K+ >5.5 mEq/L in the baseline, index
eGFR, baseline averaged systolic blood pressure, baseline averaged bicarbonate, number
of K+ measurements, thiazide use, number of outpatient visits, and non-steroidal antiinflammatory drugs use in baseline. The LR parameter estimates for the above listed
predictors were used to develop a patient-level risk score for predicting hyperkalemia.
In Aim 2 (n=21,357), hypokalemia (distant exposure) was associated with higher risk of
ischemic stroke (hazard ratio [HR], 95% CI: 1.35, 1.01-1.81). Conversely, hyperkalemia
(acute exposure) was associated with a lower risk of ischemic stroke (HR, 95% CI: 0.82,
0.68-0.98). Finally, in Aim 3 (n=21,366) using outpatient K+ levels, both hyperkalemia
(odds ratio [OR], 95% CI: 2.04, 1.88-2.21) and hypokalemia (OR, 95% CI: 1.66, 1.48-1.86)
were associated with higher risk of hospital visit within 2 calendar days of outpatient K+
measurement. Similarly, both hyperkalemia (OR, 95% CI: 1.83, 1.65-2.03) and hypokalemia
(OR, 95% CI: 1.24, 1.07-1.44) were associated with higher risk of ER visit within 2 calendar
days of outpatient K+ measurement. Across all the three study aims, the results were robust
to various sensitivity analysis.
Conclusion. In an advanced CKD population transitioning to dialysis, in the predialysis period, we developed an internally valid model for predicting hyperkalemia.
We observed that hypokalemia as a chronic exposure is associated with higher risk of
ischemic stroke and hyperkalemia as an acute exposure is associated with lower risk of
ischemic stroke. Finally, both hyper- and hypokalemia are associated with higher risk
of short-term hospital/ER visits. Further studies are needed to externally validate the
hyperkalemia risk prediction model; understand the mechanisms underlying the association
of dyskalemias with ischemic stroke; and expand on the association of dyskalemias with
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short-term hospital/ER visits by including cost as an outcome.
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Chapter 1
Introduction

1.1
1.1.1

Chronic Kidney Disease
Definition

The kidneys are two bean-shaped organs responsible for removing waste from the body,
maintaining fluid and electrolyte balance, and producing hormones important for maintaining blood pressure (BP), making red blood cells, and keeping bones strong and healthy
(National Institutes of Health. National Institute of Diabetes and Digestive and Kidney
Diseases. Your Kidneys & How They Work, 2018). Chronic kidney disease (CKD) is a
progressive disease marked by loss of kidney function over time (Centers for Disease
Control and Prevention. Chronic Kidney Disease Initiative, 2021). CKD is characterized
by persistent urine abnormalities, structural abnormalities or impaired excretory renal
function indicating a loss/damage of nephrons, the functional units of kidneys (Romagnani
et al., 2017). The National Kidney Foundation Kidney Disease Outcomes Quality Initiative
(NKF-KDQOI) and the Kidney Disease: Improving Global Outcomes (KDIGO) define CKD
as presence of kidney damage or glomerular filtration rate (GFR) <60 ml/min/1.73m2 for
≥3 months (Levey, Jong, et al., 2011).

1.1.2

Epidemiology

Globally, CKD is estimated to affect 13.4% of adults (Hill et al., 2016). In the US, CKD is
estimated to affect 15% of the adult population (approximately 37 million), most (9 in 10) of
whom are unaware of their condition (Centers for Disease Control and Prevention. Chronic
Kidney Disease Initiative, 2021). Chronic kidney disease is more common amongst adults
≥65 years (38%) as compared to younger adults (<65 years), women (15%) as compared
to men (12%), and non-Hispanic African Americans (16%) as compared to non-Hispanic
whites (13%) or Asians (12%) (Centers for Disease Control and Prevention. Chronic Kidney
Disease Initiative, 2021). Chronic kidney disease is regarded as a public health problem due
to high disease burden, disproportionate prevalence in certain groups (e.g., race, age, sex),
and lack of curative strategies; and is considered an important topic for the Department
of Health and Human Services Healthy People 2020 Initiative (Levey, Atkins, et al., 2007;
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Office of Disease Prevention and Health Promotion. HealthyPeople.gov, 2014; Schieppati
and Remuzzi, 2005; Schoolwerth et al., 2006).

1.1.3

CKD diagnosis and staging

Diagnosis
Early stages of CKD are typically asymptomatic and diagnosed by measuring serum
creatinine levels and/or by measuring the urine albumin to creatinine ratio (UACR) for
proteinuria detection (Baumgarten and Gehr, 2011; Gaitonde, Cook, and Rivera, 2017;
Romagnani et al., 2017; Vassalotti, Stevens, and Levey, 2007). Serum creatinine level is most
often used to estimate GFR, an indicator of steady state renal function (Baumgarten and
Gehr, 2011; Gaitonde, Cook, and Rivera, 2017). The GFR can be quantified as the measured
GFR (mGFR), urinary creatinine clearance (CrCl), or the estimated GFR (eGFR).
mGFR is considered as the gold standard for evaluating GFR, however, obtaining
mGFR is expensive and invasive (Hsu and Bansal, 2011; Rule and Kremers, 2016). Alternatively, GFR can be estimated by measuring 24-hour urinary CrCl; however, urinary CrCl
is confounded by tubular creatinine secretion which may lead to overestimation of GFR,
especially at lower GFR levels (Alaini et al., 2017; Rule and Kremers, 2016; Shemesh et al.,
1985). Finally, GFR can be estimated using equations such as the Modification of Diet in
Renal Disease (MDRD) equation (Levey, Bosch, et al., 1999) and the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation (Levey, Stevens, et al., 2009). In addition
to serum creatinine for eGFR estimation, both the MDRD and CKD-EPI additionally account
for age, sex, and race (Levey, Bosch, et al., 1999; Levey, Stevens, et al., 2009).
Markers of kidney damage such as proteinuria and albuminuria can be used to
diagnose CKD (Baumgarten and Gehr, 2011; Gaitonde, Cook, and Rivera, 2017; Vassalotti,
Stevens, and Levey, 2007). Proteinuria is characterized by increased excretion of any
urinary protein, including albumin and other proteins like tubular proteins. Albuminuria is
a specific type of proteinuria marked by increased excretion of albumin only in the urine.
The type of protein excreted can occasionally help detect the underlying cause of CKD.
Increased excretion of albumin is a sensitive and specific marker of CKD due to diabetes,
hypertension, and glomerular diseases.
Whereas, increased excretion of non-albumin proteins may indicate tubulointerstitial
diseases due to defective reabsorption of filtered, low molecular weight proteins. The
spot UACR or protein to creatinine ratio are widely used methods for CKD diagnosis. An
UACR greater than 30 mg/g indicates albuminuria and is a marker for CKD (Levey, Jong,
et al., 2011). Other methods for CKD diagnosis include kidney biopsy, imaging (ultrasonography, computed tomography scan, and magnetic resonance imaging), urinalysis and
urine microscopy to test for hematuria, cellular casts, chronic pyuria, tubular concentrating
defects, and insufficient renal acidification (Baumgarten and Gehr, 2011; Gaitonde, Cook,
and Rivera, 2017).
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Figure 1.1: Stages of chronic kidney disease.
Reprinted with permission from Elsevier. Levey, Jong, et al., 2011.

Staging
CKD staging is based on the recommendations by the KDIGO guidelines (Levey, Jong,
et al., 2011). Based on the GFR levels CKD stages are classified as: stage G1 (High and
optimal; GFR >90 ml/min/1.73m2 ), stage G2 (mild; GFR 60-89 ml/min/1.73m2 ), stage
G3a (mild-moderate; GFR 45-59 ml/min/1.73m2 ), stage G3b (moderate-severe; GFR 30-44
ml/min/1.73m2 ), stage G4 (severe; GFR 15-29 ml/min/1.73m2 ), and stage G5 (kidney
failure; <15 ml/min/1.73m2 ). Stage G5 is also called as end-stage renal disease (ESRD)
(Levey, Jong, et al., 2011). Similarly, based on the UACR levels, the severity of albuminuria
can be categorized as optimal and high-normal (A1; UACR <30 mg/g), high (A2; UACR
30-299 mg/g), and very high and nephrotic (A3; UACR ≥300 mg/g). Figure 1.1 describes
the stages of CKD.
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Table 1.1: Risk factors of chronic kidney disease.
Sociodemographic/
non-modifiable
Age
Sex
Race
Family history/genetics
Low birth weight
Socioeconomics

1.1.4

Behavioral/modifiable
Smoking
Physical inactivity
Diet
Obesity

Clinical factors
Acute kidney injury
Diabetes Mellitus
Hypertension
Cardiovascular Diseases

CKD risk factors

The risk factors for the development (or progression) of CKD can be broadly classified into
sociodemographic/non-modifiable factors (e.g., age, sex), behavioral/modifiable factors
(e.g., smoking, diet), and clinical factors (e.g., diabetes, hypertension). Table 1.1 lists the
different risk factors for CKD described in the sections below.
Sociodemographic/non-modifiable risk factors
Age. Kidney function decreases with age, due to the loss in the number of functioning nephrons or due to structural changes (Kazancioglu, 2013; Romagnani et al., 2017).
Chronic kidney disease is more common in older adults (Centers for Disease Control and
Prevention. Chronic Kidney Disease Initiative, 2021), and might be due to physiological
ageing, genetics, arterial hypertension, diseases causing kidney injury, increased body
weight or a combination of these factors (Romagnani et al., 2017).
Sex. The prevalence of CKD is higher in women as compared to men (Centers
for Disease Control and Prevention. Chronic Kidney Disease Initiative, 2021). However,
the progression to ESRD is higher in men than women likely due to higher prevalence of
diabetes and hypertension in men (Johansen et al., 2021).
Race. CKD is more common in African Americans than in Whites or Asians (Centers for Disease Control and Prevention. Chronic Kidney Disease Initiative, 2021). Similarly,
African Americans are at a four times higher risk of progressing to ESRD compared to
Whites (Johansen et al., 2021). This racial disparity exists due to higher prevalence of
diabetes and hypertension, socioeconomics (e.g., poor diet, lack of physical activity), and
genetic mutations in genes like apolipoprotein L1 or uromodulin in African Americans
(Kottgen et al., 2010; Norris and Agodoa, 2005; Pollak, Genovese, and Friedman, 2012).
Family history/genetics. A family history of CKD is an independent risk factor for
CKD/ESRD (Kazancioglu, 2013). Genetic mutations in genes like apolipoprotein L1 or
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uromodulin are associated with risk of CKD (Kazancioglu, 2013; Kottgen et al., 2010; Pollak,
Genovese, and Friedman, 2012).
Low birth weight. Intrauterine growth restriction might cause low nephron numbers and thus predispose to CKD (Mackenzie, Lawler, and Brenner, 1996). Low nephron
numbers may lead to intraglomerular hypertension and hyperfiltration in existing nephrons,
lower GFR, and higher UACR, thus increasing the risk of CKD (Vikse et al., 2008).
Socioeconomics. A study by Krop et al. (Krop et al., 1999) using the Atherosclerosis
Risk in Communities study cohort, observed that socioeconomic factors such as income
<$16,000 (vs. income >$35,000), belonging to a family of unskilled workers, and less than
high school education (vs. college education) were associated with increased risk of CKD.
Behavioral/modifiable factors
Smoking. Smoking has a dose dependent relationship with the development and
progression of CKD as it can lead to the development of kidney fibrosis. The nephrotoxic
chemicals in cigarette are known to adversely impact the kidneys, by causing vasoconstriction leading to transient increase in BP and decrease in kidney function (Orth and Hallan,
2008; Schrauben et al., 2019; Van Laecke and Van Biesen, 2017).
Physical inactivity. Physical inactivity is a common modifiable risk factor for the
development of chronic conditions like hypertension, cardiovascular disease (CVD), obesity,
and diabetes mellitus (DM), which may eventually lead to the development of CKD (Booth,
Roberts, and Laye, 2012). CKD is thus a secondary consequence of physical inactivity.
Regular physical activity can positively impact metabolic factors like triglycerides, BP, and
insulin resistance, subsequently reducing the risk of CKD (Johansen, 2005; Stump, 2011).
Diet. Consuming an unhealthy diet i.e. high consumption of red and processed
meat, sugar-sweetened beverages, and sodium (Na+ ) may lead to an increased risk of
CKD (Chang et al., 2013). Additionally, unhealthy diet is a known risk factor for obesity,
hypertension, CVD, and metabolic syndrome, which are known risk factors (discussed
later) for CKD (Bullo et al., 2007). Adopting a healthy diet might lower the risk of CKD
(Bach et al., 2019).
Obesity. Obesity is a potent risk factor for the development of CKD (Kovesdy,
Furth, et al., 2017; Rhee, Ahmadi, and Kalantar-Zadeh, 2016). The prevalence of obesity
amongst US adults has increased significantly over the last few decades and is currently
affecting 42.4% of the US adult population (2017-2018 estimates) (Hales et al., 2018). Obesity
can lead to the development of oxidative stress, inflammation, abnormal lipid metabolism,
activation of the renin-angiotensin-aldosterone system (RAAS), and increased production
of insulin and insulin resistance. These may consequently induce kidney damage and lead
to CKD (Kazancioglu, 2013; Kovesdy, Furth, et al., 2017).
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Clinical factors
Acute kidney injury. Acute kidney injury (AKI) is a syndrome characterized by an
abrupt (over hours to days) decline in kidney function (Ostermann and Joannidis, 2016).
The KDIGO guidelines define AKI as: 1) increase in serum creatinine by ≥0.3 mg/dl within
48 hours; or 2) increase in serum creatinine to ≥1.5 mg/dl times baseline, which is known or
presumed to have occurred within the prior 7 days; or 3) urine volume <0.5 ml/kg/hour for
6 hours (Kellum, Lameire, and Group, 2013). Maladaptive processes after an AKI event can
lead to fibrosis, vascular rarefaction, tubular loss, glomerulosclerosis, and chronic interstitial
inflammation which can result in a state mimicking accelerated kidney ageing and thus
decline in kidney function (Chawla and Kimmel, 2012; Venkatachalam, Griffin, et al., 2010;
Venkatachalam, Weinberg, et al., 2015). Studies have suggested that the incidence, severity,
frequency, and duration of AKI are strong independent risk factors for the development
and progression of CKD and ESRD (Chawla, Amdur, et al., 2011; Coca, Singanamala, and
Parikh, 2012; Mehta et al., 2018; See et al., 2019).
Diabetes mellitus. DM is a chronic disease marked by high blood sugar levels due
to impaired insulin production or function (Centers for Disease Control and Prevention. Diabetes, 2021). The prevalence of CKD amongst those with DM is estimated at 36% (Johansen
et al., 2021). In patients with DM, hyperaminoacidemia promotes glomerular hyperfiltration
and hyperperfusion, and hyperglycemia, which eventually leads to alteration of kidney
hemodynamics, and inflammation and fibrosis (Alicic, Rooney, and Tuttle, 2017). These
events can eventually lead to development and progression of CKD.
Hypertension. Hypertension is a chronic disease characterized by persistent abnormally elevated levels of BP (Centers for Disease Control and Prevention. Blood Pressure,
2021). The prevalence of CKD amongst those with hypertension is estimated at 31.9% (Johansen et al., 2021). An increase in BP leads to the development of arteriolar nephrosclerosis
with impaired kidney function (Bidani and Griffin, 2004; Lea and Nicholas, 2002). Due to
the persistent elevated BP levels there is continued damage to the kidneys thus leading to
the development and progression of CKD. Hypertension and CKD share a bidirectional
relationship i.e. either can be a cause or consequence of the other.
Cardiovascular disease. CVD refers to several types of heart diseases including
(but not limited to) ischemic heart disease (IHD; most common in US), heart attack, arrhythmia, congestive heart failure (CHF), stroke, and peripheral vascular disease (Centers for
Disease Control and Prevention. Heart Disease, 2021). The prevalence of CKD amongst
those self-reporting CVD is 39.6% (Johansen et al., 2021). CVD and CKD share traditional
risk factors including DM and hypertension (Gansevoort et al., 2013). Due to a high prevalence of risk factors like DM and hypertension amongst those with CVD, the risk for CKD
is higher. CVD and CKD share a bidirectional relationship i.e. either can be a cause or
consequence of the other.
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Table 1.2: Complications and outcomes associated with chronic kidney
disease.
Systemic
complications
(clinical outcomes)

Patient reported
outcomes

Economic burden

Fluid and electrolyte
abnormalities

Poor quality of life
(e.g., cognitive impairment,
physical dysfunction etc.)

Increased direct
(e.g., medical services) and
indirect (e.g., work
productivity loss)

Anemia
Mineral bone disorders
Metabolic acidosis
Hyperuricemia
Hypertension
Dyslipidemia
Cardiovascular disease
Endocrine dysfunction
Uremia

1.1.5

CKD-associated complications and outcomes

The development and progression of CKD leads to several downstream systemic complications (or clinical outcomes), poor patient reported outcomes (e.g., poor quality of life [QoL]),
and higher economic burden (economic outcomes). Table 1.2 lists the complications and
outcomes associated with CKD described in the sections below.
Systemic complications (or clinical outcomes)
The kidneys play an important role in removing waste from the body, maintaining fluid and
electrolyte balance, and producing hormones important for maintaining BP, making red
blood cells, and keeping bones strong and healthy (National Institutes of Health. National
Institute of Diabetes and Digestive and Kidney Diseases. Your Kidneys & How They
Work, 2018). In CKD these processes are impacted and can lead to a multitude of clinical
complications.
Fluid and electrolyte abnormalities. Derangement of Na+ and water handling
occurs in CKD. Occurrence of hypervolemia (increased fluid retention) can manifest as
hypertension, edema, and/or shortness of breath (alone or in combination). Hyponatremia
(decreased Na+ ) in the body can occur due to water retention (Dhondup and Qian, 2017).
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Potassium (K+ ; hereafter K+ means serum K+ unless otherwise noted) excretion is dependent on exchange of Na+ and fluids at the distal tubule, thus those with CKD are at a higher
risk of hyperkalemia (elevated K+ ) due to lower eGFR and reduced Na+ and fluid delivery
to the distal tubule (Romagnani et al., 2017).
Anemia. Anemia in CKD can occur due to multiple reasons including reduced
renal erythropoietin production, reduced lifespan of red blood cells, impaired intestinal iron
absorption mediated by hepcidin and repetitive blood losses in patients on hemodialysis.
Anemia can lead to fatigue, weakness, drowsiness, reduced attentiveness and low exercise
tolerance (Romagnani et al., 2017).
Mineral bone disorders. The kidneys are responsible for maintaining bone health
(National Institutes of Health. National Institute of Diabetes and Digestive and Kidney
Diseases. Your Kidneys & How They Work, 2018). In CKD, mineral bone disorders are
characterized by abnormalities in mineral metabolism, bone structure and extra skeletal
calcification. Patients with CKD experience lower levels of 25-hydroxyvitamin D and/or
1,25-dihydroxyvitamin D3, and elevated levels of parathyroid hormone and fibroblast
growth factor 23. These hormones are key for maintaining bone integrity and mineral
(calcium and phosphate) homeostasis. Patients with CKD may thus experience bone pain,
difficulty in walking, skeletal deformities, and higher risk of fractures (Romagnani et al.,
2017).
Metabolic acidosis. Metabolic acidosis occurs due to reduced total renal ammonium excretion, titratable acid excretion and bicarbonate (HCO3 - ) reabsorption. Metabolic
acidosis contributes to bone demineralization, muscle wasting and CKD progression (Kraut
and Madias, 2016; Romagnani et al., 2017).
Hyperuricemia. Decreased urinary excretion of uric acid leads to hyperuricemia
(elevated uric acid levels). Serum uric acid >7.5 mg/dl is an independent risk factor for
accelerated progression of CKD (Romagnani et al., 2017).
Hypertension. Hypertension and CKD exhibit a bidirectional relationship. Hypertension is a consequence of activation of catecholamines, aldosterone activity, RAAS
activation and hypervolemia. Amongst adults with CKD, 59.1% have prevalent hypertension.62 Controlling hypertension in CKD is critical to prevent CKD progression (Centers
for Disease Control and Prevention. Chronic Kidney Disease Initiative, 2021).
Dyslipidemia. In patients with CKD, abnormal lipid metabolism and uremic toxinrelated modifications in lipid particles promoting atherogenesis is common (Vaziri, 2006).
CKD-related post-translational modifications of lipid particles imply pro-inflammatory
effects and endothelial dysfunction (Romagnani et al., 2017; Speer et al., 2013).
Cardiovascular disease. CVD and CKD exhibit a bidirectional relationship. Patients with CKD experience a high incidence of CVD attributable to high prevalence of hypertension, dyslipidemia, hyperuricemia, abnormal glucose metabolism, obesity, systemic
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inflammation and oxidative stress (Romagnani et al., 2017). The CKD-related cardiovascular
alterations resemble an accelerated ageing process. Initial stages of CKD are marked by
atherosclerotic processes, whereas with CKD progression, inflammatory factors and media
calcification contribute to vascular wall degeneration (Romagnani et al., 2017). As GFR
declines below 60-75 ml/min/1.73m2 , the probability of CVD increases linearly, with stage
G3a to G4 CKD patients having double and triple the risk of CVD mortality, respectively,
compared to those without CKD (Sarnak et al., 2019).
Endocrine dysfunction. Patients with CKD may experience endocrine dysfunction
as kidney function declines. Abnormalities in gonadal hormones can lead to reduced
fertility in males and females. Abnormalities in thyroid function may occur (Romagnani
et al., 2017).
Uremia. Uremia is characterized by increased levels of urea and hundreds of other
proteins and metabolites in the blood. Uremia is a systemic inflammatory state that may
contribute to ESRD-related CVD, malnutrition, sarcopenia, osteoporosis, and frailty. CKDrelated intestinal barrier dysfunction causing bacterial endotoxin leakage into the circulation,
and dialysis-related or infection-related immune activation, can also contribute to uremia
(Romagnani et al., 2017).
Patient reported outcomes
Patients with CKD experience poor QoL and commonly report cognitive impairment,
dementia, sleep disturbance, pain, and emotional and physical dysfunction (Braun et al.,
2012). Perception of both general health and mental health is low across eGFR levels,
whereas that of physical health decreases with decreasing eGFR (Chin et al., 2008; Porter
et al., 2012). Studies on QoL amongst CKD patients report factors such as less education,
less exercise, depression, history of CVD, lower income, and unemployment associated
with lower QoL (Chin et al., 2008; Gorodetskaya et al., 2005; Porter et al., 2012).
Economic outcomes
Both CKD/ESRD pose a substantial burden on the society. For the year 2019, Medicare
expenditures (including Part A, B, and D) for any stage of CKD (without ESRD) and ESRD
were $87.2 billion and $51.0 billion, respectively. The per patient per year cost (2019 $) for
older and younger adults with CKD, DM, and CHF was $45,943 and $64,628, respectively.
Whereas for older and younger adults with CKD only (without ESRD) was $19,070 and
$30,208, respectively, indicating the added economic burden of comorbidities in CKD.
Hospitalization costs comprise approximately one-third of the total medical expenditures for
CKD/ESRD and are mainly driven by hospitalizations due to infections or cardiovascular
events (Johansen et al., 2021). Indirect costs for CKD/ESRD associated with presenteeism,
absenteeism, caregiver costs, and premature death are not well characterized but are
expected to be substantial, especially amongst those with stage 4-5 CKD not on dialysis and
those with ESRD (Wang et al., 2016).
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CKD management

The management of CKD is based on management of modifiable risk factors for those
at risk of/or with CKD. The prevalence of CVD is higher amongst those with CKD (vs
those without CKD) (Chen, Knicely, and Grams, 2019; Johansen et al., 2021). Additionally,
CKD worsens cardiovascular outcomes. Thus, lowering cardiovascular risk is critical in
the management of CKD. Prescription of low-to-moderate dose statins to CKD patients
aged 50 years and above is recommended (Anderson et al., 2016; Wanner, Tonelli, and
Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group,
2014). The KDIGO guidelines recommend a systolic BP (SBP) and diastolic BP (DBP) goal
of less than 120 mmHg and 80 mmHg, respectively, among adults with CKD (Kidney
Disease: Improving Global Outcomes Blood Pressure Work, 2021). The KDIGO guidelines
also recommend that adults with UACR ≥30 mg/24 hours should have their SBP and
DBP under 120 mmHg and 80 mmHg, respectively (Kidney Disease: Improving Global
Outcomes Blood Pressure Work, 2021).
Further, KDIGO guidelines recommend initiating RAAS inhibitors for those with
CKD, high BP, and albuminuria with or without DM (Kidney Disease: Improving Global
Outcomes Blood Pressure Work, 2021). Diabetes management is also critical to the management of CKD as glycemic control (hemoglobin A1c ∼ 7.0%) may delay CKD progression
(Chen, Knicely, and Grams, 2019; Stevens, Levin, and Kidney Disease: Improving Global
Outcomes Chronic Kidney Disease Guideline Development Work Group, 2013; Guideline
development, 2015; Shurraw et al., 2011). Avoiding drugs that are largely cleared by the kidneys (e.g., glyburide) and dose reducing or discontinuing drugs (e.g., metformin, and some
dipeptidyl peptidase 4 inhibitors) that are excreted by the kidneys is recommended (Chen,
Knicely, and Grams, 2019). Data from recent clinical trials such as the CREDENCE Trial
(Perkovic et al., 2019), EMPA-REG Trial (Wanner, Inzucchi, et al., 2016), and DAPA-CKD
Trial (Heerspink et al., 2020) have shown the beneficial cardio- and renoprotective effects of
Na+ -glucose cotransporter-2 inhibitors such as empagliflozin and dapagliflozin amongst
those with CKD. Further, data from the FIDELIO-DKD (Bakris et al., 2020) shows the cardioand renoprotective effects of finerenone (a nonsteroidal, selective mineralocorticoid receptor
antagonist) those with CKD and type 2 DM.
Finally, the Kidney Disease Outcomes Quality Initiative guidelines recommend
dietary protein intake to <0.6 g/kg body weight/day in adults with CKD stages 3-5 without
DM and not on dialysis (Ikizler et al., 2020). Similarly, lowering salt intake to <90 mmol/day
is recommended (Kidney Disease: Improving Global Outcomes Blood Pressure Work,
2021). Physical activity to improve cardiovascular health and tolerance (at least 30 minutes
5 times/week) to achieve healthy weight and smoking cessation is also recommended
(Kidney Disease: Improving Global Outcomes Blood Pressure Work, 2021; Ricardo et al.,
2015).
One of the key functions of the kidneys is to maintain fluid electrolyte balance. The
kidneys play a critical role in K+ homeostasis. The following sections discuss in detail the
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importance of K+ for maintaining body functions, role of kidneys in K+ homeostasis, and
the effects of CKD on K+ homeostasis and downstream outcomes.

1.2

Potassium

1.2.1

Background

Potassium is one of six major body electrolytes along with Na+ , calcium, chloride, phosphate, and magnesium. It is the most common cationic electrolyte in the body with 98%
present in the intracellular fluid (140 mEq/L) and 2% in the extracellular fluid (3.5-5.0
mEq/L) and is primarily responsible for maintaining normal cellular electrophysiologic
function which is necessary for proper function of excitable neuromuscular and cardiac
tissues (Gumz, Rabinowitz, and Wingo, 2015; Kovesdy, Appel, et al., 2017; Palmer, 2015;
Palmer and Clegg, 2019). Maintaining K+ within its homeostatic range is critical to maintain
proper tissue excitability and is carried out by various mechanisms (section 1.2.2).

1.2.2

Potassium homeostasis

The kidneys are the major organs responsible for K+ homeostasis and they maintain the
total body K+ levels by matching K+ intake with K+ excretion over several hours (Gumz,
Rabinowitz, and Wingo, 2015; Kovesdy, Appel, et al., 2017; Palmer, 2015; Palmer and
Clegg, 2019). While the kidneys regulate K+ homeostasis over several hours, insulin and
catecholamines play an important role in the initial process of K+ homeostasis by rapidly
shifting K+ from the extracellular to the intracellular space (Palmer, 2015; Palmer and
Clegg, 2019). Insulin shifts dietary K+ to the intracellular space by increasing the activity
of the sodium-potassium adenosine triphosphatase (Na+ /K+ -ATPase) pump. Similarly,
catecholamines work through β2 -adrenergic receptors which activate the Na+ /K+ -ATPase
pump leading to the shift of extracellular K+ to the intracellular space (Palmer, 2015; Palmer
and Clegg, 2019).
Kidneys and K+ homeostasis
Potassium is freely filtered by the glomerulus and almost completely reabsorbed in the
proximal convoluted tubule and ascending limb of Henle, such that less than 10% of filtered
K+ reaches the distal nephron (Gumz, Rabinowitz, and Wingo, 2015; Kovesdy, Appel, et al.,
2017; Palmer, 2015; Palmer and Clegg, 2019). The reabsorption of K+ in the proximal convoluted tubule is primarily through the paracellular pathway due to the convective flux in
association with salt and water reabsorption; whereas in the thick ascending limb of Henle,
reabsorption is transcellular and occurs by secondary active transport (Gumz, Rabinowitz,
and Wingo, 2015; Kovesdy, Appel, et al., 2017; Palmer, 2015; Palmer and Clegg, 2019). The
transcellular reabsorption is mediated by the apical membrane sodium/potassium/chlorine
cotransporter. The Na+ /K+ -ATPase creates a favorable gradient for the entry of K+ into
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the cell through the apical sodium/potassium/chlorine cotransporter (Kovesdy, Appel,
et al., 2017; Palmer, 2015; Palmer and Clegg, 2019).
Secretion of K+ begins in the early distal convoluted tubule and extends into the
collecting duct (Kovesdy, Appel, et al., 2017; Palmer, 2015; Palmer and Clegg, 2019).
Under normal conditions, delivery of K+ to the distal nephron remains small and fairly
constant; however, the rate of K+ secretion by the distal nephron varies and depends on
the physiological needs of the body (Kovesdy, Appel, et al., 2017; Palmer, 2015; Palmer
and Clegg, 2019). The cellular determinants of K+ secretion in the principal cell include
intracellular K+ concentration, luminal K+ concentration, voltage difference across luminal
membrane, and permeability of luminal membrane to K+ . Secretion of K+ is increased
when cellular concentration of K+ increases, luminal K+ concentration decreases, the lumen
is rendered more electronegative, or due to increase in the K+ permeability of the luminal
membrane (Kovesdy, Appel, et al., 2017; Palmer, 2015; Palmer and Clegg, 2019). The level
of K+ secretion in the distal region is mainly determined by mineralocorticoid activity and
distal delivery of Na+ and water.
Aldosterone is the major mineralocorticoid that affects the cellular determinants that
affect K+ secretion. Aldosterone increases the intracellular K+ concentration by stimulating
the Na+ /K+ -ATPase in the basolateral membrane. It also stimulates Na+ reabsorption
across the luminal membrane, thus increasing lumen electronegativity and increasing the
electrical gradient in favor of K+ secretion. Lastly, aldosterone directly works on the luminal
membrane to increase K+ permeability (Kovesdy, Appel, et al., 2017; Palmer, 2015; Palmer
and Clegg, 2019). Along with aldosterone, distal delivery of Na+ and water are important
to K+ secretion.
Increased distal delivery of Na+ stimulates distal Na+ absorption, which makes
the lumen electronegative and increases K+ secretion. Potassium secretion by water is
affected by increased flow rates. When K+ is secreted in the collecting duct, luminal
K+ concentration rises, thus decreasing the diffusion gradient and slowing additional K+
secretion. When the flow rate is high in the lumen, the same amount of K+ secretion
is diluted by larger volume such that rise in luminal K+ concentration is less. Thus,
increased distal delivery of Na+ and water stimulate K+ secretion by lowering luminal K+
concentration and creating an electronegative lumen potential (Palmer, 2015; Palmer and
Clegg, 2019).
CKD and K+ homeostasis
In CKD, K+ homeostasis is affected due to progressive damage to the nephrons leading to
reduced kidney function. The reduced kidney function may lead to hyperkalemia. Increased
renal excretion of K+ per residual functioning nephrons and supplementary gastrointestinal
excretion help in maintaining normal K+ mass balance in the body in patients with CKD
(Kovesdy, Appel, et al., 2017; Palmer, 2015; Palmer and Clegg, 2019). The effectiveness of
these adaptations diminishes in the advanced stages of CKD, but the exact GFR level at
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which they become ineffective is unclear (Kovesdy, Appel, et al., 2017; Palmer, 2015; Palmer
and Clegg, 2019).
Elevated K+ concentration, aldosterone, increased urine flow rate, and enhanced
activity mediate the increased K+ secretion per functioning nephron to
maintain K+ within normal levels (Kovesdy, Appel, et al., 2017; Palmer, 2015; Palmer and
Clegg, 2019). Additionally, there are increased fecal losses of K+ through the gastrointestinal
tract (Kovesdy, Appel, et al., 2017; Palmer, 2015; Palmer and Clegg, 2019). Fecal K+ excretion
may exceed 20% of intake (or even reach 75% of intake) in CKD, and especially in ESRD
(Hayes, McLeod, and Robinson, 1967).
Na+ /K+ -ATPase

In spite of the various adaptations to maintain normal levels of K+ in the body, the
high prevalence of chronic comorbid conditions (e.g., DM, hypertension, CHF), the use of
medications promoting hyperkalemia (e.g., RAAS inhibitors), and the declining kidney
function conspire to predispose patients with CKD to a high risk of hyperkalemia. Though
not as frequent as hyperkalemia, patients with CKD may also experience hypokalemia
due to diuretics use (e.g., loop or thiazide diuretics) and being African American and
females (Gilligan and Raphael, 2017). Overall, patients with CKD are at an increased risk of
experiencing dyskalemias (hypo- or hyperkalemia) and thus adverse outcomes associated
with dyskalemias. The sections below define dyskalemias, factors associated with and the
effects of dyskalemias.

1.2.3

Dyskalemias

Dyskalemias are the deviation of K+ levels from normal levels (3.5-5.0 mEq/L) and include
hypokalemia (reduced K+ levels; K+ <3.5 mEq/L) and hyperkalemia (elevated K+ levels;
K+ >5.0 mEq/L).
Hyperkalemia
Hyperkalemia is characterized by elevated levels of K+ in the extracellular fluid (K+ >5.0
mEq/L) (Gilligan and Raphael, 2017). The estimated prevalence of hyperkalemia amongst
those with CKD is 14%-50% depending on the K+ threshold used for defining hyperkalemia
and on CKD severity (Dashputre, Sumida, Potukuchi, et al., 2021; De Nicola et al., 2018;
Gilligan and Raphael, 2017). The common risk factors for hyperkalemia in CKD are
lower eGFR, RAAS inhibitor use, male sex, lower body mass index (BMI), prevalence of
malignancies, DM, and lower serum HCO3 - (Gilligan and Raphael, 2017).
Lower eGFR. Kidneys are critical to K+ homeostasis (Gumz, Rabinowitz, and
Wingo, 2015; Kovesdy, Appel, et al., 2017; Palmer, 2015; Palmer and Clegg, 2019). Those
with CKD might thus be at higher risk of hyperkalemia due to the progressive reduction in
kidney function, with those with advanced CKD stages (GFR <30 ml/min/1.73m2 ) being
at almost a 7-fold higher risk of developing hyperkalemia compared to those with normal
kidney function (Weinberg et al., 2009).
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Table 1.3: Medications inducing hyperkalemia and their mechanism of
action.
Medications
Beta blockers
Digoxin intoxication
Intravenous cationic
amino acids
Mannitol
Suxamethonium
Angiotensin converting
enzyme inhibitors
Angiotensin receptor
II blockers
Direct renin
inhibitors
NSAIDs
Calcineurin inhibitors
Aldosterone antagonists
K+ -sparing diuretics
Trimethoprim,
pentamidine
Salt substitutes and
salt alternatives
Penicillin G,
stored blood products

Mechanism of action
Decrease in activity Na+ /K+ -ATPase
activity pump and renin release
Inhibition of Na+ /K+ -ATPase pump activity
Increase in extracellular K+ shifts
Hyperosmolality with increase of extracellular K+
Prolonged depolarization of cell membrane
Blockade of angiotensin II synthesis
with decrease of aldosterone
secretion. Impaired delivery of Na+ to the
distal nephron
Competitive binding to the angiotensin II
synthesis with decrease of aldosterone synthesis
Inhibition of the conversion of angiotensinogen to
angiotensin I with decrease of aldosterone formation
Decrease of prostaglandin-mediated renin release,
renal blood flow and glomerular filtration rate
Decrease aldosterone synthesis and
Na+ /K+ -ATPase pump activity
Blockade of mineralocorticoid receptors
Blockade of luminal Na+ channels
Blockade of luminal Na+ channels
Increase in K+ supply
Increase in K+ supply

K+ : potassium; Na+ : sodium; Na+ /K+ -ATPase: sodium-potassium adenosine
triphosphatase; NSAIDs: non-steroidal anti-inflammatory drugs. Modified with
permission from Springer Nature. Ben Salem et al., 2014.
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RAAS inhibitors use. The mineralocorticoid aldosterone plays an important role
in the secretion of K+ from the distal part of the nephron (Palmer, 2015; Palmer and Clegg,
2019). RAAS inhibitors interfere with the angiotensin II-mediated stimulation of aldosterone
secretion from the adrenal gland resulting in diminished effects of aldosterone and hence
reduced renal K+ secretion (Weir and Rolfe, 2010).
Malignancy. Hyperkalemia amongst those with malignancies is typically attributed
to AKI, rhabdomyolysis, or tumor lysis syndrome (Rosner and Dalkin, 2014).
Diabetes mellitus. Patients with DM experience hyporeninemic hypoaldosteronism, which is the primary reason for hyperkalemia in patients with DM (Uribarri, Oh, and
Carroll, 1990). Additionally, the burden of DM is high amongst those with CKD (Centers for
Disease Control and Prevention. Chronic Kidney Disease Initiative, 2021), thus predisposing them to higher hyperkalemia risk due to underlying pathophysiological consequences
of DM and CKD.
Lower HCO3 - . In metabolic acidosis (lower serum HCO3 - ), the decrease in extracellular pH decreases the rate of Na+ -H+ exchange thus inhibiting inward rate of Na+ -HCO3 cotransport. The resultant loss in intracellular Na+ causes a loss of K+ into the extracellular
space. Additionally, fall in extracellular HCO3 - causes an inward movement of chlorine,
leading to an efflux of K+ into the extracellular space (Palmer, 2015). These physiological
changes in the setting of metabolic acidosis increase the risk of hyperkalemia.
Apart from these, other risk factors for hyperkalemia include active smoking, history
of heart disease or stroke, higher UACR and use of various medications like K+ -sparing diuretics (Kovesdy, Matsushita, et al., 2018), non-steroidal anti-inflammatory drugs (NSAIDs),
beta blockers, calcineurin inhibitors and others (Ben Salem et al., 2014). Table 1.3 lists
medications inducing hyperkalemia and their mechanism of action (Ben Salem et al., 2014).
Hypokalemia
Hypokalemia is characterized by reduced levels of extracellular K+ (K+ <3.5 mEq/L)
(Gilligan and Raphael, 2017). The estimated prevalence of hypokalemia amongst those with
CKD is 12%-31% depending on the K+ threshold for defining K+ and CKD severity studied
(Dashputre, Sumida, Potukuchi, et al., 2021; Gilligan and Raphael, 2017). The most common
risk factors for hypokalemia in CKD are diuretic use, African American race, female sex,
higher BMI, and malignancies (Gilligan and Raphael, 2017).
Diuretic use. Loop and thiazide diuretics increase the delivery of Na+ and water
to the distal nephron (Knochel, 1984; Tannen, 1985). The distal delivery of Na+ and water is
important to the secretion of K+ from the body (Kovesdy, Appel, et al., 2017; Palmer, 2015;
Palmer and Clegg, 2019), thus increased delivery of Na+ and water by diuretics along with
inhibition of the sodium/potassium/chlorine cotransporter (responsible for transcellular
K+ reabsorption) (Ellison and Loffing, 2009; Ellison, 2019), may cause hypokalemia due to
increased K+ secretion from the body.
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Table 1.4: Medications inducing hypokalemia and their mechanism of
action.
Medications
Antimicrobials
β2 -receptor agonists
Diuretics
Insulin
Mineralocorticoids and
Glucocorticoids
Laxatives
Xanthines
Verapamil (overdose)

Mechanism of action
Renal K+ loss
Shift of K+ from extracellular fluid to
intracellular fluid compartment
Renal K+ loss
Shift of K+ from extracellular fluid to
intracellular fluid compartment
Renal K+ loss
Stool (gastrointestinal) K+ loss
Shift of K+ from extracellular fluid to
intracellular fluid compartment
Shift of K+ from extracellular fluid to
intracellular fluid compartment

K+ : potassium. Reprinted with permission. Veltri and Mason, 2015.

Malignancy. Hypokalemia amongst those with malignancies is due to medications
causing tubular damage (e.g., cisplatin, amphotericin B, and aminoglycoside antibiotics),
poor nutrition, chemotherapy-induced gastrointestinal K+ losses, and diuretic use (Rosner
and Dalkin, 2014).
Additional risk factors for hypokalemia include higher SBP, lower serum cholesterol,
higher UACR (Kovesdy, Matsushita, et al., 2018) and drugs such as β2 -receptor agonists,
insulin, laxatives and others (Veltri and Mason, 2015). Table 1.4 lists medications inducing
hypokalemia and their mechanism of action.

1.2.4

Dyskalemia-associated outcomes

Potassium plays an important role in maintaining normal cellular function necessary
for proper function of excitable neuromuscular and cardiac tissues (Gumz, Rabinowitz,
and Wingo, 2015; Kovesdy, Appel, et al., 2017; Palmer, 2015; Palmer and Clegg, 2019).
Dyskalemias (hypo/-hyper-kalemia) can lead to deviations in membrane potential in
the skeletal myocytes and cardiac myocytes that can lead to muscle paralysis and fatal
arrhythmias, respectively (Ravens and Cerbai, 2008; Toto, 2017). Fatal arrhythmias can lead
to sudden cardiac death (Ravens and Cerbai, 2008; Toto, 2017). Across various populations
(CKD vs non-CKD), dyskalemias are associated with worse cardiovascular outcomes,
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mortality, and healthcare and economic burden (Betts et al., 2018; Collins et al., 2017;
Gilligan and Raphael, 2017; Fitch et al., 2017; Kim et al., 2019; Kovesdy, Matsushita, et al.,
2018; Luo et al., 2016; Polson et al., 2017).

1.2.5

Dyskalemia management

Hyperkalemia
Management of hyperkalemia differs based on the setting (acute vs chronic). In the acute
setting, the immediate goal is stabilization of the membrane potential with or without changing K+ concentration. The first intervention in the acute setting is typically intravenous
administration of calcium or hypertonic saline, followed by therapies that cause an influx of
K+ into the intracellular space, such as insulin and β2 -agonists (Kovesdy, 2015). Intravenous
HCO3 - might be used, however its efficacy is questionable (Kovesdy, 2015). On the other
hand, the focus of management of chronic hyperkalemia is to prevent development of
hyperkalemia by identifying and correcting defects in K+ homeostasis.
Reducing K+ intake in diet, discontinuing hyperkalemia-inducing medications (e.g.,
RAAS inhibitors) or treating metabolic acidosis can be the initial steps. However, stopping
medications like RAAS inhibitors might have adverse outcomes due to their known cardioand renoprotective effects (Remuzzi et al., 2005). The aforementioned interventions may
not be enough to prevent hyperkalemia and might require the use of K-binding resins
such as sodium-polystyrene sulphonate (SPS), patiromer calcium, or sodium zirconium
cyclosilicate (Kovesdy, 2015). These agents work by exchanging cations (Na+ for K+ [SPS];
calcium for K+ [patiromer calcium]; and Na+ and hydrogen for K+ [sodium zirconium
cyclosilicate]) (Chaitman, Dixit, and Bridgeman, 2016).
Hypokalemia
For diuretic-induced hypokalemia interventions such as using the lowest diuretic dose possible, reducing Na+ intake, and following a K+ -rich diet can be used. If these strategies aren’t
effective, oral K+ chloride supplementation (starting at 20-60 mmol/d) or administration of
K+ -sparing diuretics can be used (Kovesdy, Appel, et al., 2017).
As discussed in section 1.2.4, dyskalemias are associated with various adverse
outcomes in CKD/non-CKD population. However, there are gaps in the literature that need
to be addressed, especially amongst those with advanced CKD transitioning to dialysis.
The following sections discuss the current gap in the literature, goal of this study, and the
study significance.

1.3

Research Gaps

Dyskalemias are associated with higher incidence of cardiovascular morbidity and mortality,
and higher healthcare/economic burden (Collins et al., 2017; Fitch et al., 2017; Gilligan
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and Raphael, 2017; Kim et al., 2019; Kovesdy, Matsushita, et al., 2018; Luo et al., 2016;
Polson et al., 2017). Patients with advanced CKD transitioning to dialysis represents a
unique population which is at higher risk of dyskalemias (especially hyperkalemia) due to
low eGFR, higher prevalence of comorbidities (e.g., DM, CHF, hypertension) and use of
medications (e.g., RAAS inhibitors, diuretics) inducing dyskalemias. Though, the common
risk factors for hyperkalemia like lower eGFR, RAAS inhibitor use, DM etc. are known
and largely studied, there are no studies that have developed/used a prediction model
approach to identify predictors of hyperkalemia (in the pre-dialysis period) in advanced
CKD patients transitioning to dialysis.
Secondly, patients with CKD are at a higher risk of stroke incidence due to impaired
cerebral autoregulation, remodeled cerebral vasculature, reduced cerebral blood flow, and
high prevalence of comorbid hypertension, a strong independent risk factor for stroke (Dad
and Weiner, 2015; Johansson, 1999; Masson et al., 2015; Power, 2013; Toyoda and Ninomiya,
2014). Previous studies suggested that hypokalemia might be a marker of increased RAAS
activity potentiating the effect of stroke by resulting in extensive neurologic damage and
neurologic deficits (Brown and Brown, 1986; Mattsson et al., 2018). Further, a number of
clinical and epidemiological studies suggest that higher K+ levels leads to vasodilation and
lower K+ leads to vasoconstriction, thus potentiating effects on BP and future stroke events
(Brace, 1974; Dolson et al., 1995; Haddy, 1975; Haddy, Vanhoutte, and Feletou, 2006; Ma,
Mamaril, and Young, 2000; Paller and Linas, 1982; Pikilidou et al., 2007; Webb and Bohr,
1978; Webb, 1982). Previous studies suggested that both hypokalemia and hyperkalemia
are associated with higher risk of stroke incidence (Green et al., 2002; Johnson, Mattsson,
et al., 2017; Mattsson et al., 2018; Smith et al., 2003). However, common limitations amongst
these studies (Green et al., 2002; Johnson, Mattsson, et al., 2017; Mattsson et al., 2018; Smith
et al., 2003) are the lack of representation of an advanced CKD population, use of baseline
K+ measurement to define dyskalemia, and long follow-up times for outcome assessment
(minimum follow-up of 1 year; maximum median follow-up of 26 years).
Finally, dyskalemias are associated with higher risk of hospital/emergency room
(ER) utilization (Brunelli et al., 2017; Fitch et al., 2017; Kim et al., 2019; Luo et al., 2016;
Polson et al., 2017). However, limitations for current studies (Brunelli et al., 2017; Fitch
et al., 2017; Kim et al., 2019; Luo et al., 2016; Polson et al., 2017) are lack of representation of
advanced CKD patients and use of baseline K+ (except (Luo et al., 2016) and (Brunelli et al.,
2017)) measurement for defining dyskalemia. Overall, there is a dearth of literature on
predictors of hyperkalemia and outcomes associated with dyskalemia (in the pre-dialysis
period) amongst patients with advanced CKD transitioning to dialysis.

1.4

Goals of the Study

In the context of the current limitations, the goals of this study are to study the following
aims in the pre-dialysis period of patients with advanced CKD transitioning to dialysis:
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• Aim 1: Develop and validate a prediction model to predict risk of future hyperkalemia
events in individual patients using machine learning (ML)
• Aim 2: Assess the relationship between dyskalemias and time to incidence of first
ischemic stroke event
– Hypothesis: Dyskalemias are associated with higher risk of ischemic stroke
• Aim 3: Assess the relationship between dyskalemias and short-term hospital/ER
utilization
– Hypothesis: Dyskalemias are associated with higher risk of short-term hospital/ER utilization

1.5

Study Significance

Prediction models have extensive clinical utility and can help in assessing future risk of
events. Many such validated tools like the Framingham risk score for cardiovascular disease
risk (Wilson et al., 1998), the CHA2 DS2 -VASc score for atrial fibrillation stroke risk (Gage et
al., 2001), and the kidney failure risk equation (Tangri et al., 2011) are examples of prediction
models with excellent clinical utility. Due to the high risk of hyperkalemia in advanced
CKD patients and the lack of prediction models to assess future risk of hyperkalemia in
these patients, there is a need to develop and validate a prediction model that can be used to
assess the future risk of hyperkalemia (in the pre-dialysis period) in individual patients with
advanced CKD transitioning to dialysis. This study will develop and validate a prediction
model using ML methods to potentially help prevent hyperkalemia event.
Dyskalemias may affect BP levels that can potentially lead to a higher risk of ischemic
stroke. As discussed earlier, among the limitations of previous studies (Green et al., 2002;
Johnson, Mattsson, et al., 2017; Mattsson et al., 2018; Smith et al., 2003) are the lack of
representation of an advanced CKD population, use of a baseline K+ value to define
dyskalemia, and long follow-up assessment periods. In an advanced CKD population
transitioning to dialysis, we propose to assess the association of both baseline K+ levels
and time updated K+ levels with time to first ischemic stroke event (in the pre-dialysis
period), to further shed light on the association of dyskalemias with ischemic stroke in this
population.
Dyskalemia-associated complications (e.g., arrhythmias) are typically short term in
nature (Brunelli et al., 2017; Einhorn et al., 2009). As discussed earlier, previous studies
(Brunelli et al., 2017; Fitch et al., 2017; Kim et al., 2019; Luo et al., 2016; Polson et al., 2017)
have assessed the association between dyskalemia and hospital/ER utilization; however
they are limited by using a single K+ measurement (except (Luo et al., 2016) and (Brunelli
et al., 2017)) for defining dyskalemia and the lack of short-term assessment period for
hospital/ER utilization. In our study, we propose to use time-updated K+ measurement, to
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assess the association between dyskalemias and short-term hospital/ER utilization (in the
pre-dialysis period) in an advanced CKD population transitioning to dialysis.
Overall, these study goals will lead to the development of a validated tool with
practical clinical applications for early identification of patients with advanced CKD transitioning to dialysis at a future risk of hyperkalemia. Additionally, the study will shed light
on the association of dyskalemias with stroke and healthcare utilization amongst those with
advanced CKD transitioning to dialysis.
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Chapter 2
Development of a Prediction Model for Advanced
Chronic Kidney Disease Patients at Risk for
Hyperkalemia Using Machine Learning

2.1

Introduction

Chapter 2 describes the research question undertaken for Aim 1, mentioned in section 1.4.
Briefly, chapter 2 describes the development and validation of a prediction risk score to
identify advanced CKD patients transitioning to dialysis at risk of hyperkalemia (in the
pre-dialysis period) using various ML methods.
The kidneys play a critical role in maintaining the K+ levels in a narrow range of
3.5-5.0 mEq/L (Kovesdy, Appel, et al., 2017; Palmer and Clegg, 2019). Patients with CKD
are at a higher risk of hyperkalemia due to declining kidney function, comorbidities (e.g.,
DM, CHF etc.), and use of medications such as RAAS inhibitors (Gilligan and Raphael,
2017; Korgaonkar et al., 2010; Kovesdy, Appel, et al., 2017; McCullough et al., 2014).
The prevalence of hyperkalemia in CKD is estimated between 14-41% and differs based
on CKD stage and the K+ threshold used to define hyperkalemia, with an estimated
prevalence of 41% (K+ >5.5 mEq/L) amongst those with advanced CKD (stage 4 and 5)
(Dashputre, Sumida, Potukuchi, et al., 2021; Gilligan and Raphael, 2017; Luo et al., 2016;
Korgaonkar et al., 2010; Moranne et al., 2009; Nakhoul et al., 2015). Hyperkalemia is
associated with poor healthcare outcomes including reduced survival, increased risk of
experiencing cardiovascular events, and increased healthcare and economic burden (Collins
et al., 2017; Fitch et al., 2017; Gilligan and Raphael, 2017; Kim et al., 2019; Korgaonkar et al.,
2010; Kovesdy, Matsushita, et al., 2018; Luo et al., 2016).
Prediction models are useful tools to inform clinical decision making (Kappen et al.,
2018; Moons et al., 2015; Vogenberg, 2009), with models such as the Framingham risk
score (Wilson et al., 1998), the CHA2 DS2 -VASc score (Lip et al., 2010), and the kidney
failure risk equation (Tangri et al., 2011) score aiding clinicians to make decisions for
patient management. Further, the increased implementation of artificial intelligence and
ML in healthcare has afforded newer methods to complement or even improve traditional
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regression models such as logistic regression (LR) or Cox regression for development of
prediction models (Davenport and Kalakota, 2019; Vollmer et al., 2020).
Patients with advanced CKD transitioning to dialysis represent a unique population
with a declining kidney function, high comorbidity rate and medication burden (Johansen
et al., 2021). Such patients may thus be predisposed to a higher risk of hyperkalemia as
well. Further, owing to the clinical and economic implications of hyperkalemia in CKD
as discussed earlier, developing a prediction model to predict hyperkalemia might aid
clinical decision making for management of hyperkalemia in the advanced CKD population.
Prediction models for hyperkalemia have been previously developed amongst varied
population including CKD patients initiating lisinopril (Johnson, Weinstein, et al., 2010),
RAAS inhibitors initiators in the Stockholm Creatinine Measurements (SCREAM) cohort
(Bandak et al., 2017), and US commercial/Medicare Advantage insured CKD patients
(Sharma, Alvarez, Woods, and Dai, 2020).
However, these studies are limited by the use of only traditional methods (Cox
regression or LR) for prediction model development. Further, these studies did not focus
on advanced CKD patients transitioning dialysis, who are at a higher risk of hyperkalemia.
With the increasing use of ML in healthcare, comparing the performance of ML and traditional regression methods might help in identifying and developing more robust prediction
models. To address the current gap in the literature, the aim of our study was to compare
the performance of ML and traditional regression methods and develop and validate a
prediction model to predict the risk of hyperkalemia in individual patients with advanced
CKD prior to dialysis transition.

2.2
2.2.1

Methods
Data source

To address this research aim, data from the Transition of Care in Chronic Kidney Disease
(TC-CKD) cohort was used for this study. The TC-CKD cohort (n=102,477) is a nationally
representative cohort with longitudinal data on US Veterans transitioning to dialysis from
October 1, 2007 through March 31, 2015 identified from the United States Renal Data System
(USRDS) (Dashputre, Sumida, Potukuchi, et al., 2021; Dashputre, Potukuchi, et al., 2021;
Sumida et al., 2021). The TC-CKD cohort has a median (25-75th ) of 6.2 (2.8-9.3) years and
1.6 (0.6-2.3) years of data availability prior to and following dialysis initiation, respectively.

2.2.2

Study population

The aim of this study was to develop and validate a prediction model using ML methods
for the risk of hyperkalemia in the pre-dialysis period of an advanced CKD population
transitioning to dialysis. From the TC-CKD cohort, an initial sample of 60,520 US Veterans
with any pre-dialysis outpatient eGFR data was identified. Amongst these, 36,644 with two
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Figure 2.1: Study design for Aim 1. eGFR: estimated glomerular filtration
rate; K+ : potassium.

outpatient eGFR <30 ml/min/1.73m2 (CKD stages 4 and 5, not yet on dialysis) measured
90-365 days apart, with the second eGFR serving as the index were further identified.
Further, the sample was restricted to 23,363 with at least one-year each of look back period
(baseline) and follow-up period (prior to dialysis initiation) from the index to allow for
sufficient baseline and follow-up period to capture predictors and outcome, respectively.
Amongst these, 21,669 had at least 1 inpatient/outpatient K+ value each in the baseline
(to establish baseline K+ value) and follow-up (to establish outcome K+ value) period.
Finally, we excluded 15 patients (age <18 years at index [n=1] and with incorrect zip code
data [n=14]) to yield a final sample size of 21,654 patients. The study design is shown in
Figure 2.1 and sample selection is shown in Figure 2.2.

2.2.3

Predictors

A total of 51 predictors (48 clinical risk factors and 3 interaction terms) including demographics, smoking status, comorbidities, healthcare utilization, medication use, vital signs,
and laboratory measures were identified based on clinical knowledge, published literature
and availability in the data (Gilligan and Raphael, 2017; Kovesdy, Matsushita, et al., 2018;
Palmer and Clegg, 2019). Demographic characteristics such as date of birth, sex, and race
were extracted from the USRDS Patient and Medical Evidence file, whereas marital status
was extracted from Veterans Affairs (VA) records and were ascertained as of the index date
(McGinnis et al., 2011; Soohoo et al., 2019). Smoking status was extracted from the VA
records(McGinnis et al., 2011; Soohoo et al., 2019) and ascertained as of the index date.
Pre-existing comorbidities as of the index date were identified from the VA Inpatient
and Outpatient Medical SAS, and the VA/Centers for Medicare and Medicaid Services
(CMS) databases using a 2 outpatient or 1 inpatient claims algorithm of the International
Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic and
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Figure 2.2: Sample selection criteria for Aim 1. eGFR: estimated
glomerular filtration rate; K+ : potassium.
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Current Procedural Terminology (CPT) codes. Comorbidities include DM, CHF, hypertension, IHD, peripheral vascular disease, cerebrovascular disease, chronic lung disease,
peptic ulcer disease, para-/hemiplegia, anemia, atrial fibrillation, liver disease, and malignancies. The Charlson Comorbidity Index (CCI) score was calculated using the Deyo
modification for administrative datasets as a measure of comorbidity burden with kidney
disease excluded from the algorithm (Deyo, Cherkin, and Ciol, 1992). Healthcare utilization
measures included outpatient, hospital, emergency room, and nephrology visits identified
from the VA Inpatient and Outpatient Medical SAS and the VA/CMS databases and were
ascertained in the one-year baseline period.
Prescribed medications were sourced from the VA pharmacy dispensation records
and CMS Medicare Part D and ascertained in the one-year baseline period. Patients were
considered to be users if they had at least one 30-day supply dispensation for chronic
medications (RAAS inhibitors, loop diuretics, K+ -sparing diuretics, thiazide diuretics,
NSAIDs, digoxin, beta blockers, calcium channel blockers, insulin, oral hypoglycemics, β2
agonist, and calcineurin inhibitors) and at least one dispensation of any day supply for
sodium polystyrene sulphonate (SPS), trimethoprim, azole antifungals, and laxatives. Vital
signs including BMI, SBP, and DBP were extracted from the VA Clinical Data Warehouse
(CDW) Vital Signs file and captured over the one-year baseline.
Laboratory data on K+ and HCO3 - levels was identified from the Decision Support
System Lab Results Extract (DSS-LAR) and was captured over the one-year baseline. Further, K+ characteristics such as number of K+ measurements, hyperkalemia events (K+
>5.5 mEq/L), and number of hyperkalemia events in the one-year baseline were used as
predictors. Serum creatinine was extracted from the VA CDW LabChem file and eGFR
was calculated by the CKD-EPI equation (Levey, Stevens, et al., 2009). The index eGFR
was used as a predictor in the model. Finally, three pre-specified interactions were used
in the model including race*prevalent DM, race*RAAS inhibitors use, RAAS inhibitors
use*SPS use based on strong association of these risk factors with the outcome (Gilligan
and Raphael, 2017; Kovesdy, Matsushita, et al., 2018; Palmer and Clegg, 2019). A complete
list of predictors is shown in (Table 2.1).

2.2.4

Outcome

The outcome of interest was occurrence of hyperkalemia, defined as any K+ >5.5 mEq/L
(Sumida et al., 2021) anytime during the one-year follow-up from the index. The outcome
was binary in nature, expressed as “yes” vs “no”, based on the K+ threshold above.

2.2.5

Prediction model methods

We used multivariable LR as a traditional regression model and Random Forest (RF),
Support Vector Machines (SVM), and Extreme Gradient Boosting (XGBoost) as ML models.
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Table 2.1: List of predictors for hyperkalemia.
Predictor

Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Age
Sex
Race
Marital Status
Smoking status
Diabetes Mellitus
Congestive heart failure
Hypertension
Peripheral vascular disease
Cerebrovascular disease
Chronic lung disease
Peptic ulcer disease
Ischemic heart disease
Paraplegia/hemiplegia
Anemia
Atrial fibrillation
Liver disease
Malignancies
Charlson comorbidity index
Outpatient visits
Hospital visits
Emergency room visits
Nephrology visits

24

Renin angiotensin aldosterone system inhibitors

25

Loop diuretics

26

K+ sparing diuretics

27

Thiazide diuretics

28

Sodium polystyrene sulphonate

29

Nonsteroidal anti-inflammatory drugs

30

Digoxin

31

Beta Blockers

32

Calcium channel blockers

33

Insulin

34

Oral hypoglycemics

35

Calcineurin inhibitors

36

β2 agonists

37

Trimepthoprim

38

Azole antifungals

39

Laxatives

40
41
42
43
44

Body mass index
Systolic blood pressure
Diastolic blood pressure
Estimated glomerular filtration rate
Bicarbonate

45

Last K+

46
47
48
49

Number of K+ measurements
Hyperkalemia (K+ >5.5 mEq/L) event
Number of hyperkalemia (K+ >5.5 mEq/L) events
Race*Diabetes Mellitus

50

Race* Renin angiotensin aldosterone system inhibitors use

51

Renin angiotensin aldosterone system inhibitors use*
sodium polystyrene sulphonate use
K+ : potassium.

Definition
As of the index date
As of the index date
As of the index date
As of the index date
As of the index date
Anytime prior to index date
Anytime prior to index date
Anytime prior to index date
Anytime prior to index date
Anytime prior to index date
Anytime prior to index date
Anytime prior to index date
Anytime prior to index date
Anytime prior to index date
Anytime prior to index date
Anytime prior to index date
Anytime prior to index date
Anytime prior to index date
Anytime prior to index date
Number of visits in the baseline
Number of visits in the baseline
Number of visits in the baseline
Number of visits in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
At least one 30-day supply prescription
in the baseline
Time-averaged value in the baseline
Time-averaged value in the baseline
Time-averaged value in the baseline
Measured at index date
Time-averaged value in the baseline
Measured as the last K+ value
prior to the index date in the baseline
Counts of K+ measurements in the baseline
At least one event of hyperkalemia in the baseline
Counts of hyperkalemia events in the baseline
Interaction term of race by prevalent diabetes mellitus
Interaction term of race by
Renin angiotensin aldosterone system inhibitors use
Interaction term of Renin angiotensin aldosterone system
inhibitors use by sodium polystyrene sulphonate use
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Random Forest
RF is a supervised ensemble ML method which builds multiple decision trees to predict
or classify an outcome of interest. At each iteration, RF generates a random subset of the
predictors to build a decision tree. This process is repeated multiple times where simple
decision trees are obtained and embedded into the RF framework to predict or classify
the outcome (Breiman, 2001). For our study, we employed 500 individual trees for the RF
algorithm and used the default “\sqrt{n}” predictors to build individual decision trees as
RF error rates are largely insensitive to number of predictors selected at each node (Breiman,
2001).
Support Vector Machine
SVM is a supervised ML method that can be most commonly applied to classification
problems (Cortes and Vapnik, 1995). The SVM algorithm tries to find a hyperplane (decision
boundary) to distinctly classify data points. SVM tries to find a hyperplane which has
maximum margin i.e. maximum distance between data points (outcome) of a classification
problem. For our study we used the linear kernel.
Extreme Gradient Boosting
XGBoost (Tianqi and Guestrin, 2016) is an ensemble ML method based on gradient boosting
(Friedman, 2001), which sequentially constructs and combines a series of weak prediction
models with the aim to correct errors made at each time in the prediction by the previous
model to eventually form a strong prediction model. XGBoost is essentially a computationally faster implementation of gradient boosting, which controls for over-fitting and
provides better performance than gradient boosting (Friedman, 2001). For this study, we
used the default learning rate of 0.3 and interaction depth of 6 as hyperparameters for the
XGBoost model (Friedman, 2001).

2.2.6

Prediction modeling and statistical analysis

Prediction modeling
We first compared the performance of our ML methods (LR, RF, SVM, and XGBoost) and
chose the best performing model for final model development and validation as described
hereafter.
As our main model building and validation method, we split our data into training
and test set based on geographical splitting (Akbilgic et al., 2019; Moons et al., 2015). We
used this method to avoid and address possible geographical-based overfitting. To employ
this method, for example, we selected patients with zip codes starting with 0 to 8 as our
training set and built a 10-fold cross validated model (internal validation). A 10-fold cross
validation was implemented on the training set to address overfitting due to random data
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Figure 2.3: Geographical splitting with 10-fold cross validation.

splitting. This internally validated data was then tested on the test set (external validation)
that consisted of patients belonging to zip codes starting with 9. This process was repeated
10 times such that each zip code from 9 to 0 served as a test set with those zip codes not
a part of the test set being a part of the training set (Figure 2.3). The described method
was implemented based on a previously published paper by Akbilgic et al. (Akbilgic et al.,
2019).
The geographical-based splitting method was implemented for all the ML methods
(LR, RF, SVM, and XGBoost) using the 51 predictors. The performance of these methods
was compared using the area under the receiver operating curve (AUROC) statistic. The
AUROC is a plot of the sensitivity versus 1-specificity with a value ranging from 0.5-1.0,
where 0.5 means no class separation capacity and 1.0 means perfect measure of separability
(Mandrekar, 2010; Zou, O’Malley, and Mauri, 2007). The method yielding the highest
cross-validated AUROC was used as the method of choice to develop and validate the final
prediction model. In our study LR had the best AUROC of all the tested methods and hence
was used as our method of choice to further develop and validate the final prediction model.
As a sensitivity, we also used the split-sample method by splitting the data as 70%:30%
(training: test set) (Moons et al., 2015). A 10-fold cross validation was implemented on
the training set (70%; internal validation) and performance was tested on the test set (30%;
external validation). Finally, the geographical-splitting method was also conducted using
complete case analysis (n=15,236).
The most important predictors associated with the outcome of hyperkalemia for the
LR method were ascertained by the absolute value of the z-statistic (Herrin et al., 2021;
Kuhn, 2008; Moons et al., 2015; Nusinovici et al., 2020). For comparison, the most important
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variables ascertained by the RF and XGBoost methods were also assessed using the mean
decrease accuracy metric. The mean decrease accuracy was reported on a normalized
scale of 0-100, where 0 indicates minimum importance (lowest decrease in accuracy when
excluded) and 100 represents maximum importance (highest decrease in accuracy when
excluded from the model). The SVM method does not inherently identify important
predictors and hence important predictors ascertained by this method were not presented.
To derive a model with clinical applicability, a reduced model with top 10 predictors
identified by the LR method based on absolute value of the z-statistic was constructed.
Further, calibration plots by deciles of predicted probability were constructed to assess
how well the predicted probability reflected the observed probability using the reduced
model. Slope and intercept were reported to assess calibration with a slope of 1 and
intercept of 0 indicating perfectly calibrated model (Miller et al., 1993; Steyerberg et al.,
2010). Subgroup analysis using the reduced model was conducted to test the model
robustness after categorizing patients by age, race, prevalent DM and CHF, baseline use of
SPS, RAAS inhibitors, and index eGFR.
A patient-level risk score to assess the predicted risk of hyperkalemia (PRHK) was
developed by using the LR parameter estimates from the reduced model of top 10 predictors.
The risk score is calculated as the sum of the parameter estimates (∑ β) derived from the
reduced LR model with the top 10 predictors. The PRHK for each individual patient can
then be calculated as follows (Grant, Collins, and Nashef, 2018; Moons et al., 2015; Pavlou
et al., 2015):
PRHK = exp(∑ β)/1 + exp(∑ β)
Statistics
Patient characteristics were summarized for the entire analytic sample and by the outcome
category (i.e. K+ >5.5 mEq/L vs K+ ≤5.5 mEq/L). Data were presented as counts (percentages), mean (standard deviation [SD]), or median (25-75th percentile) and differences
across categories were ascertained by chi-square tests, independent samples t-test, and
Mann-Whitney U test as appropriate. Missingness was observed for marital status (0.05%),
smoking status (0.1%), SBP and DBP (0.7% each), medications (1.1%), BMI (10.9%), and
HCO3 - (22.2%). As our main approach, we used single regression imputation to impute the
missing variables based on the complete variables. Subgroup analysis using the reduced
model as discussed earlier was conducted using singly imputed data.
Compared to those included in the study cohort (n=21,654), those excluded (n=81,823)
were older (70.3 vs 68.7), less likely to be males (91.9% vs 98.1%), African Americans (24.3%
vs 28.2%), married (55.0% vs 57.8%), current smokers (19.8% vs 32.3%), and have DM (59.5%
vs 68.9%). Data manipulation was conducted in SAS Enterprise guide v8.2 (SAS Institute;
Cary, NC) and prediction modeling was conducted in R version 4.0.2 using “gmodels”,
“randomForest”, “e1071”, “xgboost”, “caret” packages. The study was approved by the
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Institutional Review Board of the Memphis VA Medical Center, with exemption from
informed consent.

2.3
2.3.1

Results
Baseline characteristics

The baseline characteristics of the analytic sample are described in Table 2.2. The mean
(SD) age of the sample was 68.7 (10.4) years; 98.1% were males; 28.2% were African Americans; and 68.9% had DM. The most commonly used medications were RAAS inhibitors
(73.6%), beta blockers (67.9%), and calcium channel blockers (65.3%). Approximately 8%
of the patients used SPS. The median (25-75th percentile) index eGFR was 24.8 (20.9-27.6)
ml/min/1.73m2 . Patients had a median (25-75th percentile) of 3 (2-6) K+ measurements,
with a mean (SD) last K+ prior to index of 4.6 (0.6) mEq/L in the baseline. Approximately
17% of the patients experienced at least 1 hyperkalemia event in the baseline. Those who
had at least 1 K+ >5.5 mEq/L in the follow-up period (vs those who did not have K+ >5.5
mEq/L) were more likely to be younger; African American; current smokers; have prevalent DM and liver disease; have frequent healthcare encounters; use RAAS inhibitors, loop
diuretics, K+ sparing diuretics, SPS, NSAIDs, beta blockers, insulin, oral hypoglycemics,
trimethoprim, azole antifungals, β2 agonists, and laxatives; have higher levels of SBP, DBP,
and last K+ (prior to index), but, lower levels of BMI, eGFR and HCO3 - (all p-values <0.05).

2.3.2

Prediction modeling

A total of 5,061 patients (23.4%) experienced a hyperkalemia event (K+ >5.5 mEq/L) in the
one-year follow-up. Using the geographical splitting method with 10-fold cross validation,
LR showed the best performance across the training and test set, followed by RF, XGBoost,
and SVM (Table 2.3). The average AUROC (95% confidence interval [CI]) for the training
set using the geographic splitting method for LR, RF, XGBoost, and SVM was 0.765 (0.7560.774), 0.754 (0.747-0.763), 0.752 (0.734-0.780), and 0.734 (0.727-0.742) respectively. The
average AUROC (95% CI) for the test set for LR, RF, XGBoost, and SVM was 0.763 (0.7530.771), 0.758 (0.743-0.787), 0.753 (0.736-0.785), 0.733 (0.725-0.741), respectively. Results
were consistent using the split-sample method (70% training: 30% test) with 10-fold cross
validation, with LR yielding the best performance, followed by RF, XGBoost, and SVM
(Table 2.4). Further, using complete cases only (n=15,236), both the geographical splitting
and split-sample methods with 10-fold cross-validation showed that LR yielded the best
performance, followed by RF, XGBoost, and SVM (Table 2.5 A, B, respectively).
As LR yielded the best performance using the geographical splitting method with
singly imputed data, LR was chosen as the primary method to identify the top 10 predictors.
The LR parameter estimates and z-statistic using all the 51 predictors are shown in Table 2.6.
Based on the absolute value of the z-statistic, the top 10 predictors (ranked as decreasing
absolute z-statistic value) were last K+ value prior to index, age at index, having at least
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Table 2.2: Sample baseline characteristics for Aim 1 (n=21,654).
Characteristic
Age at index (years)
Males
African Americans
Married
Zip codee
0
1
2
3
4
5
6
7
8
9
Smoking status
Current
Past
Never
Comorbidities
Diabetes Mellitus
Congestive heart failure
Hypertension
Peripheral vascular disease
Cerebrovascular disease
Chronic lung disease
Peptic ulcer disease
Ischemic heart disease
Paraplegia/hemiplegia
Anemia
Atrial fibrillation
Liver disease
Malignancies
Charlson comorbidity index
Utilization measures
Outpatient visits
Hospital visits
Emergency room visits
Nephrology visits
Medications
RAAS inhibitors
Loop diuretics
K+ sparing diuretics
Thiazide diuretics
SPS
NSAIDs
Digoxin
Beta blockers
Calcium channel blockers
Insulin
Oral hypoglycemics
Calcineurin inhibitors
Trimethoprim
Azole antifungals
β2 -agonists
Laxatives
Vitals
Body mass index, kg/m2
Systolic blood pressure, mm/Hg
Diastolic blood pressure, mm/Hg
Laboratory measures
Index eGFR, ml/min/1.73m2
Last K+ , mEq/L
Number of K+ measurements
Bicarbonate, mEq/L
Hyperkalemia event
At least 1 K+ >5.5 mEq/L
Number of K+ >5.5 mEq/L

All
(N=21,654)

K+ >5.5 mEq/La
(N=5,061)

K+ ≤5.5 mEq/La
(N=16,593)

68.7 (10.4)
21,248 (98.1)
6,111 (28.2)
12,518 (57.8)

66.4 (10.1)
4,962 (98.0)
1,511 (29.9)
2,650 (52.4)

69.4 (10.4)
16,286 (98.2)
4,600 (27.7)
9,868 (59.5)

1,582 (7.3)
1,982 (9.2)
2,758 (12.7)
3,806 (17.6)
2,407 (11.1)
1,120 (5.2)
1,784 (8.2)
2,759 (12.7)
1,276 (5.9)
2,180 (10.1)

455 (8.9)
485 (9.6)
662 (13.1)
856 (16.9)
546 (10.8)
203 (4.0)
378 (7.5)
614 (12.1)
280 (5.5)
582 (11.5)

1,127 (6.8)
1,497 (9.0)
2,096 (12.6)
2,950 (17.8)
1,861 (11.2)
917 (5.5)
1,406 (8.5)
2,145 (12.9)
996 (6.0)
1,598 (9.6)

7,004 (32.4)
7,635 (35.3)
6,989 (32.3)

1,858 (36.7)
1,652 (32.6)
1,551 (30.7)

5,146 (31.0)
5,983 (36.1)
5,438 (32.8)

14,937 (68.9)
7,567 (34.9)
20,944 (96.7)
6,688 (30.9)
5,485 (25.3)
6,397 (29.5)
1,014 (4.7)
10,727 (49.5)
523 (2.4)
10,307 (47.6)
2,494 (11.5)
1,585 (7.3)
4,297 (19.8)
4 (2-6)

3,797 (75.0)
1,651 (32.6)
4,878 (96.4)
1,440 (28.5)
1,093 (21.6)
1,380 (27.3)
259 (5.1)
2,297 (45.4)
135 (2.7)
2,389 (47.2)
434 (8.6)
451 (8.9)
867 (17.1)
4 (2-5)

11,140 (67.1)
5,916 (35.7)
16,066 (96.8)
5,248 (31.6)
4,392 (26.5)
5,017 (30.2)
755 (4.6)
8,430 (50.8)
388 (2.3)
7,918 (47.7)
2,060 (12.4)
1,134 (6.8)
3,430 (20.7)
4 (2-6)

<0.0001c
<0.0001c
0.12c
<0.0001c
<0.0001c
<0.0001c
0.09c
<0.0001c
0.18c
0.52c
<0.0001c
<0.0001c
<0.0001c
0.053d

16 (9-28)
0 (0-1)
0 (0-1)
0 (0-1)

19 (11-32)
0 (0-1)
0 (0-1)
0 (0-2)

15 (9-26)
0 (0-1)
0 (0-1)
0 (0-1)

<0.0001c
<0.0001d
<0.0001d
<0.0001d

15,939 (73.6)
12,010 (55.5)
1,959 (9.0)
6,988 (32.3)
1,689 (7.8)
7,226 (33.4)
1,007 (4.6)
14,699 (67.9)
14,134 (65.3)
8,718 (40.3)
7,532 (34.8)
228 (1.1)
393 (1.8)
2,312 (10.7)
3,226 (14.9)
5,893 (27.2)

4,014 (79.3)
2,911 (57.5)
478 (9.4)
1,522 (30.1)
835 (16.5)
2,026 (40.0)
212 (4.2)
3,566 (70.5)
3,249 (64.2)
2,428 (47.9)
1,912 (37.8)
66 (1.3)
101 (2.0)
656 (12.9)
828 (16.4)
1,694 (33.5)

11,925 (71.9)
9,099 (54.8)
1,481 (8.9)
5,466 (32.9)
854 (5.2)
5,200 (31.3)
795 (4.8)
11,133 (67.1)
10,885 (65.6)
6,290 (37.9)
5,620 (33.9)
162 (0.9)
292 (1.8)
1,656 (9.9)
2,398 (14.5)
4,199 (25.3)

<0.0001c
<0.0001c
0.0003c
<0.0001c
<0.0001c
<0.0001c
<0.0001c
<0.0001c
<0.0001c
<0.0001c
<0.0001c
<0.0001c
0.0003c
<0.0001c
<0.0001c
<0.0001c

29.8 (6.1)
143.6 (16.3)
74.9 (10.8)

29.6 (6.3)
144.9 (15.9)
75.4 (10.3)

29.9 (5.9)
143.2 (16.4)
74.8 (11.0)

<0.0001b
<0.0001b
<0.0001b

24.8 (20.9-27.6)
4.6 (0.6)
3 (2-6)
24.9 (3.2)

24.4 (20.4-27.5)
4.9 (0.6)
4 (2-9)
24.0 (3.1)

24.9 (21.0-27.6)
4.5 (0.6)
3 (2-6)
25.2 (3.2)

<0.0001d
<0.0001b
<0.0001d
<0.0001b

3,746 (17.3)
0 (0-0)

1,886 (37.3)
0 (0-1)

1,860 (11.2)
0 (0-0)

<0.0001c
<0.0001d

P-value
<0.0001b
0.63c
0.003c
<0.0001c
<0.0001c

<0.0001c

Data are presented as n (%), mean (standard deviation), median (25-75th percentile). eGFR: estimated
glomerular filtration rate; K+ : potassium; NSAIDs: nonsteroidal anti-inflammatory drug; RAAS:
renin-angiotensin-aldosterone system; SPS: sodium polystyrene sulphonate. a Number of patients
based on outcome K+ >5.5 mEq/L observed during 1-year of follow-up from index; b p-value for
independent samples t-test; c p-value for chi-square test; d p-value for Mann-Whitney U test; e First
digit of a 5-digit zip code.
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Table 2.3: Prediction model performance across the machine learning
methods using geographical splitting (n=21,654).
Data split
Training
Test

Logistic
Regression

Random
Forest

Extreme Gradient
Boosting

Support Vector
Machine

0.765 (0.756-0.774)
0.763 (0.753-0.771)

0.754 (0.747-0.763)
0.758 (0.743-0.787)

0.752 (0.734-0.780)
0.753 (0.736-0.785)

0.734 (0.727-0.742)
0.733 (0.725-0.741)

Data presented as area under the receiver operating curve (95% CI) as the average of the
10-fold cross-validation using geographical splitting. CI: confidence interval.

Table 2.4: Prediction model performance across the machine learning
methods using split-sample (70%:30%) method (n=21,654).
Data split
Training
Test

Logistic
Regression

Random
Forest

Extreme Gradient
Boosting

Support Vector
Machine

0.761 (0.748-0.773)
0.762 (0.749-0.775)

0.755 (0.750-0.768)
0.756 (0.739-0.767)

0.753 (0.736-0.789)
0.744 (0.729-0.757)

0.729 (0.716-0.742)
0.731 (0.717-0.744)

Data presented as area under the receiver operating curve (95% CI) as the average of the
10-fold cross-validation using split-sample validation. CI: confidence interval.

Table 2.5: Prediction model performance across the machine learning
methods using geographical splitting and split-sample (70%:30%)
method for complete cases (n=15,236).
Data split

Logistic
Regression

Training
Test

0.765 (0.757-0.773)
0.762 (0.753-0.771)

Training
Test

0.756 (0.746-0.766)
0.762 (0.752-0.772)

Random
Forest

Extreme Gradient
Boosting

(A) Geographical splitting
0.753 (0.745-0.763) 0.749 (0.731-0.778)
0.757 (0.727-0.778) 0.749 (0.730-0.776)
(B) Split-sample (70%:30%)
0.752 (0.743-0.764) 0.749 (0.739-0.759)
0.755 (0.736-0.768) 0.750 (0.738-0.762)

Support Vector
Machine
0.745 (0.737-0.753)
0.742 (0.732-0.751)
0.731 (0.717-0.745)
0.739 (0.725-0.753)

Data presented as area under the receiver operating curve (95% CI) as the average of the
10-fold cross-validation. CI: confidence interval.
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Table 2.6: Parameter estimates and z-statistic for the logistic regression
model using all 51 predictors (n=21,654).
Characteristic
Age at index
Males (vs Females)
Others vs (African American)
Married (vs Unmarried)
Current smoker (vs Never smoker)
Past smoker (vs Never Smoker)
Diabetes Mellitus
Congestive heart failure
Hypertension
Peripheral vascular disease
Cerebrovascular disease
Chronic lung disease
Peptic ulcer disease
Ischemic heart disease
Paraplegia/hemiplegia
Anemia
Atrial fibrillation
Liver disease
Malignancies
Charlson comorbidity index
(1 comorbidity increase)
Outpatient visits
Hospital visits
Emergency room visits
Nephrology visits
RAAS inhibitors
Loop diuretics
K+ sparing diuretics
Thiazide diuretics
SPS
NSAIDs
Digoxin
Beta blockers
Calcium channel blockers
Insulin
Oral hypoglycemics
Calcineurin inhibitors
Trimethoprim
Azole antifungals
β2 agonists
Laxatives
Body mass index, kg/m2
Systolic blood pressure, mm/Hg
Diastolic blood pressure, mm/Hg
Index eGFR, ml/min/1.73m2
Last K+ , mEq/L
Number of K+ measurements
Bicarbonate, mEq/L
At least 1 K+ >5.5 mEq/L
Number of K+ >5.5 mEq/L
Race*Diabetes Mellitus
Race*RAAS inhibitor use
RAAS inhibitor use*SPS use

Parameter
Estimate

P-value

z-statistic

-0.024
0.214
-0.376
-0.156
0.66
0.032
0.128
-0.049
-0.011
-0.035
-0.142
0.006
0.258
-0.102
0.144
-0.045
-0.078
0.096
-0.001

<0.0001
0.10
<0.0001
<0.0001
0.14
0.477
0.126
0.31
0.91
0.44
0.003
0.91
0.002
0.018
0.223
0.247
0.239
0.170
0.98

-9.004
-1.636
-3.797
-4.231
1.459
0.711
1.53
-1.023
-0.111
-0.766
-2.941
0.115
3.053
-2.361
1.217
-1.157
-1.176
1.369
-0.025

-0.017

0.19

-1.295

0.005
-0.0001
0.033
0.004
0.075
-0.069
0.128
-0.198
0.434
0.172
-0.016
0.071
-0.161
0.123
0.033
0.064
-0.174
0.053
0.075
0.118
-0.013
0.01
-0.009
-0.031
1.04
0.015
-0.041
0.52
0.078
0.147
0.321
-0.286

<0.0001
0.99
0.02
0.648
0.37
0.09
0.04
<0.0001
0.0004
<0.0001
0.86
0.087
<0.0001
0.006
0.44
0.70
0.19
0.35
0.16
0.006
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.005
0.09
0.0008
0.03

4.858
-0.003
2.301
0.456
0.903
-1.674
2.03
-4.94
3.53
4.38
-0.179
1.708
-4.117
2.73
0.775
0.379
-1.3
0.93
1.389
2.763
-4.22
7.07
-3.927
-7.96
28.99
5.71
-6.82
8.16
2.81
1.66
3.35
-2.117

eGFR: estimated glomerular filtration rate; K+ : potassium; NSAIDs:
nonsteroidal anti-inflammatory drugs; RAAS: renin angiotensin aldosterone system; SPS: sodium polystyrene sulphonate.
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Table 2.7: Parameter estimates and z-statistic for the logistic regression
model using top 10 predictors (n=21,654).
Characteristic

Parameter
Estimate

P-value

z-statistic

Absolute value
of z-statistic

Last K+ , mEq/L
Age at index
At least 1 K+ >5.5 mEq/L
Index eGFR
Systolic blood pressure
Bicarbonate, mEq/L
Number of K+ measurements
Thiazide diuretics
Outpatient visits
NSAIDs

1.04
-0.024
0.52
-0.031
0.01
-0.041
0.015
-0.198
0.005
0.172

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

28.99
-9.004
8.16
-7.96
7.07
-6.82
5.71
-4.94
4.858
4.38

28.99
9.004
8.16
7.96
7.07
6.82
5.71
4.94
4.86
4.38

Rank
1
2
3
4
5
6
7
8
9
10

eGFR: estimated glomerular filtration rate; K+ : potassium; NSAIDs: nonsteroidal antiinflammatory drugs.

Table 2.8: Comparison of top 10 predictors across logistic regression,
random forest, and extreme gradient boosting (n=21,654).
Random
Forest

Logistic Regression
Predictor

Absolute
z-statistic

1
2
3

Last K+ , mEq/L
Age at index
At least 1 K+ >5.5 mEq/L

28.99
9.004
8.16

4

Index eGFR

7.96

5
6

Systolic blood pressure
Bicarbonate
Number of K+
measurements
Thiazide diuretics use
Outpatient visits
NSAIDs

7.07
6.82

Rank

7
8
9
10

5.71
4.94
4.86
4.38

Predictor
Last K+ , mEq/L
Number of K+ >5.5 mEq/L
At least 1 K+ >5.5 mEq/L
Number of K+
measurements
Age at index
Bicarbonate
Sodium polystyrene
sulphonate use
Outpatient visits
Charlson comorbidity index
Diastolic blood pressure

Extreme Gradient
Boosting
Mean decrease
accuracy

Predictor

Mean decrease
accuracy

59.51
25.70
22.62

Last K+ , mEq/L
At least 1 K+ >5.5 mEq/L
Number of K+ measurements

100
64.29
26.54

19.56

At least 1 K+ >5.5 mEq/L

23.52

16.39
12.76

Age at index
Bicarbonate

19.66
12.03

11.64

Index eGFR

8.45

11.42
10.20
7.95

Systolic blood pressure
Outpatient visits
Body mass index

6.45
4.62
4.09

Top 10 predictors for logistic regression ranked by absolute value of z-statistic and mean decrease accuracy for random forest and extreme
gradient boosting. eGFR: estimated glomerular filtration rate; K: potassium; NSAIDs: nonsteroidal anti-inflammatory drugs.
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Table 2.9: Performance of logistic regression model with top 10
predictors using geographical splitting overall and by subgroups
(n=21,654).
Subgroup
Overall (n=21,654)
Age <65 years (n=8,016)
Age ≥65 years (n=13,638)
African American (n=6,111)
Other Race (n=15,543)
Diabetes Mellitus (n=14,937)
No Diabetes Mellitus (n=6,717)
Congestive heart failure (n=7,567)
No congestive heart failure (n=14,087)
RAAS inhibitors use (n=16,080)
No RAAS inhibitors use (n=5,574)
SPS use (n=1,693)
No SPS use (n=19,961)
eGFR <20/ml/min/1.73m2 (n=4,471)
eGFR ≥20/ml/min/1.73m2 (n=17,183)

Training set

Test set

0.756 (0.749-0.764)
0.740 (0.727-0.753)
0.754 (0.744-0.764)
0.739 (0.725-0.754)
0.764 (0.755-0.773)
0.754 (0.744-0.764)
0.757 (0.741-0.772)
0.753 (0.738-0.767)
0.759 (0.749-0.769)
0.749 (0.741-0.756)
0.780 (0.765-0.796)
0.659 (0.634-0.685)
0.747 (0.738-0.756)
0.742 (0.724-0.759)
0.759 (0.751-0.768)

0.758 (0.750-0.766)
0.737 (0.724-0.749)
0.754 (0.743-0.764)
0.746 (0.729-0.763)
0.764 (0.755-0.773)
0.755 (0.746-0.765)
0.757 (0.742-0.772)
0.751 (0.738-0.764)
0.760 (0.751-0.769)
0.750 (0.741-0.759)
0.779 (0.763-0.795)
0.642 (0.613-0.671)
0.749 (0.740-0.757)
0.737 (0.720-0.755)
0.762 (0.753-0.771)

Data presented as average of the 10-fold cross-validation using geographical splitting. CI: confidence interval; eGFR: estimated glomerular filtration
rate; RAAS: renin angiotensin aldosterone system; SPS: sodium polystyrene
sulphonate.

1 K+ >5.5 mEq/L in the baseline, index eGFR, baseline averaged SBP, baseline averaged
HCO3 - , number of K+ counts in baseline, thiazide use, number of outpatient visits, and
NSAIDs use in the baseline (Table 2.7). Further, Table 2.8 compares the top 10 predictors
from the LR model (based on absolute z-statistic value) to those identified by RF and
XGBoost (based on mean decrease in accuracy). Overall, the top 10 predictors identified
across LR, RF, XGBoost methods were very similar (with some discrepancies), with last K+
prior to index consistently identified as the most important predictor (Table 2.8).
The model performance using the 10 predictors from the LR method based on
geographical splitting was slightly lower than the full model (51 predictors) but was
consistent across training (AUROC, 95% CI: 0.756, 0.749-0.764) and test set (AUROC, 95%
CI: 0.758, 0.750-0.766) (Table 2.9). Further, the model performance using geographical
splitting with 10-fold cross-validation was consistent by the subgroups of age (<65 years vs
≥65 years), race (African Americans vs Others), prevalent DM and CHF, baseline use of SPS,
RAAS inhibitors, and index eGFR (<20 ml/min/1.73m2 vs. ≥20 ml/min/1.73m2 ) across
the training and test set (Table 2.9). Overall, the model was well calibrated with a slope of
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Figure 2.4: Calibration plot of observed versus predicted probability by
deciles of predicted risk for the outcome of hyperkalemia using top 10
predictors from the logistic regression.
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Table 2.10: Logistic regression parameter estimates using top 10
predictors (n=21,654).
Characteristic
Intercept
Last K+
Age at index
At least 1 K+ >5.5 mEq/L
eGFR
Systolic blood pressure
Bicarbonate
Number of K+ measurements
Thiazide use
Outpatient visits
NSAIDs

Parameter
Estimate
-4.345
1.054
-0.024
0.731
-0.024
0.0079
-0.047
0.022
-0.129
0.007
0.227

Odds ratio
(95% CI)
2.86 (2.68-3.07)
0.97 (0.97-0.98)
2.08 (1.89-2.27)
0.98 (0.97-0.98)
1.01 (1.01-1.01)
0.95 (0.94-0.96)
1.02 (1.02-1.03)
0.88 (0.82-0.95)
1.01 (1.00-1.01)
1.25 (1.16-1.35)

P-value
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

eGFR; estimated glomerular filtration rate; K+ : potassium; NSAIDs:
nonsteroidal anti-inflammatory drugs.

1.06 and intercept of 0.06. Figure 2.4 shows the calibration plot of the observed vs predicted
probability by deciles of predicted probability. Table 2.10 shows the parameter estimates for
the top 10 predictors derived from the LR model. For a hypothetical patient “A” with last K+
prior to index of 4.5 mEq/L, aged 69 years, with occurrence of at least 1 K+ >5.5 mEq/L in
baseline, eGFR of 20 ml/min/1.73m2 , SBP of 145 mm/Hg, 4 K+ measurements in baseline,
no thiazide diuretics use, 6 outpatient visits in the baseline, and NSAIDs use (Table 2.11),
the hyperkalemia risk score (∑ β) over one-year follow-up from index is -0.376. Further, the
PRHK is 0.4072 (or 40.72%). Table 2.11 provides more examples of hyperkalemia risk score
and predicted risk for hypothetical patients with different characteristics.

2.4

Discussion

In a nationally representative cohort of US Veterans with advanced CKD transitioning to
dialysis, we developed and validated a prediction model to predict the risk of hyperkalemia
in the pre-dialysis period. Using geographical splitting with 10-fold cross validation method,
LR had the best performance for hyperkalemia prediction compared to RF, XGBoost, and
SVM. Further, we developed and validated a reduced model with top 10 predictors identified by the LR method for clinical applicability. The parameter estimates from the reduced
model with top 10 predictors can be implemented in clinical practice for hyperkalemia risk
prediction. Overall, the reduced model with top 10 predictors had good calibration. Our
results were robust to sensitivity analyses including split-sample method (70%:30%) with
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Table 2.11: Risk of hyperkalemia for hypothetical patients based on top
10 predictors from logistic regression.
Patient
A
B
C
D
E
F

Last K+ ,
mEq/L

Age at index,
years

At least 1
K+ >5.5 mEq/Ld

eGFR

SBP

Bicarbonate,
mEq/L

Number
of K+
measurements

Thiazide
Diuretics
used

Outpatient
visits

NSAIDs
used

Hyperkalemia
risk scorea,b

% Predicted
risk of hyperkalemiaa,c

4.5
3.5
6.5
6.0
5.2
5.0

69
72
65
70
62
80

1
0
1
0
1
1

20
25
10
28
24
5

145
140
150
130
130
150

18
25
15
25
22
17

4
2
7
3
1
7

0
1
0
1
0
0

6
2
10
4
12
9

1
0
1
0
0
1

-0.376
-3.146
2.34
-0.580
-0.121
0.417

40.72
4.13
91.23
35.90
46.98
60.27

eGFR; estimated glomerular filtration rate; K+ : potassium; NSAIDs: nonsteroidal anti-inflammatory drugs; SBP: systolic blood pressure. a Risk is assessed over a 1-year follow-up
period from the index; b Hyperkalemia risk score = ∑ β (including the intercept [Intercept= -4.34]), where β is the parameter estimates for each predictor from the logistic regression
model; c Predicted risk of hyperkalemia calculated as– exp (∑ β)/1+exp(∑ β), where β is the parameter estimates for each predictor from the logistic regression model; d 1= Yes; 0= No.
Example: Patient A has thiazide diuretics= 0, which means patient A did not have a prescription for thiazide diuretics.

10-fold cross validation for model development and validation, various subgroup analysis,
and using complete cases only.
The predictive performance of our model with top 10 predictors was promising
(AUROC, 95% CI: 0.756, 0.749-0.764). In comparison, the model performance (AUROC,
95% CI) amongst RAAS inhibitors initiators in the Stockholm Creatinine Measurements
(SCREAM) cohort (Bandak et al., 2017) (LR model) and US commercial/Medicare Advantage insured CKD patients (Sharma, Alvarez, Woods, and Dai, 2020) (LR model) was 0.854
(0.840-0.869) and 0.843 (95% CI not reported), respectively. However, a direct comparison
cannot be made between the model performance of our study and the previous studies due
to differences in study design, study population, and predictors in the final model. Further,
compared to the previous studies, our study employed and tested various ML methods and
developed the final model using the method (LR in our study) with the best performance
In our study, the most important predictors associated with hyperkalemia risk
were last K+ value prior to index, age at index, having at least 1 K+ >5.5 mEq/L in the
baseline, index eGFR, baseline averaged SBP, baseline averaged HCO3 - , number of K+
measurements, thiazide diuretics use, number of outpatient visits, and NSAIDs use in the
baseline as identified by the LR model. Higher levels of previous K+ value and past event
of hyperkalemia (K+ >5.5 mEq/L) were associated with higher risk of hyperkalemia and
indeed mechanistically would be associated with such a higher future risk of experiencing
a hyperkalemia event. Number of K+ measurements and outpatient visits were associated
with higher risk of hyperkalemia. This might be indicative that patients requiring frequent
interactions with the healthcare system/closer monitoring might be at a higher risk of a
future hyperkalemia event. Systolic blood pressure increase was associated with higher risk
of hyperkalemia. In our cohort, 74% patients used RAAS inhibitors which are associated
with higher risk of hyperkalemia (Gilligan and Raphael, 2017; Kovesdy, Furth, et al., 2017;
Kovesdy, Matsushita, et al., 2018). Patients with higher SBP, might be more frequently
treated by these medications, hence increasing the risk of hyperkalemia. Finally, NSAIDs use
was associated with higher risk of hyperkalemia. Non-steroidal anti-inflammatory drugs
are known to induce hyporeninemic hypoaldosteronism resulting in decreased excretion of
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K+ and hence increased risk of hyperkalemia (Ben Salem et al., 2014).
Conversely, age, eGFR, HCO3 - , and thiazide use were associated with lower risk of
hyperkalemia. Previous studies suggest that increase in age is associated with lower risk
of hyperkalemia (Gilligan and Raphael, 2017; Nakhoul et al., 2015). Potassium levels are
a function of eGFR and hence higher levels of eGFR would be associated with lower risk
of hyperkalemia (Kovesdy, Appel, et al., 2017; Palmer and Clegg, 2019). Similarly, HCO3 levels have an inverse relationship with K+ levels, with lower levels of HCO3 - (metabolic
acidosis) associated with higher risk of hyperkalemia, whereas higher levels of HCO3 associated with a lower risk of hyperkalemia (Kovesdy, Appel, et al., 2017; Palmer and
Clegg, 2019). Finally, thiazide use was associated with lower risk of hyperkalemia as they
increase the secretion of K+ from the body (Knochel, 1984; Tannen, 1985).
Our study findings have several practical implications. We developed and validated
a prediction model to predict the risk of hyperkalemia using data that is readily available
to physicians in electronic medical records. Direct access to patient data would allow
system-wide implementation of our prediction model to assess the risk of hyperkalemia.
Our risk score with the top 10 predictors associated with hyperkalemia provides physicians
with a simple tool that can be used in everyday practice. Further, the risk score can be used
to assign a numerical risk of hyperkalemia based on the patient characteristics. This would
allow physicians in early identification of patients at a higher risk of hyperkalemia and
early implementation of interventions to reduce the risk of future hyperkalemia events.
Our study results need to be interpreted in light of several limitations. First, our
cohort consisted of predominantly male US Veterans, thus limiting generalizability to
women or to a broader general population. Second, we used predictors available within
the TC-CKD cohort and hence limited the scope of assessed predictors, e.g., we lacked
data on dietary intake of K+ . Third, we developed and validated the model to predict risk
of hyperkalemia in the pre-dialysis period amongst patients with advanced CKD using
a cohort that transitions to dialysis. Hence, our results might not be generalizable to the
post-dialysis period or to those who do not initiate dialysis. Finally, our results are internally
valid as we did not have access to an independent external data for external validation and
further validation in an external cohort is warranted.

2.5

Conclusion

In conclusion, we compared the performance of various ML methods including LR, RF,
XGBoost, and SVM and observed that LR outperformed all the other methods for prediction
of hyperkalemia risk. Using LR as our primary method, we developed and validated a
prediction model to assess the risk of hyperkalemia in the pre-dialysis period amongst
advanced CKD population transitioning to dialysis. The risk score from our validated
model can be used by clinicians in daily practice to assess the future risk of hyperkalemia
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for a patient with advanced CKD. Further studies are required for the external validation of
our hyperkalemia risk model.
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Chapter 3
Association of Dyskalemias with Ischemic Stroke in
Advanced Chronic Kidney Disease Patients
Transitioning to Dialysis1

3.1

Introduction

Chapter 3 describes the research question undertaken for Aim 2, mentioned in section
1.4. Briefly, chapter 3 describes association of dyskalemias with ischemic stroke (in the
pre-dialysis period) in an advanced CKD population transitioning to dialysis.
The kidneys play a critical role in maintaining normal serum K+ homeostasis and
thus patients with CKD are prone to dyskalemias (hypo- and hyperkalemia, especially
the latter) due to the disturbed serum K+ homeostasis as a result of the declining kidney
function (Kovesdy, Appel, et al., 2017; Palmer and Clegg, 2019). The higher prevalence of
comorbid conditions such as DM and CVD, use of medications such as RAAS inhibitors
and diuretics (all risk factors for dyskalemia), further increase the risk of experiencing
dyskalemias in CKD (Clase et al., 2020; Gilligan and Raphael, 2017; Kovesdy, Appel, et al.,
2017; Palmer and Clegg, 2019). Further, the prevalence/incidence of dyskalemias (especially
hyperkalemia) increases as kidney function worsens (Dashputre, Sumida, Potukuchi, et al.,
2021; Gilligan and Raphael, 2017; Korgaonkar et al., 2010; Luo et al., 2016; Moranne et al.,
2009; Nakhoul et al., 2015). Dyskalemias are associated with adverse outcomes, including
higher mortality and cardiovascular morbidity, and healthcare burden (Collins et al., 2017;
Fitch et al., 2017; Gilligan and Raphael, 2017; Kim et al., 2019; Korgaonkar et al., 2010;
Kovesdy, Matsushita, et al., 2018; Luo et al., 2016; Nakhoul et al., 2015; Polson et al., 2017).
Ischemic stroke is the most common type of stroke (87% of all strokes) characterized
by restriction of blood flow to the brain (Virani et al., 2020). Patients with CKD are at
1 Portions of chapter from previously published article; final submission modified with permission of S.
Karger AG, Basel. A. A. Dashputre, K. Sumida, F. Thomas, et al. (2021). “Association of Dyskalemias with
Ischemic Stroke in Advanced Chronic Kidney Disease Patients Transitioning to Dialysis”. In: Am J Nephrol.
Type: Journal Article, pp. 1–9. ISSN: 1421-9670 (Electronic) 0250-8095 (Linking). DOI: 10.1159/000516902. URL:
https://www.ncbi.nlm.nih.gov/pubmed/34289468.
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a higher risk of experiencing an ischemic stroke likely due to endothelial dysfunction,
chronic inflammation, oxidative stress, atherogenesis and arteriosclerosis as a result of
downstream effects of declining kidney function (Lee, Saver, et al., 2010; Masson et al.,
2015). Further, as discussed earlier, CKD is associated with higher risk of dyskalemia events
(Dashputre, Sumida, Potukuchi, et al., 2021; Korgaonkar et al., 2010; Kovesdy, Matsushita,
et al., 2018; Gilligan and Raphael, 2017; Luo et al., 2016; Moranne et al., 2009; Nakhoul
et al., 2015). Patients with advanced CKD transitioning to dialysis represents a unique
population with high comorbidity burden (e.g. hypertension and CVD) and in frequent
need of pharmacotherapeutic interventions (e.g. RAAS inhibitors and diuretics) (Johansen
et al., 2021). These patients may thus be at a higher risk of experiencing dyskalemias and
ischemic stroke events.
Previous studies suggested that dyskalemias (especially hypokalemia) are associated
with a higher risk of ischemic stroke (Green et al., 2002; Johnson, Mattsson, et al., 2017;
Mattsson et al., 2018; Smith et al., 2003). Among the general population (Mattsson et al.,
2018), diuretics users (Green et al., 2002), and treated hypertensive patients (Smith et al.,
2003), hypokalemia was associated with a higher risk of ischemic stroke. Conversely, a
study in the general population (Johnson, Mattsson, et al., 2017) showed that higher levels
of K+ were associated with a higher risk of ischemic stroke. However, the association
between dyskalemias and ischemic stroke has not been examined in an advanced CKD
population, who might be at a higher risk of ischemic stroke events due to the higher
prevalence of dyskalemia events. Further, all the previous studies used baseline K+ levels
and long follow-up times (minimum follow-up 1 year and maximum median follow-up
26.9 years) to assess dyskalemia-ischemic stroke association (Green et al., 2002; Johnson,
Mattsson, et al., 2017; Mattsson et al., 2018; Smith et al., 2003).
The effects of dyskalemia are short-term in nature (Brunelli et al., 2017; Einhorn
et al., 2009) and hence using most recent (updated) K+ levels might be a more appropriate
method to assess the association between dyskalemia and ischemic stroke. Considering
the previous literature and limitations, the aim of our study was to assess the association
of dyskalemias (treated separately as a chronic distant exposure and acute exposure) with
ischemic stroke (prior to dialysis initiation) in an advanced CKD population transitioning
to dialysis. We hypothesized that both hypokalemia and hyperkalemia are associated with
a higher risk of ischemic stroke.

3.2
3.2.1

Methods
Data source

Data from the TC-CKD cohort was used to address this research aim. Section 2.2.1 describes
the TC-CKD cohort in detail.
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Figure 3.1: Study design for Aim 2. eGFR: estimated glomerular filtration
rate; K+ : potassium.

3.2.2

Study population

The aim of this study was to assess the association between dyskalemias, both as a chronic
exposure (distant) and as an acute exposure (time-updated) separately with time to first
ischemic stroke in the pre-dialysis period of an advanced CKD population transitioning to
dialysis. To assess this association, an initial sample of 60,520 US veterans with pre-dialysis
outpatient eGFR data was identified from the TC-CKD cohort. Amongst these, 36,644 with
two outpatient eGFR <30 ml/min/1.73m2 (CKD stage 4 and 5, not yet on dialysis) measured
90-365 days apart were identified, with the second eGFR serving as the index. Further, the
sample was restricted to 23,363 with at least one-year each of look back period (baseline)
and follow-up period (prior to dialysis initiation) from the index. Amongst these, 21,669
had at least 1 inpatient or outpatient K+ value each in the baseline (to establish chronic
exposure) and follow-up period (to establish acute exposure). Finally, we excluded 312
patients (age <18 years at index [n=1], without medication data [n=235], and with ischemic
stroke event at the index [n=76]) to yield a final sample size of 21,357 patients. The study
design and sample selection are shown in Figure 3.1 and Figure 3.2, respectively.

3.2.3

Exposure

As discussed earlier, the aim of our study was to assess the association of dyskalemias as a
chronic exposure and as an acute exposure with time to ischemic stroke. Previous studies
have treated dyskalemia a chronic exposure (distant; baseline K+ value) (Green et al., 2002;
Johnson, Mattsson, et al., 2017; Mattsson et al., 2018; Smith et al., 2003). However, given the
short-term association of dyskalemia with clinical outcomes (Brunelli et al., 2017; Einhorn
et al., 2009), in our study we also treated dyskalemia as an acute exposure (time-updated
K+ value).
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glomerular filtration rate; K+ : potassium.
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The chronic exposure was defined as the time-average of all the K+ measurements
over the one-year baseline. The acute exposure was captured as the time-updated K+ levels
through end of follow-up (defined later). For both the exposures, K+ levels were categorized
as hypokalemia (K+ <3.5 mEq/L), hyperkalemia (K+ >5.5 mEq/L) and referent (3.5 ≤K+
≤5.5 mEq/L) (Sumida et al., 2021). Finally, K+ levels were also treated as a continuous
exposure. Potassium levels were extracted from the DSS-LAR.

3.2.4

Covariates/confounders

The covariates/confounders used in this study were identified based on published literature,
expert clinical opinion, biological reasoning, and availability in the database (Gilligan and
Raphael, 2017; Green et al., 2002; Johnson, Mattsson, et al., 2017; Kovesdy, Matsushita,
et al., 2018; Mattsson et al., 2018; Palmer and Clegg, 2019; Smith et al., 2003). Broadly,
the identified covariates/confounders can be classified as demographics, smoking status,
comorbidities, healthcare utilization, medication use, vital signs, and laboratory measures.
Patient demographic characteristics (date of birth, sex, race) were extracted from the USRDS
Patient and Medical Evidence file, whereas marital status, region of residence, and income
were extracted from the VA records only and were ascertained as of the index date (McGinnis
et al., 2011; Soohoo et al., 2019). Smoking status as of the index was ascertained from VA
records and ascertained as of the index (McGinnis et al., 2011; Soohoo et al., 2019).
Pre-existing comorbidities as of the index were identified from the VA Inpatient
and Outpatient Medical SAS, and the VA/CMS databases with a diagnosis defined as the
presence of 2 outpatient or 1 inpatient claims for the condition according to the ICD-9-CM
diagnostic and CPT codes. Comorbidities include DM, CHF, hypertension, hyperlipidemia,
ischemic stroke/transient ischemic attack (TIA), IHD, peripheral vascular disease, cerebrovascular disease, chronic lung disease, peptic ulcer disease, para-/hemiplegia, anemia,
atrial fibrillation, liver disease, and malignancies. The CCI score was calculated using
the Deyo modification for administrative datasets with kidney disease excluded from the
algorithm (Deyo, Cherkin, and Ciol, 1992). Healthcare utilization measures including the
average number of outpatient, hospital, emergency, and nephrology visits were captured
over the one-year baseline.
Data on prescribed medications were collected both in the one-year baseline and
as a time-varying covariate for the follow-up period from inpatient and outpatient VA
pharmacy dispensation records and CMS Medicare Part D. For the one-year baseline,
patients were considered to be users if they had at least one 30-day supply dispensation
for medications used for chronic therapy (RAAS inhibitors, loop diuretics, K+ -sparing
diuretics, thiazide diuretics, NSAIDs, antiplatelet agents, aspirin, anticoagulants, lipid
lowering agents, antiarrhythmics, digoxin, beta blockers, calcium channel blockers, insulin,
oral hypoglycemic drugs, β2 agonist, and calcineurin inhibitors) and at least 1 dispensation
of any day supply for SPS, trimethoprim, azole antifungals, and laxatives. Time-varying
medications were captured at each K+ measurement during the follow-up period and were
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deemed to be present if the prescription date was the same as the K+ measurement date
or if the K+ measurement fell within the time period covered by the day supply of the
medication.
Laboratory measurements other than K+ included serum creatinine (to calculate
eGFR), HCO3 - , Na+ , low density lipoprotein (LDL), high density lipoprotein (HDL), total
cholesterol, and triglycerides. Serum creatinine was extracted from the VA CDW LabChem
file, whereas all the other aforementioned laboratory measures were extracted from the
DSS-LAR. The eGFR was calculated using the CKD-EPI equation (Levey, Stevens, et al.,
2009), and captured at the index as well as a time-varying confounder captured at each
time-updated K+ . The Na+ levels were captured as the average of all Na+ measurements in
the one-year baseline as well as a time-varying confounder captured at each time-updated
K+ . The HCO3 - , LDL, HDL, total cholesterol, and triglycerides levels were captured as the
average of all measurements in the one-year baseline. Vital signs including BMI, SBP, and
DBP were extracted from the VA CDW Vital Signs file and captured as the average of all
measurements over the one-year baseline. Finally, the number of K+ measurements, the
presence of at least one hyperkalemia event, hypokalemia event, and co-occurrence of both
hyperkalemia and hypokalemia (for the same patient) each was ascertained in the one-year
baseline.

3.2.5

Outcome

The outcome of interest was time to first ischemic stroke over the follow-up period. Ischemic
stroke was ascertained based on ICD-9-CM diagnosis codes (433.01, 433.11, 433.21, 433.31,
433.81, 433.91, 434.00-434.91, and 436) (Russo and Andrews, 2008) captured as the primary
diagnosis at an outpatient or inpatient visit. Follow-up started from index eGFR and
patients were followed through first ischemic stroke or censored at dialysis initiation for
those who did not experience the stroke event, whichever occurred first.

3.2.6

Statistical analysis

Patient characteristics were summarized for the entire analytic sample and by hypokalemia
(K+ <3.5 mEq/L), hyperkalemia (K+ >5.5 mEq/L) and referent (3.5 ≤K+ ≤5.5 mEq/L)
categories based on the baseline time-averaged K+ levels. Data were presented as counts
(percentages), mean (SD) or median (25-75th percentile), and the differences between the K+
categories were assessed using chi-square tests, one-way analysis of variance, and KruskalWallis test, as appropriate. The association of dyskalemia categories as a chronic exposure
(using baseline time-averaged K+ levels) with time to ischemic stroke was assessed using
multivariable-adjusted Cox regression models (models 1-4 and model 5 as an additional
exploratory) which incrementally accounted for confounders listed in section 3.2.4. The
models were conducted as follows:
Model 1: Unadjusted.
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Model 2: Model 1 + age, sex, race, marital status, region of residence, and income.
Model 3: Model 2 + smoking status, comorbidities (listed in section 3.2.4), CCI, outpatient,
hospital, emergency, and nephrology visits during the baseline period.
Model 4 (fully-adjusted): Model 3 + baseline medications (listed in section 3.2.4), index
eGFR, baseline averaged levels of Na+ , HCO3 - , BMI, LDL, HDL, total cholesterol,
and triglycerides and number of K+ measurements and occurrence of at least one
hypokalemia, hyperkalemia, and both (those who experienced both hyper- and hypokalemia) event in the baseline.
Model 5 (additional): Model 4 + SBP, DBP.
Model 4 was our fully-adjusted model, whereas model 5 was our additional exploratory model which accounted for SBP and DBP due to their potential mediatory effects
on the outcome of ischemic stroke. Similarly, the association of dyskalemia categories
as an acute exposure (using time-updated K+ levels) and ischemic stroke was assessed
in incrementally multivariable-adjusted Cox regression models as described above, with
additionally accounting for time-varying medications, eGFR, and Na+ levels and baseline time-averaged K+ levels and Na+ levels in model 4 and model 5. Cox regressions
using cubic splines and fractional polynomials by treating the K+ levels (for both chronic
and acute exposure) as a continuous exposure were used to assess non-linearity in the
exposure-outcome relationship.
Missingness was observed for marital status (0.05%), smoking status and region of
residence (0.07% each), Na+ (0.4%), SBP and DBP (0.7% each), BMI (10.8%), total cholesterol (12.3%), triglycerides (13.5%), HDL (14.5%), LDL (17.2%), and HCO3 - (22.3%) and
time-varying Na+ (2.3%) and eGFR (6.5%). The main analysis (models 1-4 and model
5) for the exposure-outcome relationship was conducted using singly imputed data for
missing baseline covariates derived from regression imputation. In the time-updated K+
level exposure models, time-varying Na+ and eGFR at each K+ were imputed using last
observation carried forward method.
We conducted subgroup analyses after categorizing patients by age, race, region of
residence, prevalent DM, CHF, IHD, and ischemic stroke/TIA, baseline use of SPS, RAAS
inhibitors, loop diuretics and antiplatelet agents, BMI and index eGFR using singly imputed data. Potential interactions between dyskalemia categories and selected subgroups
were tested by including interactions terms. We conducted several sensitivity analyses.
The exposure-outcome association was assessed by categorizing the K+ levels into granular categorizes as K+ <3.5 mEq/L, 3.5-<4.0 mEq/L, 4.0-<4.5 mEq/L [reference], 4.5-<5.0
mEq/L, 5.0-<5.5 mEq/L, 5.5-<6.0 mEq/L, and ≥6.0 mEq/L. Further, the exposure-outcome
association was assessed amongst those without baseline history of ischemic stroke/TIA
(n=18,096). Finally, analyses were repeated using multiple imputation (imputation n=25)
and complete cases (n=12,388 [model 1-5] for baseline time-averaged K+ exposure [after
excluding missing baseline covariates]; n=6,542 [model 1-5] for time-updated K+ exposure
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[after excluding missing baseline and time-varying covariates]). Multiple imputation was
conducted using the fully conditional specification method as it performs well with both
missing continuous and categorical data (Lee and Carlin, 2010; Buuren, 2007).
Compared to those included in the cohort (n=21,357), those excluded (n=81,120)
were older (70.3 vs 68.6), less likely to be males (91.9% vs 98.2%), African Americans (24.3%
vs 28.3%), married (55.1% vs 57.7%), current smokers (19.8% vs 32.5%), and have DM (59.6%
vs 69.1%). A two-sided p-value of <0.05 was used as a threshold of statistical significance.
Analyses were conducted in SAS Enterprise guide v8.2 (SAS Institute; Cary, NC) and
STATA/MP Version 15 (STATA Corporation, College Station, TX). The study was approved
by the Institutional Review Board of the Memphis VA Medical center, with exemption from
informed consent.

3.3
3.3.1

Results
Baseline characteristics

Baseline characteristics of the study sample are described in Table 3.1. The mean (SD) age
of the sample was 68.6 (10.4) years; 98.2% were males; 28.3% were African American; and
68.1% had DM. The most commonly used medications were lipid lowering agents (76.9%),
RAAS inhibitors (74.4%), and beta blockers (68.6%). Approximately 8% of the patients
used SPS. The median (25-75th percentile) index eGFR was 24.8 (20.9-27.6) ml/min/1.73m2 .
Patients had a median (25-75th percentile) of 3 (2-6) K+ measurements, with a mean (SD)
K+ of 4.5 (0.5) mEq/L in the baseline. Approximately 3% and 1.9% of the sample had
time-averaged baseline K+ levels >5.5 mEq/L and <3.5 mEq/L, respectively. Those with
time-averaged baseline K+ levels >5.5 mEq/L were more likely to be older, white, have
prevalent hyperlipidemia and anemia, SPS users and have lower eGFR, HCO3 - , SBP, DBP,
and BMI levels. Conversely, those with time-averaged baseline K+ levels <3.5 mEq/L
were more likely to be younger, African American, users of loop, K+ sparing, and thiazide
diuretics and insulin, and have higher eGFR, HCO3 - , SBP, DBP, and BMI levels.

3.3.2

Association of baseline time-averaged dyskalemia categories (chronic exposure) with ischemic stroke

A total of 2,638 (12.4%) ischemic stroke events (crude event rate 41.9 per 1,000 patient
years; 95% CI 40.4-43.6) occurred over a median (25-75th percentile) follow-up time of 2.56
(1.59-3.89) years. Crude event rates for the overall cohort and by baseline time-averaged K+
categories are shown in Table 3.2.
In the unadjusted analysis, only hypokalemia was associated with higher risk of
ischemic stroke (hazard ratio [HR], 95% CI: 1.37, 1.06-1.76) (Figure 3.3 [Model 1]). Similarly,
in the multivariable-adjusted model, only hypokalemia (HR, 95% CI: 1.35, 1.01-1.81) was
associated with higher risk of ischemic stroke (Figure 3.3 [Model 4]). The association for
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Table 3.1: Sample baseline characteristics for Aim 2 (n=21,357).
Characteristic
Age at index (years)
Males
Race
White
African American
Other
Married
Region
Northeast
Mid-West
South
West
Other
Income ($)
Smoking status
Current
Past
Never
Comorbidities
Diabetes Mellitus
Congestive heart failure
Hypertension
Hyperlipidemia
Peripheral vascular disease
Cerebrovascular disease
Chronic lung disease
Peptic ulcer disease
Ischemic heart disease
Paraplegia/hemiplegia
Anemia
Atrial fibrillation
Liver disease
Malignancies
Ischemic stroke/Transient ischemic stroke
Charlson comorbidity index
Utilization measures
Outpatient visits
Hospital visits
Emergency room visits
Nephrology visits
Medications
RAAS inhibitors
Loop diuretics
K+ sparing diuretics
Thiazide diuretics
SPS
NSAIDs
Digoxin
Beta blockers
Calcium channel blockers
Anticoagulants
Antiplatelets
Lipid lowering agents
Antiarrhythmics
Aspirin
Insulin
Oral hypoglycemics
Calcineurin inhibitors
Trimethoprim
Azole antifungals
β2 agonists
Laxatives
Vitals
Body mass index, kg/m2
Systolic blood pressure, mm/Hg
Diastolic blood pressure, mm/Hg
Low density lipoprotein, mg/dl
High density lipoprotein, mg/dl
Total cholesterol, mg/dl
Triglycerides, mg/dl
Laboratory measures
Index eGFR, ml/min/1.73m2
Average K+ , mEq/L
Number of K+ measurements
Bicarbonate, mEq/L
Sodium, mEq/L
At least 1 dyskalemia event
K+ >5.5 mEq/L
K+ <3.5 mEq/L
Both K+ <3.5 and K+ >5.5 mEq/L

All
(N=21,357)

K+ <3.5 mEq/L
(N=402)

K+ 3.5-5.5 mEq/L
(N=20,287)

K+ >5.5 mEq/L
(N=668)

68.6 (10.4)
20,963 (98.2)

65.6 (10.2)
395 (98.3)

68.6 (10.4)
19,912 (98.2)

70.6 (10.2)
656 (98.2)

14,712 (68.9)
6,044 (28.3)
601 (2.8)
12,309 (57.7)

190 (47.3)
203 (50.5)
9 (2.2)
216 (54.0)

13,392 (68.9)
5,725 (28.2)
570 (2.8)
11,670 (57.6)

530 (79.3)
116 (17.4)
22 (3.3)
423 (63.3)

3,155 (14.8)
4,776 (22.4)
9,648 (45.2)
3,459 (16.2)
305 (1.4)
18,036
(6,492-34,662)

36 (8.9)
87 (21.6)
229 (56.9)
46 (11.4)
4 (1.0)
17,734
(4,524-34,992)

3,007 (14.8)
4,562 (22.5)
9,105 (44.9)
3,332 (16.4)
267 (1.3)
18,036
(6,684-34,675)

112 (16.8)
127 (19.0)
314 (47.0)
81 (12.1)
34 (5.1)
18,042
(1,722-33,876)

P-value
<0.0001a
0.98b
<0.0001b

0.008b
<0.0001b

0.58c
0.18b

6,928 (32.5)
7,524 (35.3)
6,892 (32.3)

122 (30.4)
134 (33.3)
146 (36.3)

6,610 (32.6)
7,147 (35.3)
6,517 (32.1)

196 (29.3)
243 (36.4)
229 (34.3)

14,752 (69.1)
7,466 (34.9)
20,678 (96.8)
16,669 (78.1)
6,579 (30.8)
5,359 (25.1)
6,308 (29.5)
1,001 (4.7)
10,573 (49.5)
507 (2.4)
10,145 (47.5)
2,456 (11.5)
1,563 (7.3)
4,238 (19.8)
3,261 (15.3)
4 (2-6)

284 (70.7)
153 (38.1)
392 (97.5)
289 (71.9)
96 (23.9)
87 (21.6)
107 (26.6)
14 (3.5)
195 (48.5)
8 (1.9)
167 (41.5)
55 (13.7)
33 (8.2)
71 (17.7)
64 (15.9)
3 (2-5)

14,004 (69.0)
7,097 (34.9)
19,649 (96.9)
15,842 (78.1)
6,257 (30.8)
5,095 (25.1)
6,013 (29.6)
948 (4.7)
10,032 (49.5)
489 (2.4)
9,624 (47.4)
2,321 (11.4)
1,491 (7.4)
4,044 (19.9)
3,109 (15.3)
4 (2-6)

464 (69.5)
216 (32.3)
637 (95.4)
538 (80.5)
226 (33.8)
177 (26.5)
188 (28.1)
39 (5.8)
346 (51.8)
10 (1.5)
354 (52.9)
80 (11.9)
39 (5.8)
123 (18.4)
88 (13.2)
4 (2-6)

0.77b
0.16b
0.07b
0.004b
0.003b
0.19b
0.31b
0.19b
0.45b
0.27b
0.001b
0.35b
0.26b
0.34b
0.29b
0.22c

16 (9-28)
0 (0-1)
0 (0-1)
0 (0-1)

17 (10-28)
0 (0-1)
0 (0-1)
0 (0-1)

17 (9-28)
0 (0-1)
0 (0-1)
0 (0-1)

12 (7-20)
0 (0-1)
0 (0-0)
0 (0-0)

<0.0001c
<0.0001c
0.009c
<0.0001c

15,892 (74.4)
11,986 (56.1)
1,955 (9.2)
6,969 (32.6)
1,684 (7.9)
7,188 (33.7)
1,007 (4.7)
14,650 (68.6)
14,089 (65.9)
1,839 (8.6)
3,300 (15.5)
16,441 (76.9)
499 (2.3)
6,004 (28.1)
8,698 (40.7)
7,506 (35.2)
227 (1.1)
392 (1.8)
2,304 (10.8)
3,224 (15.1)
5,881 (27.5)

292 (72.6)
253 (62.9)
76 (18.9)
228 (56.7)
2 (0.5)
137 (34.1)
22 (5.5)
303 (75.4)
307 (76.4)
42 (10.5)
41 (10.2)
297 (73.9)
16 (3.9)
106 (26.4)
177 (44.0)
153 (38.1)
4 (1.0)
9 (2.2)
34 (8.5)
57 (14.2)
101 (25.1)

15,114 (74.5)
11,428 (56.3)
1,840 (9.1)
6,547 (32.3)
1,496 (7.4)
6,892 (33.9)
961 (4.7)
13,931 (68.7)
13,414 (66.1)
1,757 (8.7)
3,157 (15.6)
15,638 (77.1)
468 (2.3)
5,783 (28.5)
8,291 (40.9)
7,103 (35.0)
215 (1.1)
368 (1.8)
2,225 (10.9)
3,095 (15.3)
5,674 (27.9)

486 (72.8)
305 (45.7)
39 (5.8)
194 (29.0)
186 (27.8)
159 (23.8)
24 (3.6)
416 (62.3)
368 (55.1)
40 (5.9)
102 (15.3)
506 (75.8)
15 (2.3)
115 (17.2)
230 (34.4)
250 (37.4)
8 (1.2)
15 (2.3)
45 (6.7)
72 (10.8)
106 (15.9)

0.42b
<0.0001b
<0.0001b
<0.0001b
<0.0001b
<0.0001b
0.30b
<0.0001b
<0.0001b
0.02b
0.01b
0.24b
0.09b
<0.0001b
0.002b
0.20b
0.93b
0.59b
0.0009b
0.006b
<0.0001b

29.9 (6.1)
143.6 (16.3)
74.9 (10.8)
94.5 (36.6)
40.0 (13.1)
172.1 (47.1)
188.5 (145.3)

31.4 (6.3)
147.7 (18.8)
80.1 (13.2)
96.8 (40.1)
40.7 (13.2)
174.5 (50.1)
184.6 (136.6)

29.9 (6.1)
143.5 (16.2)
74.9 (10.8)
94.5 (36.6)
39.9 (13.1)
172.1 (47.1)
188.9 (146.0)

29.0 (5.8)
143.8 (17.6)
72.9 (11.0)
93.5 (35.2)
40.4 (11.8)
169.9 (43.7)
177.7 (127.3)

<0.0001a
<0.0001a
<0.0001a
0.41a
0.48a
0.35a
0.17a

24.8 (20.9-27.6)
4.5 (0.5)
3 (2-6)
24.9 (3.2)
139.5 (2.7)

24.1 (20.3-27.4)
3.3 (0.2)
3 (2-6)
27.9 (3.9)
139.9 (2.8)

24.9 (20.9-27.6)
4.5 (0.5)
3 (2-7)
24.9 (3.2)
139.5 (2.7)

23.4 (19.2-27.3)
5.7 (0.2)
2 (1-4)
22.8 (3.1)
139.4 (2.7)

<0.0001c
<0.0001a
<0.0001c
<0.0001a
0.0009a

3,709 (17.4)
2,431 (11.4)
371 (1.7)

2 (0.5)
402 (100)
2 (0.5)

3,309 (14.9)
2,029 (10.0)
369 (1.8)

668 (100)
0
0

<0.0001b
<0.0001b
0.0003b

Data are presented as n (%), mean (standard deviation), median (25-75th percentile). eGFR: estimated glomerular filtration rate;
K+ : potassium; NSAIDs: nonsteroidal anti-inflammatory drug; RAAS: renin-angiotensin-aldosterone system; SPS: sodium
polystyrene sulphonate. a p-value for one-way analysis of variance; b p-value for chi-square test; c p-value for Kruskal-Wallis
test.
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Table 3.2: Crude event rates, follow-up time and number of events
overall and by baseline time-averaged potassium categories (n=21,357).
Stroke events and
crude event rate
Follow-up time in years,
median (25-75th )
N(%) ischemic stroke events
Crude event rate
per 1,000 patient years
(95% CI)

Overall
(n=21,357)

Hypokalemia
(K+ <3.5 mEq/L)
(N=402)

Referent
(K+ 3.5-5.5 mEq/L)
(N=20,287)

Hyperkalemia
(K+ >5.5 mEq/L)
(N=668)

2.56 (1.59-3.89)

2.18 (1.42-3.43)

2.57 (1.61-3.90)

2.64 (1.67-3.87)

2,638 (12.4%)

61 (15.2)

2,489 (12.3)

88 (13.2)

41.9 (40.4-43.6)

57.9 (45.1-74.5)

41.6 (39.9-43.2)

44.4 (36.0-54.7)

CI: confidence interval; K+ : potassium; N: number.

hypokalemia (HR, 95% CI: 1.34, 0.99-1.79) was attenuated after adjustment for SBP and
DBP (Figure 3.3 [Model 5]).
Continuous K+ levels showed a non-linear association (p-value for quadratic term:
0.002), with lower K+ levels associated with higher risk of ischemic stroke (Figure 3.4).
Associations for the categorized K+ levels were robust to multiple imputation and
complete case analyses (Table 3.3A, B, respectively).
In the multivariable-adjusted model, the association of granular K+ level categories
showed a lower risk (vs K+ 4.0-<4.5 mEq/L) of ischemic stroke associated with K+ 4.5-<5.0
mEq/L (HR, 95% CI: 0.87, 0.79-0.96) and K+ 5.0-<5.5 mEq/L (HR, 95% CI: 0.84, 0.73-0.96)
(Table 3.4).
No significant differences were observed across subgroups (Table 3.5).
Amongst the 84.7% (n=18,096) without baseline history of stroke/TIA, hypokalemia
was associated with higher risk (HR, 95% CI: 1.65, 1.10-2.45) of ischemic stroke (Table 3.6).

3.3.3

Association of time-updated dyskalemia categories (acute exposure) with
ischemic stroke

Over the follow-up time (median [25-75th percentile]: 2.56 [1.59-3.89] years), there were a
total of 489,486 K+ measurements with median (25-75th percentile) of 15 (6-30) K+ measurements per patient, of which 21,382 (4.5%) and 27,318 (5.6%) were categorized as hypokalemia
and hyperkalemia, respectively. Table 3.7 shows the distribution of the K+ categories using
the last time-updated K+ level prior to ischemic stroke by the baseline time-averaged K+
categories amongst those who experienced a stroke event (n=2,368).
Table 3.8 shows the distribution of time-updated K+ categories across all K+ measurements during follow-up by baseline time-averaged K+ categories. In the unadjusted
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Figure 3.3: Association of baseline time-averaged potassium categories
with time to ischemic stroke (n=21,357). Models 1-5 conducted as
described in section 3.2.6. CI: confidence interval; K+ : potassium.

51

Chapter 3. Association of Dyskalemias with Ischemic Stroke in Advanced Chronic
Kidney Disease Patients Transitioning to Dialysis

Figure 3.4: Association of baseline continuous time-averaged potassium
with time to ischemic stroke (n=21,357). Dashed and solid lines represent
hazard ratio and 95% confidence interval, respectively. Model adjusted for
confounders accounted in model 4 as described in section 3.2.6.
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Table 3.3: Association of baseline time-averaged potassium categories
with time to ischemic stroke using multiple imputation and complete
case analyses.
Hypokalemia
(K+ <3.5 mEq/L)

Model

N (patients)
1
2
3
4 (fully-adjusted)
5 (additional model)
N (patients)
1
2
3
4 (fully-adjusted)
5 (additional model)

Referent
(K+ 3.5-5.5 mEq/L)

Hyperkalemia
(K+ >5.5 mEq/L)

(A) Multiple imputation (n=21,357)
402
20,287
1.37 (1.06-1.76)
1 [Reference]
1.33 (1.03-1.72)
1 [Reference]
1.32 (1.02-1.71)
1 [Reference]
1.35 (1.01-1.81)
1 [Reference]
1.34 (0.99-1.79)
1 [Reference]
(B) Complete case (n=12,388)
261
11,822
1.37 (0.99-1.89)
1 [Reference]
1.30 (0.94-1.80)
1 [Reference]
1.35 (0.98-1.87)
1 [Reference]
1.42 (0.98-2.05)
1 [Reference]
1.39 (0.97-2.02)
1 [Reference]

668
1.07 (0.86-1.32)
1.07 (0.87-1.33)
1.20 (0.97-1.49)
1.25 (0.98-1.59)
1.24 (0.97-1.58)
305
0.98 (0.70-1.37)
0.99 (0.71-1.39)
1.14 (0.81-1.59)
1.23 (0.85-1.78)
1.24 (0.86-1.79)

Data reported as hazard ratio (95% confidence interval). Models 1-5 conducted as
described in section 3.2.6. K+ : potassium; N: number.

Table 3.4: Association of baseline time-averaged granular potassium
categories with time to ischemic stroke (n=21,357).
K+ levels
Model
N (%) ischemic
stroke events
1
2
3
4 (fully-adjusted)
5 (additional model)

<3.5 mEq/L
(N=402)

3.5-<4.0 mEq/L
(N=2,617)

4.0-<4.5 mEq/L
(N=6,602)

4.5-<5.0 mEq/L
(N=7,369)

5.0-<5.5 mEq/L
(N=3,534)

5.5-<6.0 mEq/L
(N=738)

≥6.0 mEq/L
(N=95)

61 (15.2)

328 (12.5)

867 (13.1)

876 (11.9)

403 (11.4)

90 (12.2)

13 (13.7)

1.25 (0.97-1.62)
1.24 (0.95-1.60)
1.24 (0.96-1.61)
1.33 (0.98-1.82)
1.32 (0.97-1.79)

1.00 (0.88-1.14)
0.99 (0.87-1.13)
0.98 (0.86-1.11)
0.99 (0.86-1.14)
0.99 (0.86-1.14)

1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]

0.86 (0.78-0.95)
0.87 (0.79-0.96)
0.89 (0.82-0.98)
0.87 (0.79-0.96)
0.88 (0.79-0.97)

0.83 (0.74-0.93)
0.84 (0.75-0.95)
0.88 (0.79-0.99)
0.84 (0.73-0.96)
0.85 (0.74-0.97)

0.90 (0.73-1.12)
0.90 (0.73-1.12)
0.99 (0.79-1.23)
0.92 (0.72-1.19)
0.93 (0.72-1.20)

1.02 (0.59-1.77)
1.04 (0.60-1.80)
1.27 (0.73-2.20)
1.18 (0.67-2.09)
1.18 (0.67-2.08)

Data reported as hazard ratio (95% confidence interval). Models 1-5 conducted as described in section 3.2.6. K+ : potassium; N: number.
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Table 3.5: Association of baseline time-averaged potassium categories
with time to ischemic stroke by subgroups (n=21,357).
Subgroup
N (%) ischemic stroke events
Age <65 years (n=7,930)
Age ≥65 years (n=13,427)
White (n=14,712)
African American (n=6,044)
Residence in US South (n=9,650)
Residence in other US regions (n=11,707)
Diabetes Mellitus (n=14,752)
No diabetes Mellitus (n=6,605)
Congestive heart failure (n=7,466)
No congestive heart failure (n=13,891)
Ischemic heart disease (n=10,573)
No ischemic heart disease (n=10,784)
Stroke/TIA (n=3,261)
No stroke/TIA (n=18,096)
RAAS inhibitors (n=15,982)
No RAAS inhibitors (n=5,465)
SPS (n=1,684)
No SPS (n=19,673)
Loop diuretics (n=11,986)
No loop diuretics (n=9,371)
Antiplatelet agents (n=3,300)
No antiplatelet agents (n=18,057)
BMI <30 kg/m2 (n=12,102)
BMI ≥30 kg/m2 (n=9,255)
eGFR <20 ml/min/1.73m2 (n=4,373)
eGFR ≥20 ml/min/1.73m2 (n=16,984)

Hypokalemia
(K+ <3.5 mEq/L)
(N=402)

Referent
(K+ 3.5-5.5 mEq/L)
(N=20,287)

Hyperkalemia
(K+ >5.5 mEq/L)
(N=668)

61 (15.2)
1.55 (1.00-2.38)
1.25 (0.84-1.88)
1.33 (0.87-2.04)
1.35 (0.89-2.04)
1.38 (0.94-2.04)
1.31 (0.93-1.84)
1.31 (0.93-1.84)
1.51 (0.83-2.75)
1.01 (0.64-1.62)
1.79 (1.22-2.62)
1.29 (0.85-1.96)
1.59 (1.04-2.41)
1.18 (0.76-1.82)
1.63 (1.09-2.43)
1.43 (1.02-2.01)
1.13 (0.63-2.03)
N/A
1.41 (1.05-1.89)
1.19 (0.81-1.74)
1.69 (1.05-2.69)
1.12 (0.59-2.15)
1.43 (1.02-1.99)
1.13 (0.75-1.70)
1.65 (1.07-2.53)
0.86 (0.42-1.79)
1.50 (1.09-2.07)

2,489 (12.3)
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]

88 (13.2)
0.88 (0.51-1.52)
1.32 (1.00-1.75)
1.23 (0.93-1.62)
1.06 (0.59-1.92)
1.32 (0.93-1.89)
1.24 (0.94-1.63)
1.24 (0.94-1.63)
1.22 (0.74-2.02)
1.34 (0.92-1.98)
1.25 (0.91-1.71)
1.12 (0.82-1.53)
1.52 (1.02-2.25)
1.26 (0.86-1.86)
1.23 (0.90-1.69)
1.29 (0.97-1.69)
1.05 (0.63-1.74)
1.34 (0.83-2.18)
1.18 (0.88-1.57)
0.97 (0.66-1.43)
1.53 (1.10-2.13)
0.75 (0.45-1.26)
1.49 (1.13-1.97)
1.32 (0.98-1.79)
1.13 (0.75-1.71)
1.39 (0.82-2.38)
1.20 (0.91-1.59)

P-value
for
interaction
0.31
0.63
0.75
0.77
0.22
0.36
0.95
0.99
0.61
0.22
0.63
0.90
0.22

Data reported as hazard ratio (95% confidence interval). Model conducted using confounders in model 4 as
described in section 3.2.6. BMI: body mass index; eGFR; estimated glomerular filtration rate; K+ : potassium; N:
number; N/A: not applicable; RAAS: renin-angiotensin-aldosterone system; SPS: sodium polystyrene sulphonate;
TIA: transient ischemic stroke.
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Table 3.6: Association of baseline time-averaged potassium categories
with time to ischemic stroke amongst those without baseline history of
stroke (n=18,096).

Model
N (%) ischemic stroke events
1
2
3
4 (fully-adjusted)
5 (additional model)

Hypokalemia
(K+ <3.5 mEq/L)
(N=338)

Referent
(K+ 3.5-5.5 mEq/L)
(N=17,178)

Hyperkalemia
(K+ >5.5 mEq/L)
(N=580)

34 (10.1)
1.36 (0.97-1.91)
1.36 (0.96-1.91)
1.40 (0.99-1.97)
1.63 (1.09-2.43)
1.65 (1.10-2.45)

1,424 (8.3)
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]

54 (9.3)
1.12 (0.85-1.46)
1.11 (0.85-1.46)
1.09 (0.83-1.44)
1.23 (0.90-1.69)
1.22 (0.89-1.67)

Data reported as hazard ratio (95% confidence interval). Models 1-5 conducted as
described in section 3.2.6. K+ : potassium; N: number.

Table 3.7: Distribution of potassium categories using the last
time-updated potassium level prior to ischemic stroke by baseline
time-averaged potassium categories amongst those experiencing
ischemic stroke (n=2,368).

Baseline time-averaged K+
Time-updated

K+

Hypokalemia
(K+ <3.5 mEq/L)
Referent
(K+ 3.5-5.5 mEq/L)
Hyperkalemia
(K+ + >5.5 mEq/L)

Hypokalemia
(K+ <3.5 mEq/L)
(N=61)

(K+

Referent
3.5-5.5 mEq/L)
(N=2,489)

Hyperkalemia
(K+ >5.5 mEq/L)
(N=88)

14 (22.9)

63 (2.5)

0

47 (77.1)

2,324 (93.4)

64 (72.7)

0

102 (4.1)

24 (27.3)

Data reported as N (%). K+ : potassium; N: number.
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Table 3.8: Distribution of time-updated potassium categories by baseline
time-averaged potassium categories (n=21,357).
Time-updated K+
Baseline time-averaged K+

N of time-updated
K+ measurementsa

Hypokalemia
(K+ <3.5 mEq/L)

Referent
(K+ 3.5-5.5 mEq/L)

Hyperkalemia
(K+ >5.5 mEq/L)

At least 1 event belonging
to other two
K+ categoriesb

8,452

5.4

90.5

4.1

11.9

470,354

26.8

72.3

0.9

10.2

10,680

1.1

80.8

18.1

8.9

Hypokalemia
(K+ <3.5 mEq/L)
(N=402)
Referent
(K+ 3.5-5.5 mEq/L)
(N=20,287)
Hyperkalemia
(K+ >5.5 mEq/L)
(N=668)

Data presented as row percentages unless otherwise noted. a Number of time-updated K+ measurements by baseline time-averaged
K+ levels; b Row percentages reporting percentage of patients in each baseline time-averaged K+ category who had at least one event
belonging to each of the K+ categories (using time-updated K+ levels) other than for which data is reported. K+ : potassium; N: number.

analysis, hyperkalemia was associated with lower risk of ischemic stroke (HR, 95% CI: 0.75,
0.63-0.89; Figure 3.5 [Model 1]. The results were similar in the multivariable-adjusted model
(HR, 95% CI: 0.82, 0.68-0.98; Figure 3.5 [Model 4]. Results were similar after adjusting for
SBP and DBP (HR, 95% CI: 0.82, 0.68-0.98; Figure 3.5 [Model 5].
Continuous K+ levels showed a non-linear association (p-value for quadratic term:
0.009), with higher K+ levels associated lower risk of ischemic stroke (Figure 3.6).
Association of time-updated K+ categories with time to ischemic stroke were similar to the main analysis when using multiple imputation and complete case analyses
(Table 3.9A, B, respectively). In the multivariable-adjusted model, the association of granular K+ level categories showed a lower risk (vs K+ 4.0-<4.5 mEq/L) of ischemic stroke
associated with K+ 5.5-<6.0 mEq/L (HR, 95% CI: 0.81, 0.67-0.98) (Table 3.10).
In the subgroup analysis, significant differences were observed by region of residence
(Table 3.11).
Amongst the 84.7% (n=18,096) without baseline history of stroke/TIA, lower risk of
ischemic stroke associated with hyperkalemia could no longer be established (Table 3.12).

3.4

Discussion

In a nationally representative cohort of US veterans with advanced CKD who transitioned
to dialysis, in the pre-dialysis period, hypokalemia (chronic exposure) was associated with
a higher risk of ischemic stroke irrespective of baseline history of ischemic stroke/TIA.
Conversely, hyperkalemia (time-updated, acute exposure) was associated with a lower risk
of ischemic stroke. Our results for both the chronic and acute exposure were robust to
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Figure 3.5: Association of time-updated potassium categories with time
to ischemic stroke (n=21,357). Models 1-5 conducted as described in section
3.2.6 with further accounting for baseline time-averaged potassium and
sodium levels and time-varying medications, estimated glomerular filtration
rate and sodium levels in model 4 and 5. CI: confidence interval; K+ :
potassium.
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Figure 3.6: Association of continuous time-updated potassium with time
to ischemic stroke (n=21,357). Dashed and solid lines represent hazard ratio
and 95% confidence interval, respectively. Model adjusted for confounders
accounted in model 4 as described in section 3.2.6 with further accounting
for baseline time-averaged potassium and sodium levels and time-varying
medications, estimated glomerular filtration rate and sodium levels.
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Table 3.9: Association of time-updated potassium categories with time to
ischemic stroke using multiple imputation and complete case analyses.

Hypokalemia
(K+ <3.5 mEq/L)

Model

Referent
(K+ 3.5-5.5 mEq/L)

Hyperkalemia
(K+ >5.5 mEq/L)

(A) Multiple imputation (n=21,357)
N (row %) of repeated
K+ measurements
1
2
3
4 (fully-adjusted)
5 (additional model)
N (row %) of repeated
K+ measurements
1
2
3
4 (fully-adjusted)
5 (additional model)

5,508 (4.7)

105,858 (90.4)

0.96 (0.77-1.21)
1 [Reference]
0.96 (0.76-1.20)
1 [Reference]
0.89 (0.71-1.12)
1 [Reference]
0.84 (0.66-1.06)
1 [Reference]
0.84 (0.67-1.06)
1 [Reference]
(B) Complete case (n=6,542)

5,713 (4.9)
0.75 (0.63-0.89)
0.75 (0.63-0.90)
0.79 (0.66-0.94)
0.82 (0.68-0.98)
0.82 (0.68-0.98)

5,508 (4.7)

105,858 (90.4)

5,713 (4.9)

1.13 (0.79-1.61)
1.09 (0.77-1.56)
1.08 (0.76-1.54)
1.08 (0.75-1.55)
1.08 (0.75-1.56)

1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]

0.68 (0.48-0.96)
0.69 (0.49-0.97)
0.71 (0.50-0.99)
0.75 (0.53-1.08)
0.75 (0.53-1.07)

Data reported as hazard ratio (95% confidence interval). Models 1-5 conducted as
described in section 3.2.6 with further accounting for time-varying medications,
estimated glomerular filtration rate, and sodium levels and baseline time-averaged
K+ levels and sodium levels in model 4 and 5. K+ : potassium; N: number.

Table 3.10: Association of time-updated granular potassium categories
with time to ischemic stroke (n=21,357).
K+ levels
Model
N (row %) of
repeated K+ measurements
1
2
3
4 (fully-adjusted)
5 (additional model)

≥6.0 mEq/L

<3.5 mEq/L

3.5-<4.0 mEq/L

4.0-<4.5 mEq/L

4.5-<5.0 mEq/L

5.0-<5.5 mEq/L

5.5-<6.0 mEq/L

21,832 (4.5)

75,727 (15.5)

139,112 (28.4)

139,898 (28.6)

77,528 (15.8)

26,798 (5.5)

8,391 (1.7)

0.92 (0.73-1.16)
0.92 (0.73-1.16)
0.86 (0.68-1.09)
0.84 (0.66-1.06)
0.84 (0.66-1.07)

1.05 (0.92-1.19)
1.04 (0.92-1.18)
1.02 (0.89-1.16)
1.01 (0.89-1.15)
1.01 (0.89-1.15)

1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]

0.95 (0.86-1.05)
0.95 (0.86-1.05)
0.98 (0.89-1.08)
1.01 (0.91-1.12)
1.01 (0.91-1.11)

0.87 (0.78-0.98)
0.88 (0.78-0.98)
0.89 (0.79-1.01)
0.95 (0.84-1.07)
0.95 (0.84-1.07)

0.73 (0.60-0.88)
0.73 (0.61-0.89)
0.77 (0.64-0.93)
0.81 (0.67-0.98)
0.81 (0.67-0.98)

0.71 (0.51-0.98)
0.72 (0.52-0.99)
0.73 (0.64-0.93)
0.78 (0.55-1.08)
0.77 (0.55-1.08)

Data reported as hazard ratio (95% confidence interval). Models 1-5 conducted as described in section 3.2.6 with further accounting for time-varying
medications, estimated glomerular filtration rate, and sodium levels and baseline time-averaged K+ levels and sodium levels in model 4 and 5. K+ :
potassium; N: number.
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Table 3.11: Association of time-updated potassium categories with time
to ischemic stroke by subgroups (n=21,357).
Subgroup
N (row %) of
repeated K+ measurements
Age <65 years (n=7,930)
Age ≥65 years (n=13,427)
White (n=14,712)
African American (n=6,044)
Residence in US South (n=9,650)
Residence in other US regions (n=11,707)
Diabetes Mellitus (n=14,752)
No diabetes Mellitus (n=6,605)
Congestive heart failure (n=7,466)
No congestive heart failure (n=13,891)
Ischemic heart disease (n=10,573)
No ischemic heart disease (n=10,784)
Stroke/TIA (n=3,261)
No stroke/TIA (n=18,096)
RAAS inhibitors (n=15,982)
No RAAS inhibitors (n=5,465)
SPS (n=1,684)
No SPS (n=19,673)
Loop diuretics (n=11,986)
No loop diuretics (n=9,371)
Antiplatelet agents (n=3,300)
No antiplatelet agents (n=18,057)
BMI <30 kg/m2 (n=12,102)
BMI ≥30 kg/m2 (n=9,255)
eGFR <20 ml/min/1.73m2 (n=4,373)
eGFR ≥20 ml/min/1.73m2 (n=16,984)

Hypokalemia
(K+ <3.5 mEq/L)

Referent
(K+ 3.5-5.5 mEq/L)

Hyperkalemia
(K+ >5.5 mEq/L)

21,832 (4.5)

440,336 (89.9)

27,318 (5.6)

0.76 (0.55-1.06)
1.25 (0.84-1.88)
0.78 (0.56-1.09)
0.88 (0.63-1.23)
1.05 (0.78-1.41)
0.63 (0.43-0.92)
0.80 (0.61-1.05)
0.94 (0.59-1.49)
0.67 (0.46-0.98)
0.98 (0.73-1.34)
0.81 (0.59-1.12)
0.85 (0.60-1.19)
0.74 (0.52-1.06)
0.92 (0.68-1.25)
0.92 (0.71-1.19)
0.56 (0.31-1.00)
0.78 (0.24-2.56)
0.83 (0.66-1.06)
0.87 (0.65-1.16)
0.75 (0.49-1.13)
0.67 (0.41-1.09)
0.91 (0.69-1.19)
0.70 (0.49-0.98)
0.99 (0.72-1.38)
0.78 (0.43-1.41)
0.85 (0.66-1.10)

1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]

0.89 (0.72-1.11)
1.32 (1.00-1.75)
0.85 (0.68-1.09)
0.77 (0.54-1.08)
0.97 (0.75-1.26)
0.72 (0.55-0.93)
0.81 (0.65-1.00)
0.84 (0.58-1.22)
0.84 (0.62-1.14)
0.79 (0.63-1.01)
0.85 (0.67-1.19)
0.76 (0.57-1.02)
0.76 (0.57-1.03)
0.86 (0.68-1.09)
0.84 (0.68-1.04)
0.74 (0.51-1.08)
0.73 (0.46-1.17)
0.84 (0.69-1.03)
0.76 (0.58-0.99)
0.88 (0.68-1.13)
0.66 (0.44-0.99)
0.88 (0.72-1.09)
0.89 (0.71-1.11)
0.69 (0.49-0.96)
0.95 (0.64-1.39)
0.78 (0.63-0.96)

P-value
for interaction

0.09
0.67
0.04
0.75
0.15
0.55
0.83
0.33
0.96
0.39
0.44
0.18
0.19

Data reported as hazard ratio (95% confidence interval). Model conducted using confounders in model 4 as described
in section 3.2.6 with further accounting for time-varying medications, estimated glomerular filtration rate, and sodium
levels and baseline time-averaged K+ levels and sodium levels. BMI: body mass index; eGFR: estimated glomerular
filtration rate; K+ : potassium; N: number; RAAS: renin-angiotensin-aldosterone system; SPS: sodium polystyrene
sulphonate; TIA: transient ischemic stroke.
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Table 3.12: Association of time-updated potassium categories with time
to ischemic stroke amongst those without baseline history of stroke
(n=18,096).
Model
N (row %) of
repeated K+ measurements
1
2
3
4 (fully-adjusted)
5 (additional model)

Hypokalemia
(K+ <3.5 mEq/L)

Referent
(K+ 3.5-5.5 mEq/L)

Hyperkalemia
(K+ >5.5 mEq/L)

19,144 (4.4)

390,973 (89.9)

24,489 (5.6)

0.97 (0.72-1.32)
0.98 (0.73-1.33)
0.95 (0.70-1.29)
0.92 (0.68-1.25)
0.92 (0.68-1.26)

1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]

0.79 (0.63-1.00)
0.81 (0.64-1.01)
0.82 (0.65-1.03)
0.86 (0.68-1.09)
0.85 (0.67-1.08)

Data reported as hazard ratio (95% confidence interval). Models 1-5 conducted as
described in section 3.2.6 with further accounting for time-varying medications, estimated glomerular filtration rate, and sodium levels and baseline time-averaged K+
levels and sodium levels in model 4 and 5. K+ : potassium; N: number.

various sensitivity analyses including use of granular K+ categories, amongst those without
baseline history of ischemic stroke/TIA, complete case analysis, and multiple imputation.
Our results align with existing research which suggests that hypokalemia (chronic
exposure) is associated with higher risk of ischemic stroke. Amongst diuretic users (Green et
al., 2002), general population (Mattsson et al., 2018), and a treated hypertensive population
(Smith et al., 2003), hypokalemia was associated with a 2.5-, 2.1-, and 2-fold higher risk
of ischemic stroke, respectively. On the other hand, in a general population (Johnson,
Mattsson, et al., 2017), K+ levels between 4.3-8.4 mmol/L and a 1 mEq/L increase in K+
levels were associated with 1.3-fold higher risk of ischemic stroke. However, all these
studies are characterized by the use of baseline K+ levels (chronic exposure) to define
dyskalemias and long follow-up times for outcome assessment (minimum follow-up 1 year
and maximum median follow-up 26.9 years) (Green et al., 2002; Johnson, Mattsson, et al.,
2017; Mattsson et al., 2018; Smith et al., 2003).
Previous studies have hypothesized that hypokalemia might be a marker of increased
RAAS activity (Brown and Brown, 1986) and an increased activity in the systemic and
cerebral RAAS system could potentiate the effect of a stroke, by resulting in more extensive
neurologic damage and neurologic deficits (Mattsson et al., 2018). This may explain the
association of hypokalemia (chronic exposure) with higher risk of ischemic stroke. Further,
after adjusting for BP, we observed that the association of hypokalemia and ischemic stroke
was no longer statistically significant. The attenuation of the association of hypokalemia
with ischemic stroke after accounting for BP might be due to the mediating effects of BP on
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the hypokalemia-ischemic stroke relationship (described in detail below).
To determine the short-term risk associated with dyskalemias, we also assessed the
association of time-updated dyskalemias (acute exposure) with ischemic stroke where we
observed that hyperkalemia (and higher levels of K+ ) was associated with a lower risk
of ischemic stroke. Several studies (animal models and epidemiological research) (Brace,
1974; Dolson et al., 1995; Haddy, 1975; Haddy, Vanhoutte, and Feletou, 2006; Ma, Mamaril,
and Young, 2000; Paller and Linas, 1982; Pikilidou et al., 2007; Webb and Bohr, 1978; Webb,
1982), suggested that higher levels of K+ lead to vasodilation, whereas lower levels of K+
lead to vasoconstriction by exerting effects through the Na+ /K+ -ATPase in the vascular
smooth muscle cell.
A recent study (Li et al., 2018) in a rat model observed that elevated serum K+
levels alleviated cerebral ischemia-reperfusion injury. The lower risk of ischemic stroke
associated with time-updated hyperkalemia levels could be explained by these biological
changes exerted by higher levels of K+ , especially in the acute setting. Patients with
advanced CKD are at a higher risk of hyperkalemia (Dashputre, Sumida, Potukuchi, et
al., 2021; Gilligan and Raphael, 2017) and the hemodynamic effects exerted by repeated
hyperkalemia events may acutely potentiate lower BP levels and hence lower the risk of
ischemic stroke. It is also noteworthy that in our cohort, we observed that those in the
hyperkalemia group (vs hypokalemia group) based on the baseline time-averaged K+ levels
had lower SBP (143.8 vs 147.7 mmHg) and DBP (72.9 vs 80.1 mmHg) levels, which supports
the hypothesis that vasodilatory effects of hyperkalemia could lower the risk of ischemic
stroke. Further, higher dietary intake of K+ is associated with better BP control and lower
risk of ischemic stroke (Filippini et al., 2020; Hunt and Cappuccio, 2014; Vinceti et al., 2016).
However, current guidelines recommend restriction of dietary intake of K+ due to the risk
of hyperkalemia,180 despite the lack of association between dietary K+ intake and serum
K+ levels or hyperkalemia (Clase et al., 2020) and the known health benefits of high dietary
K+ intake (Palmer and Clegg, 2019). However, lack of dietary K+ intake data did not allow
us to assess the association of dietary intake of K+ (in concurrence with serum K+ ) with
ischemic stroke.
Our study results need to be interpreted in light of several limitations. First, our
cohort consisted of predominantly male US veterans, thus limiting generalizability to
women or to a broader general population. Second, we cannot infer causality due to
the observational nature of the study. Thirdly, we cannot eliminate the possibility of
unmeasured confounding due to lack of access to dietary intake of K+ . Several studies have
noted the beneficial effects of dietary K+ intake and lowering of BPand stroke risk (Filippini
et al., 2020; Hunt and Cappuccio, 2014; Vinceti et al., 2016). Finally, our source cohort
is designed such that outcomes such as mortality are only observed following dialysis
initiation, but for this study we assessed dyskalemia-ischemic stroke association in the
pre-dialysis period. Thus, caution should be exercised when interpreting the association of
time-updated hyperkalemia and lower risk of ischemic stroke, as dyskalemias are associated
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with short-term risk of death,105,132 which could not be ascertained due to the nature of
our cohort.

3.5

Conclusion

In conclusion, in patients with advanced CKD transitioning to dialysis, in the pre-dialysis
period, hypokalemia as a chronic exposure was associated with a higher risk of ischemic
stroke, while hyperkalemia as an acute exposure was associated with lower risk of ischemic
stroke. While the association of hypokalemia with higher risk of ischemic stroke aligns
with published literature in other patient populations, the association of hyperkalemia as
an acute exposure with lower risk of ischemic stroke is novel; hence, further studies are
needed to explore the latter association and shed light on the possible mechanisms driving
this relationship.
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Chapter 4
Association of Dyskalemias with Short-term
Hospital/Emergency Room Utilization in Advanced
Chronic Kidney Disease Patients Transitioning to
Dialysis1

4.1

Introduction

Chapter 4 describes the research question undertaken for Aim 3, mentioned in section
1.4. Briefly, chapter 4 describes association of dyskalemias with short-term hospital/ER
utilization (in the pre-dialysis period) in an advanced CKD population transitioning to
dialysis.
Potassium levels are maintained within a narrow range of 3.5-5.0 mEq/L by the kidneys, thus patients with CKD are prone to dyskalemias (hypo-and hyperkalemia, especially
the latter) due to the declining kidney function (Kovesdy, Matsushita, et al., 2018; Palmer
and Clegg, 2019). Additionally, patients with CKD have a higher burden of comorbidities such as DM and CVD, use medications such as RAAS inhibitors and diuretics, and
are recommended a reduced dietary intake of K+ , all of which are known risk factors for
dyskalemias, and further increase the risk of experiencing dyskalemias in CKD (Clase et al.,
2020; Gilligan and Raphael, 2017; Kovesdy, Appel, et al., 2017; Palmer and Clegg, 2019). The
prevalence of hypo- and hyperkalemia in CKD (irrespective of CKD stage and depending
on the K+ threshold) is between 12-31% and 14-41%, respectively, with a higher prevalence
amongst those with advanced CKD (Dashputre, Sumida, Potukuchi, et al., 2021; Gilligan
and Raphael, 2017; Korgaonkar et al., 2010; Luo et al., 2016; Moranne et al., 2009; Nakhoul
et al., 2015). Across various populations, dyskalemias are associated with adverse outcomes
1 Portions of chapter from previously published article; final submission modified with permission of
Journal of Managed Care and Specialty Pharmacy. A. A. Dashputre, J. Gatwood, et al. (2021). “Association of
dyskalemias with short-term health care utilization in patients with advanced CKD”. in: J Manag Care Spec
Pharm 27.10, pp. 1403–1415. ISSN: 2376-1032 (Electronic). DOI: 10.18553/jmcp.2021.27.10.1403. URL:
https://www.ncbi.nlm.nih.gov/pubmed/34595956
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including higher mortality, cardiovascular events, and healthcare burden (Dashputre, Sumida, Potukuchi, et al., 2021; Fitch et al., 2017; Korgaonkar et al., 2010; Kovesdy, Matsushita,
et al., 2018; Luo et al., 2016).
Dyskalemias induce arrhythmias and may also lead to sudden cardiac death (Gilligan
and Raphael, 2017; Kovesdy, Appel, et al., 2017) which may require immediate hospital/ER
visits. Previous research in CKD and hemodialysis populations suggests that dyskalemias
are associated with higher risk of hospital and ER visits (Brunelli et al., 2017; Fitch et al.,
2017; Kim et al., 2019; Luo et al., 2016; Polson et al., 2017; Sharma, Alvarez, Woods, Fogli,
et al., 2021). Some of the previous studies (Fitch et al., 2017; Kim et al., 2019; Polson et al.,
2017; Sharma, Alvarez, Woods, Fogli, et al., 2021) assessed the association of hyperkalemia
(using a single K+ value) with hospital/ER visits observed over 6-months or more following
a measured K+ value. Others (Brunelli et al., 2017; Luo et al., 2016), used repeated K+ values
and assessed outcomes over patient-period following each K+ value or within 4 days of
K+ measurement. While the studies using a single K+ value (Fitch et al., 2017; Kim et al.,
2019; Polson et al., 2017; Sharma, Alvarez, Woods, Fogli, et al., 2021) showed how a single
dyskalemia event might affect future distant outcomes, the latter two studies (Brunelli et al.,
2017; Luo et al., 2016) –using repeated K+ values and short outcome assessments period
–better mimic the transient nature of dyskalemia-associated events.
Patients with advanced CKD transitioning to dialysis represent a unique population
with high comorbidity burden (e.g. hypertension and CVD) and in frequent need of
pharmacotherapeutic interventions (e.g. RAAS inhibitors and diuretics) (Johansen et al.,
2021). These patients are thus at a higher risk of dyskalemias (especially hyperkalemia)
due to the gradually declining kidney function, comorbidities, and use of medications
affecting K+ levels and may experience higher rates of dyskalemia-associated hospital/ER
visits. Though, previous studies in CKD have described the association of dyskalemias
with hospital/ER visits, they are either limited by use of single K+ value and long outcome
assessment periods following the K+ value (Fitch et al., 2017; Kim et al., 2019; Polson et al.,
2017; Sharma, Alvarez, Woods, Fogli, et al., 2021), use of patient-period (which might
be long or short) following K+ value (Luo et al., 2016), focused on hemodialysis patients
(Brunelli et al., 2017), or focused mainly on hyperkalemia (and not hypokalemia) (Brunelli
et al., 2017; Fitch et al., 2017; Kim et al., 2019; Polson et al., 2017; Sharma, Alvarez, Woods,
Fogli, et al., 2021). Considering the limitations of the published literature, the aim of our
study was to assess the association of dyskalemias with short-term hospital/ER visits (in
the pre-dialysis period) in an advanced CKD population transitioning to dialysis. We
hypothesized that both hypokalemia and hyperkalemia are associated with a higher risk of
short-term hospital/ER visits.
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Figure 4.1: Study design for Aim 3. eGFR: estimated glomerular filtration
rate; K+ : potassium.

4.2
4.2.1

Methods
Data source

Data from the TC-CKD cohort was used to address this research aim. Section 2.2.1 describes
the TC-CKD cohort in detail.

4.2.2

Study population

The aim of this study was to assess the association between dyskalemias with short-term
hospital/ER visits in the pre-dialysis period of an advanced CKD population transitioning
to dialysis. To assess this association, an initial sample of 60,520 US Veterans with predialysis outpatient eGFR data was identified from the TC-CKD cohort. Amongst these, we
identified 36,644 with two outpatient eGFR <30 ml/min/1.73m2 measured 90-365 days
apart, with the second eGFR serving as the index. Further, the sample was restricted to
23,363 with at least one-year each of look back period (baseline) and follow-up period
(prior to dialysis initiation) from the index. Amongst these, 21,602 had at least 1 K+ value
(inpatient/outpatient) in the baseline (to establish a baseline K+ value) and 1 outpatient
K+ (oK+ ; to establish exposure K+ value) in the follow-up period. Finally, we excluded
236 patients (age <18 years at index [n=1] and without medication data [n=235]) to yield a
final sample size of 21,366 patients. Figure 4.1 and Figure 4.2 show the design and sample
selection criteria, respectively.
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Figure 4.2: Sample selection criteria for Aim 3. eGFR: estimated
glomerular filtration rate; K+ : potassium.
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Exposure

As discussed earlier, the aim of our study was to assess the association of dyskalemias
with short-term hospital/ER visits. For our study, the exposure of interest was the timeupdated oK+ value captured during the one-year follow-up period from the index. Each
time-updated oK+ value was categorized as hypokalemia (K+ <3.5 mEq/L), hyperkalemia
(K+ >5.5 mEq/L) and referent (3.5 ≤K+ ≤5.5 mEq/L) (Sumida et al., 2021). Potassium
levels were extracted from the Decision Support System Lab Results Extract (DSS-LAR).

4.2.4

Covariates/confounders

The covariates/confounders used in this study were identified based on published literature,
expert clinical opinion, biological reasoning, and availability in the database (Brunelli et al.,
2017; Fitch et al., 2017; Gilligan and Raphael, 2017; Kim et al., 2019; Kovesdy, Matsushita,
et al., 2018; Luo et al., 2016; Palmer and Clegg, 2019; Polson et al., 2017; Sharma, Alvarez,
Woods, Fogli, et al., 2021). Broadly, the identified covariates/confounders can be classified
as demographics, smoking status, comorbidities, healthcare utilization, medication use,
vital signs, and laboratory measures. Patient demographic characteristics (date of birth, sex,
race) were extracted from the USRDS Patient and Medical Evidence file, whereas marital
status, region of residence, and income were extracted from the VA records only and were
ascertained as of the index date (McGinnis et al., 2011; Soohoo et al., 2019). Smoking status
as of the index was ascertained from VA records and ascertained as of the index (McGinnis
et al., 2011; Soohoo et al., 2019).
Pre-existing comorbidities as of the index were identified from the VA Inpatient
and Outpatient Medical SAS, and the VA/CMS databases with a diagnosis defined as the
presence of 2 outpatient or 1 inpatient claims for the condition according to the ICD-9-CM
diagnostic and CPT codes. Comorbidities include DM, CHF, hypertension, IHD, peripheral
vascular disease, cerebrovascular disease, chronic lung disease, peptic ulcer disease, para/hemiplegia, anemia, atrial fibrillation, liver disease, and malignancies. The CCI score
was calculated using the Deyo modification for administrative datasets as a measure of
comorbidity burden with kidney disease excluded from the algorithm (Deyo, Cherkin, and
Ciol, 1992). Healthcare utilization measures including the average number of outpatient,
hospital, emergency, and nephrology visits were captured over the one-year baseline.
Data on prescribed medications were collected both in the one-year baseline and
as a time-varying covariate for the follow-up period from inpatient and outpatient VA
pharmacy dispensation records and CMS Medicare Part D. For the one-year baseline,
patients were considered to be users if they had at least one 30-day supply dispensation for
medications used for chronic therapy (RAAS inhibitors, loop diuretics, K+ sparing diuretics,
thiazide diuretics, NSAIDs, digoxin, beta blockers, calcium channel blockers, insulin, oral
hypoglycemic drugs, β2 agonist, and calcineurin inhibitors) and at least 1 dispensation
of any day supply for SPS, trimethoprim, azole antifungals, and laxatives. Time-varying
medications were captured at each oK+ measurement during the follow-up period and
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were deemed to be present if the prescription date was the same as the oK+ measurement
date or if the oK+ measurement fell within the time period covered by the day supply of
the medication. Laboratory measurements other than K+ included serum creatinine (to
calculate eGFR) and HCO3 - .
Serum creatinine was extracted from the VA CDW LabChem file, whereas HCO3 - was
extracted from the DSS-LAR. The eGFR was calculated using CKD-EPI equation (Levey,
Stevens, et al., 2009), and captured at the index as well as a time-varying confounder
captured at each time-updated oK+ . The index eGFR year as a covariate was identified as
the year when the index eGFR was ascertained. The HCO3 - levels were captured as the
average of all HCO3 - measurements in the one-year baseline. Vital signs including BMI,
SBP, and DBP were extracted from the VA CDW Vital Signs file and captured as the average
of all measurements over the one-year baseline. Finally, the number of K+ measurements,
the presence of at least one hyperkalemia event, hypokalemia event, and co-occurrence of
both hyperkalemia and hypokalemia (for the same patient) each was ascertained in the
one-year baseline.

4.2.5

Outcomes

The outcomes of interest were hospital visits and ER visits (treated as separate events)
observed within 2 calendar days of each time-updated oK+ value captured during the oneyear follow-up period from the index. A short-term outcome assessment period following
each time-updated oK+ was used due to the transient nature of the effects of dyskalemia
(Brunelli et al., 2017; Luo et al., 2016). ER visits that were observed on the same day or
on the day prior to a hospital visit were not counted as an ER visit, as they potentially
lead to the subsequent hospital visit. Reason for hospital visit was identified based on the
primary diagnosis and categorized into “diagnosis chapters” as specified by the Agency
for Healthcare Research and Quality (AHRQ) Clinical Classifications Software (CCS) for
ICD-9-CM (HCUP CCS. Healthcare Cost and Utilization Project (HCUP). March 2017.
Agency for Healthcare Research and Quality, Rockville, MD, 2017).

4.2.6

Statistical analysis

Patient characteristics were summarized for the entire analytic sample and by hypokalemia
(K+ <3.5 mEq/L), hyperkalemia (K+ >5.5 mEq/L) and referent (3.5 ≤K+ ≤5.5 mEq/L)
categories on average K+ levels in the baseline. Data were presented as counts (percentages),
mean (SD), or median (25-75th percentile) and differences across K categories were assessed
using chi-square tests, one-way analysis of variance and Kruskal-Wallis test as appropriate.
In the one-year follow-up from the index, the proportion (95% CI) of hospital and ER visits
over all the measured oK+ values were reported using binomial proportions. The association
between categorized time-updated oK+ value (clustered within each individual patient)
and hospital/ER visits within 2 calendar days of the oK+ measurement was assessed using
generalized estimating equations with a binomial distribution, logit link and independent
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correlation matrix. Incrementally multivariable-adjusted models (models 1-6) accounting
for confounders listed in section 4.2.4 were conducted as follows:
Model 1: Unadjusted.
Model 2: Model 1 + age, sex, race, marital status, region of residence, and income.
Model 3: Model 2 + smoking status, comorbidities (listed in section 4.2.4), CCI, average
of outpatient, hospital, emergency, and nephrology visits, SBP, DBP, BMI during the
baseline.
Model 4: Model 3 + baseline medication use (listed in section 4.2.4).
Model 5: Model 4 + index eGFR, index eGFR year, average K+ and HCO3 - during the
baseline, number of K+ measurements and occurrence of at least one hypokalemia
(K+ <3.5 mEq/L), hyperkalemia (K+ >5.5 mEq/L), and both (those who experienced
both hyper- and hypokalemia) event in the baseline.
Model 6: Model 5 + time-varying medications (listed in section 4.2.4) and outpatient timevarying eGFR captured on the same date as each oK+ during the one-year follow-up.
We also assessed the relationship between categorized time-varying oK+ and hospital
visits categorized as “diseases of the circulatory system” (AHRQ CCS 96-121, event of
interest; treated as a nominal multinomial outcome with “no hospital visit” as reference).
Further, we also assessed the association between categorized time-varying oK+ value
with hospital visits due to “arrhythmias” (AHRQ CCS 105-107). Similarly, we assessed the
relationship between categorized time-varying oK+ value and hospital visit categorized
as “endocrine, nutritional, and metabolic diseases and immunity disorders” (AHRQ CCS
48-58, event of interest; treated as a nominal multinomial outcome with “no hospital visit”
as reference). Further, we also assessed the association between categorized time-varying
oK+ value with hospital visits due to “fluid and electrolyte disorders” (AHRQ CCS 55). For
these analyses, the generalized estimating equations model with a nominal multinomial
distribution, a logit link, and an independent correlation matrix with the incrementally
multivariable-adjusted models as discussed above was used.
Missingness was observed for marital status (0.05%), smoking status and region
of residence (0.07% each), SBP and DBP (0.7% each), BMI (10.8%), HCO3 - (22.2%) and
time-varying eGFR (13.5%). Baseline characteristics (marital status, smoking status, region
of residence, SBP, DBP, BMI, and HCO3 - ) were imputed using single regression imputation,
modeled on other complete covariates. Time-varying eGFR was imputed by estimating the
eGFR values based on intra-individual eGFR slopes calculated from linear mixed-effects
models using all available outpatient eGFR measured over the one-year follow-up. The
main analysis (models 1-6) was conducted using singly imputed data.
We conducted subgroup analyses after categorizing patients by age, race, region
of residence, prevalent DM and CHF, baseline use of SPS, RAAS inhibitors, and loop
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diuretics, and index eGFR using singly imputed data. Potential interactions between
dyskalemia categories and selected subgroups were tested by including interactions terms.
The exposure-outcome association was assessed by categorizing the oK+ into granular
categorizes as oK+ <3.5 mEq/L, 3.5-<4.0 mEq/L, 4.0-<4.5 mEq/L (reference), 4.5-<5.0
mEq/L, 5.0-<5.5 mEq/L, 5.5-<6.0 mEq/L, and ≥6.0 mEq/L using singly imputed data.
Finally, analyses were repeated using multiple imputation (imputation n=25) for baseline
characteristics using the fully conditional specification method (Lee and Carlin, 2010;
Buuren, 2007) and complete cases (n=11,239 for models 1-6) after excluding those with
missing baseline covariates and time-varying eGFR.
Compared to those included in the study cohort (n=21,366), those excluded (n=81,111)
were older (70.3 vs 68.6), less likely to be males (91.9% vs 98.1%), African Americans (24.3%
vs 28.3%), married (55.1% vs 57.7%), current smokers (19.8% vs 32.5%), and have DM (59.5%
vs 68.9%). A two-sided p-value of <0.05 was used as a threshold of statistical significance
for all statistical analyses. All analyses were conducted in SAS Enterprise guide v8.2 (SAS
Institute; Cary, NC) and STATA/MP Version 15 (STATA Corporation, College Station, TX).
The study was approved by the Institutional Review Board of the Memphis VA Medical
center with exemption from informed consent.

4.3
4.3.1

Results
Baseline characteristics

Table 4.1 describes the baseline characteristics of the study sample. The mean (SD) age of
the sample was 68.6 (10.4) years; 98.1% were males; 28.3% were African Americans; and
68.9% had DM. The most commonly used medications were RAAS inhibitors (74.5%), beta
blockers (68.7%), and calcium channel blockers (66.1%). Approximately 8% of the patients
used SPS. The median (25-75th percentile) index eGFR was 24.8 (20.9-27.6) ml/min/1.73m2 .
Patients had a median (25-75th percentile) of 3 (2-6) K+ measurements, with a mean (SD)
K+ of 4.5 (0.5) mEq/L in the baseline. At least 1 hyperkalemia and hypokalemia event in
the baseline was experienced by 17.3% and 11.3% patients, respectively. Approximately
3% and 1.9% of the sample had average baseline K+ levels >5.5 mEq/L and <3.5 mEq/L,
respectively. Those with average baseline K+ levels >5.5 mEq/L were more likely (all
p-values <0.05) to be older, white, married, have prevalent peripheral vascular disease and
anemia, SPS users and have lower eGFR, HCO3 - , SBP, DBP, and BMI levels.

4.3.2

Exposure potassium characteristics

During the one-year follow-up, a total of 125,266 oK+ values were observed, with a median (25-75th percentile) of 5 (2-8) measurements/patient, of which 6.8% and 3.7% were
categorized as hyper- and hypokalemia, respectively.
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Table 4.1: Sample baseline characteristics for Aim 3 (n=21,366).
Characteristic
Age at index (years)
Males
Race
White
African American
Other
Married
Region
Northeast
Mid-West
South
West
Other
Income ($)
Smoking status
Current
Past
Never
Comorbidities
Diabetes Mellitus
Congestive heart failure
Hypertension
Peripheral vascular disease
Cerebrovascular disease
Chronic lung disease
Peptic ulcer disease
Ischemic heart disease
Paraplegia/hemiplegia
Anemia
Atrial fibrillation
Liver disease
Malignancies
Charlson comorbidity index
Utilization measures
Outpatient visits
Hospital visits
Emergency room visits
Nephrology visits
Medications
RAAS inhibitors
Loop diuretics
K+ sparing diuretics
Thiazide diuretics
SPS
NSAIDs
Digoxin
Beta blockers
Calcium channel blockers
Insulin
Oral hypoglycemics
Calcineurin inhibitors
Trimethoprim
Azole antifungals
β2 agonists
Laxatives
Vitals
Body mass index, kg/m2
Systolic blood pressure, mm/Hg
Diastolic blood pressure, mm/Hg
Laboratory measures
Index eGFR, ml/min/1.73m2
K+ , mEq/L
Number of K+ measurements
Bicarbonate, mEq/L
At least 1 dyskalemia event
K+ >5.5 mEq/L
K+ <3.5 mEq/L
Both K+ <3.5 and K+ >5.5 mEq/L
Index eGFR year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014

All
(N=21,366)

K+ <3.5 mEq/L
(N=401)

K+ 3.5-5.5 mEq/L
(N=20,295)

K+ >5.5 mEq/L
(N=670)

P-value

68.6 (10.4)
20,969 (98.1)

65.6 (10.2)
394 (98.3)

68.6 (10.4)
19,917 (98.1)

70.7 (10.2)
658 (98.2)

<0.0001a
0.98b

14,726 (68.9)
6,041 (28.3)
599 (2.8)
12,329 (57.7)

189 (47.1)
203 (50.6)
9 (2.2)
216 (54.1)

14,007 (69.0)
5,721 (28.2)
567 (2.2)
11,689 (57.6)

530 (79.1)
117 (17.5)
23 (3.4)
424 (63.3)

<0.0001b

3,153 (14.7)
4,782 (22.4)
9,655 (45.2)
3,457 (16.2)
305 (1.4)
18,012
(6,492-34,532)

36 (8.9)
87 (21.7)
228 (56.9)
46 (11.5)
267 (1.3)
17,796
(4,524-34,992)

3,004 (14.8)
4,568 (22.5)
9,113 (44.9)
3,329 (16.4)
4 (1.0)
18,020
(6,648-34,598)

113 (16.9)
127 (1.9)
314 (46.9)
82 (12.2)
34 (5.1)
18,042
(1,788-33,876)

<0.0001b

6,930 (32.5)
7,529 (35.3)
6,893 (32.3)

121 (30.2)
134 (33.4)
146 (36.4)

6,613 (32.6)
7,152 (35.3)
6,516 (32.1)

196 (29.3)
243 (36.3)
231 (34.5)

0.15b

14,715 (68.9)
7,351 (34.4)
20,668 (96.7)
6,432 (30.1)
5,298 (24.8)
6,207 (29.1)
977 (4.6)
10,477 (49.0)
492 (2.3)
9,990 (46.8)
2,381 (11.1)
1,530 (7.2)
4,180 (19.6)
4 (2-5)

283 (70.6)
152 (37.9)
390 (97.3)
93 (23.2)
85 (21.2)
104 (25.9)
14 (3.5)
189 (47.1)
7 (1.8)
164 (40.9)
54 (13.5)
31 (7.7)
71 (17.7)
3 (2-5)

13,967 (68.8)
6,983 (34.4)
19,639 (96.8)
6,116 (30.1)
5,037 (24.8)
5,915 (29.2)
924 (4.6)
9,940 (48.9)
474 (2.3)
9,476 (46.7)
2,250 (11.1)
1,461 (7.2)
3,986 (19.6)
4 (2-5)

465 (69.4)
216 (32.2)
639 (95.4)
223 (33.3)
176 (26.3)
188 (28.1)
39 (5.8)
348 (51.9)
11 (1.6)
350 (52.2)
77 (11.5)
38 (5.7)
123 (18.4)
4 (2-6)

0.72b
0.17b
0.11b
0.002b
0.17b
0.32b
0.18b
0.24b
0.38b
0.001b
0.31b
0.29b
0.45b
0.23b

16 (9-28)
0 (0-1)
0 (0-1)
0 (0-1)

17 (10-28)
0 (0-1)
0 (0-1)
0 (0-1)

17 (9-28)
0 (0-1)
0 (0-1)
0 (0-1)

12 (7-20)
0 (0-1)
0 (0-0)
0 (0-0)

<0.0001c
<0.0001c
0.008c
<0.0001c

15,923 (74.5)
11,996 (56.2)
1,958 (9.2)
6,982 (32.7)
1,662 (7.8)
7,209 (33.7)
1,007 (4.7)
14,681 (68.7)
14,126 (66.1)
8,703 (40.7)
7,525 (35.2)
226 (1.1)
388 (1.8)
2,296 (10.8)
3,224 (15.1)
5,848 (27.4)

292 (72.8)
253 (63.1)
76 (18.9)
228 (56.9)
2 (0.5)
137 (34.2)
22 (5.5)
303 (75.6)
307 (76.6)
177 (44.1)
153 (38.2)
4 (1.0)
9 (2.2)
34 (8.5)
57 (14.2)
101 (25.2)

15,143 (74.6)
11,437 (56.4)
1,843 (9.1)
6,560 (32.3)
1,474 (7.3)
6,912 (34.1)
961 (4.7)
13,960 (68.8)
13,450 (66.3)
8,296 (40.9)
7,120 (35.1)
214 (1.1)
364 (1.8)
2,217 (10.9)
3,094 (15.3)
5,641 (27.8)

488 (72.8)
306 (45.7)
39 (5.8)
194 (28.9)
186 (27.8)
160 (23.9)
24 (3.6)
418 (62.4)
369 (55.1)
230 (34.3)
252 (37.6)
8 (1.2)
15 (2.2)
45 (6.7)
73 (10.9)
106 (15.8)

0.43b
<0.0001b
<0.0001b
<0.0001b
<0.0001b
<0.0001b
0.29b
<0.0001b
<0.0001b
0.001b
0.19b
0.93b
0.57b
0.0008b
0.007b
<0.0001b

29.9 (6.1)
143.6 (16.3)
74.9 (10.8)

31.4 (6.3)
147.7 (18.8)
80.1 (13.2)

29.9 (6.1)
143.5 (16.2)
74.9 (10.8)

29.0 (5.8)
143.8 (17.6)
72.9 (11.0)

<0.0001a
<0.0001a
<0.0001a

24.8 (20.9-27.6)
4.5 (0.5)
3 (2-6)
24.9 (3.2)

24.9 (20.9-27.6)
3.3 (0.2)
3 (2-6)
27.9 (3.9)

24.0 (20.2-27.4)
4.5 (0.5)
3 (2-7)
24.9 (3.2)

23.3 (19.1-27.3)
5.8 (0.2)
2 (1-4)
22.8 (3.1)

<0.0001c
<0.0001a
<0.0001c
<0.0001a

3,696 (17.3)
2,417 (11.3)
362 (1.7)

2 (0.5)
401 (100)
2 (0.5)

3,024 (14.9)
2,016 (9.9)
360 (1.8)

670 (100)
0
0

<0.0001b
<0.0001b
<0.0001b
<0.0001b

3,459 (16.2)
3,322 (15.6)
3,193 (14.9)
2,758 (12.9)
2,474 (11.6)
2,307 (10.8)
1,853 (8.7)
1,312 (6.1)
657 (3.1)
31 (0.2)

41 (10.2)
53 (13.2)
64 (15.9)
59 (14.7)
56 (13.9)
37 (9.2)
44 (10.9)
25 (6.2)
22 (5.5)
0

3,289 (16.2)
3,143 (15.5)
3,023 (14.9)
2,607 (12.8)
2,349 (11.6)
2,204 (10.9)
1,765 (8.7)
1,265 (6.2)
619 (3.0)
31 (0.2)

129 (19.3)
126 (18.8)
106 (15.8)
92 (13.7)
69 (10.3)
66 (9.8)
44 (6.6)
22 (3.3)
16 (2.4)
0

0.009b

0.60c

Data are presented as n (%), mean (standard deviation), median (25-75th percentile). eGFR: estimated glomerular
filtration rate; K+ : potassium; NSAIDs: nonsteroidal anti-inflammatory drug; RAAS: renin-angiotensin-aldosterone
system; SPS: sodium polystyrene sulphonate. a p-value for one-way analysis of variance; b p-value for chi-square test;
c p-value for Kruskal-Wallis test.
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Figure 4.3: Association of time-updated outpatient potassium
with hospital visits (n=21,366). Models 1-6 conducted as specified in
section 4.2.6. CI: confidence interval; oK+ : outpatient potassium.

4.3.3

Association of dyskalemias with hospital visits

Over the one-year follow-up, a total of 8,635 (40%) patients experienced a hospital visit with
a total (median [25-75th percentile]) of 18,374 (2 [1-3]) hospital visits. Across the 125,266 oK+
measurements in the one-year follow-up period, a total of 8,542 (6.8%; proportion, 95% CI:
0.068, 0.067-0.069) hospital visits were observed within 2 calendar days of the measured
oK+ . In the unadjusted analysis, both hyperkalemia (odds ratio [OR], 95% CI: 2.08, 1.92-2.24)
and hypokalemia (OR, 95% CI: 2.09, 1.89-2.32) were associated with significantly higher
odds of a hospital visit (Figure 4.3 [Model 1]).
In the multivariable-adjusted model, though the point estimates were slightly attenuated, both hyperkalemia (OR, 95% CI: 2.04, 1.88-2.21) and hypokalemia (OR, 95% CI:
1.66, 1.48-1.86) were associated with significantly higher odds of a hospital visit (Figure 4.3
[Model 6]). In the multivariable-adjusted model, the association of granular oK+ value
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Table 4.2: Association of granular outpatient potassium categories with
hospital visits (n=21,366).
Outpatient K+ levels
Model
N (%) of repeated
oK+ measurements
N (%) hospital visits
within 2 calendar days
following oK+
1
2
3
4
5
6

<3.5 mEq/L

3.5-<4.0 mEq/L

4.0-<4.5 mEq/L
(reference)

4.5-<5.0 mEq/L

5.0-<5.5 mEq/L

5.5-<6.0 mEq/L

≥6.0 mEq/L

4,612 (3.7)

16,293 (13.0)

34,019 (27.2)

37,182 (29.7)

22,286 (17.8)

8,087 (6.5)

2,787 (2.2)

562 (12.2)

1,322 (8.1)

2,174 (6.4)

2,110 (5.7)

1,199 (5.4)

596 (7.4)

579 (20.8)

2.03 (1.83-2.26)
1.91 (1.72-2.13)
1.78 (1.59-1.99)
1.81 (1.62-2.02)
1.73 (1.54-1.94)
1.71 (1.51-1.92)

1.29 (1.20-1.39)
1.28 (1.18-1.36)
1.22 (1.13-1.32)
1.23 (1.15-1.33)
1.20 (1.11-1.30)
1.18 (1.09-1.28)

1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]

0.88 (0.87-0.94)
0.89 (0.84-0.95)
0.93 (0.87-0.99)
0.93 (0.87-0.99)
0.94 (0.88-1.01)
0.94 (0.88-1.00)

0.83 (0.77-0.89)
0.84 (0.79-0.91)
0.89 (0.82-0.96)
0.88 (0.81-0.95)
0.90 (0.83-0.98)
0.89 (0.82-0.97)

1.16 (1.05-1.29)
1.17 (1.05-1.29)
1.22 (1.10-1.35)
1.21 (1.09-1.34)
1.24 (1.11-1.38)
1.19 (1.07-1.33)

3.84 (3.44-4.28)
3.77 (3.38-4.21)
3.91 (3.49-4.37)
3.87 (3.46-4.33)
3.91 (3.48-4.39)
3.56 (3.15-4.02)

Data reported as odds ratio (95% confidence interval). Models 1-6 conducted as described in section 4.2.6. oK+ : outpatient potassium; N: number.

categories showed a U-shaped association with hospital visits, with significantly higher
odds of a hospital visit (vs oK+ 4.0-<4.5 mEq/L) associated with oK+ <3.5 mEq/L (OR, 95%
CI: 1.71, 1.51-1.92) and oK+ ≥6.0 mEq/L (OR, 95% CI: 3.56, 3.15-4.02) (Table 4.2 [Model 6]).
The association of dyskalemias with hospital visits was similar using multiple imputation
and complete case analyses (Table 4.3A, B, respectively).
Amongst the 8,542 hospital visits, 36% were due to “diseases of the circulatory
system” (of which 5.6% [172 of 3,078] were due to “arrhythmias”), 15.2% were due to
“diseases of the genitourinary system”, and 12.2% were due to “endocrine, nutritional, and
metabolic diseases, and immunity disorders” (of which 34.3% [356 of 1,039] were due to
“fluid and electrolyte disorders”) (Table 4.4).
In the multivariable-adjusted model, both hyperkalemia (OR, 95% CI: 1.39, 1.201.63) and hypokalemia (OR, 95% CI: 1.52, 1.28-1.79) were associated with higher odds of
a hospital visit due to “diseases of the circulatory system”, but showed a nonsignificant
higher odds of hospital visit due to “arrhythmias” (Table 4.5A, B [Model 6] respectively).
Similarly, in the multivariable-adjusted model both hyperkalemia (OR, 95% CI: 4.47,
3.82-5.23) and hypokalemia (OR, 95% CI: 2.43, 1.83-3.21) were associated with higher odds
of a hospital visit due to “endocrine, nutritional, and metabolic diseases and immunity
disorders” (Table 4.6A [Model 6]).
Especially, hyperkalemia (OR, 95% CI: 11.86, 9.30-15.11) and hypokalemia (OR,
95% CI: 4.44, 2.77-7.14) were associated with higher odds of hospital visit due to “fluid
and electrolyte disorders” (Table 4.6B [Model 6]). In the subgroup analysis, significant
differences were found by the loop diuretic users’ subgroup, with those using loop diuretics
having lower odds of a hospital visit following a hypokalemia event (vs hypokalemia in
non-users) (Figure 4.4).
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Table 4.3: Association of time-updated outpatient potassium with
hospital visits using multiple imputation and complete case analyses.
Hypokalemia
(oK+ <3.5 mEq/L)

Model

Referent
(oK+ 3.5-5.5 mEq/L)

Hyperkalemia
(oK+ >5.5 mEq/L)

(A) Multiple imputation (n=21,366)
N (%) of repeated
oK+ measurements
N (%) hospital visits
within 2 calendar days
following oK+
1
2
3
4
5
6
N (%) of repeated
oK+ measurements
N (%) hospital visits
within 2 calendar days
following oK+
1
2
3
4
5
6

4,612 (3.7)

112,196 (89.6)

8,458 (6.8)

562 (12.2)

6,959 (6.2)

1,021 (12.1)

2.09 (1.89-2.32)
1 [Reference]
1.96 (1.77-2.17)
1 [Reference]
1.78 (1.60-1.98)
1 [Reference]
1.80 (1.62-2.01)
1 [Reference]
1.66 (1.49-1.86)
1 [Reference]
1.66 (1.48-1.86)
1 [Reference]
(B) Complete case (n=11,239)

2.08 (1.92-2.24)
2.06 (1.91-2.22)
2.11 (1.95-2.28)
2.09 (1.94-2.26)
2.15 (1.98-2.33)
2.04 (1.88-2.21)

2,524 (3.9)

59,022 (90.3)

3,821 (5.8)

322 (12.8)

3,902 (6.6)

509 (13.3)

2.06 (1.81-2.36)
1.95 (1.71-2.22)
1.75 (1.52-2.02)
1.77 (1.53-2.04)
1.69 (1.46-1.96)
1.68 (1.44-1.96)

1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]

2.17 (1.95-2.42)
2.15 (1.93-2.40)
2.20 (1.97-2.46)
2.17 (1.94-2.43)
2.16 (1.93-2.42)
1.99 (1.76-2.24)

Data reported as odds ratio (95% confidence interval). Models 1-6 conducted as
described in section 4.2.6. oK+ : outpatient potassium; N: number.

Table 4.4: Types of hospital visits as ascertained by The Agency for
Healthcare Research and Quality Clinical Classifications Software
(n=21,366).
Type of hospital visitsa
All hospital visits due to any reason
Diseases of the circulatory system
Arrhythmias
Endocrine, nutritional, and metabolic
diseases and immunity disorders
Fluid and electrocyte disorders
Diseases of the genitourinary system
a

N (%)
8,542 (100)
3,078 (36.0)
172 (5.6)
1,039 (12.2)
356 (34.3)
1,300 (15.2)

Hospital visits assessed within 2 calendar days of
outpatient K+ (n=125,266) observed over one-year
follow-up. N: number.
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Table 4.5: Association of time-updated outpatient potassium with
hospital visits due to diseases of the circulatory system and arrhythmias
(n=21,366).
Model

Hypokalemia
(oK+ <3.5 mEq/L)

(oK+

Referent
3.5-5.5 mEq/L)

Hyperkalemia
(oK+ >5.5 mEq/L)

(A) Diseases of the circulatory system
N (%) of repeated
oK+ measurements
N (%) hospital visits
within 2 calendar days
following oK+
1
2
3
4
5
6
N (%) of repeated
oK+ measurements
N (%) hospital visits
within 2 calendar days
following oK+
1
2
3
4
5
6

4,612 (3.7)

112,196 (89.6)

8,458 (6.8)

216 (4.7)

2,633 (2.4)

229 (2.7)

2.13 (1.83-2.48)
1 [Reference]
1.98 (1.69-2.30)
1 [Reference]
1.69 (1.44-1.98)
1 [Reference]
1.67 (1.42-1.96)
1 [Reference]
1.52 (1.28-1.79)
1 [Reference]
1.52 (1.28-1.79)
1 [Reference]
(B) Arrhythmias

1.23 (1.07-1.42)
1.23 (1.07-1.42)
1.29 (1.12-1.49)
1.30 (1.13-1.50)
1.39 (1.20-1.62)
1.39 (1.20-1.63)

4,612 (3.7)

112,196 (89.6)

8,458 (6.8)

7 (0.2)

147 (0.1)

18 (0.2)

1.24 (0.58-2.65)
1.29 (0.60-2.79)
1.12 (0.51-2.44)
1.18 (0.54-2.59)
1.16 (0.52-2.59)
1.15 (0.52-2.52)

1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]

1.73 (1.06-2.82)
1.78 (1.09-2.88)
1.89 (1.16-3.07)
1.77 (1.08-2.91)
1.77 (1.06-2.96)
1.57 (0.93-2.66)

Data reported as odds ratio (95% confidence interval). Models 1-6 conducted as
described in section 4.2.6. oK+ : outpatient potassium; N: number.
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Table 4.6: Association of time-updated outpatient potassium with
hospital visits due to (A) endocrine, nutritional, and metabolic diseases
and immunity disorders and (B) fluid and electrolyte disorders
(n=21,366).
Model

Hypokalemia
(oK+ <3.5 mEq/L)

Referent
(oK+ 3.5-5.5 mEq/L)

Hyperkalemia
(oK+ >5.5 mEq/L)

(A) Endocrine, nutritional, and metabolic diseases and immunity disorders
N (%) of repeated
4,612 (3.7)
112,196 (89.6)
8,458 (6.8)
oK+ measurements
N (%) hospital visits
within 2 calendar days
72 (1.6)
694 (0.6)
273 (3.2))
+
following oK
1
2.69 (2.10-3.45)
1[Reference]
5.57 (4.80-6.45)
2
2.45 (1.90-3.14)
1[Reference]
5.43 (4.68-6.30)
3
2.41 (1.88-3.09)
1[Reference]
5.23 (4.49-6.09)
4
2.46 (1.91-3.17)
1[Reference]
5.19 (4.46-6.06)
5
2.39 (1.82-3.17)
1[Reference]
5.04 (4.30-5.89)
6
2.43 (1.83-3.21)
1[Reference]
4.47 (3.82-5.23)
(B) Fluid and electrolyte disorders
N (%) of repeated
4,612 (3.7)
112,196 (89.6)
8,458 (6.8)
oK+ measurements
N (%) hospital visits
within 2 calendar days
26 (0.6)
151 (0.1)
179 (2.1)
+
following oK
1
4.47 (2.91-6.87)
1[Reference]
16.77 (13.42-20.97)
2
4.13 (2.68-6.36)
1[Reference]
16.79 (13.40-21.02)
3
4.02 (2.62-6.19)
1[Reference]
16.64 (13.24-20.91)
4
4.05 (2.61-6.29)
1[Reference]
16.36 (13.00-20.58)
5
4.29 (2.68-6.86)
1[Reference]
15.81 (12.42-20.12)
6
4.44 (2.77-7.14)
1[Reference]
11.86 (9.30-15.11)
Data reported as odds ratio (95% confidence interval). Models 1-6 conducted as
described in section 4.2.6. oK+ : outpatient potassium; N: number.

Chapter 4. Association of Dyskalemias with Short-term Hospital/Emergency Room
Utilization in Advanced Chronic Kidney Disease Patients Transitioning to Dialysis

Figure 4.4: Association of time-updated outpatient potassium with
hospital visits by subgroups (n=21,366). Model adjusted for confounders
accounted in model 6 as described in section 4.2.6. CI: confidence interval;
oK+ : outpatient potassium.
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Figure 4.5: Association of time-updated outpatient potassium with
emergency room visits (n=21,366). Models 1-6 conducted as specified in
section 4.2.6. CI: confidence interval; oK+ : outpatient potassium.

4.3.4

Association of dyskalemias with ER visits

Over the one-year follow-up, a total of 7,135 (33.4%) patients experienced an ER visit with
a total (median [25-75th percentile]) of 14,368 (1 [1-2]) ER visits. Across the 125,266 oK+
measurements in the one-year follow-up, a total of 5,114 (4.1%; proportion, 95% CI: 0.041,
0.039-0.042) ER visits were observed within 2 calendar days of the measured oK+ . In the
unadjusted analysis, both hyperkalemia (OR; 95% CI: 1.72; 1.56-1.89) and hypokalemia
(OR, 95% CI: 1.52, 1.33-1.75) were associated with significantly higher odds of an ER visit
(Figure 4.5 [Model 1]). Similarly, in the multivariable-adjusted model, both hyperkalemia
(OR, 95% CI: 1.83, 1.65-2.03) and hypokalemia (OR, 95% CI: 1.24, 1.07-1.44) were associated
with significantly higher odds of an ER visit (Figure 4.5 [Model 6]).
In the multivariable-adjusted model, the association of granular oK+ value categories
showed a U-shaped association with ER visits, with significantly higher odds of an ER visit
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Table 4.7: Association of granular outpatient potassium categories with
emergency room visits (n=21,366).
Outpatient K+ levels
Model
N (%) of repeated
oK+ measurements
N (%) ER visits
within 2 calendar days
following oK+
1
2
3
4
5
6

<3.5 mEq/L

3.5-<4.0 mEq/L

4.0-<4.5 mEq/L
(reference)

4.5-<5.0 mEq/L

5.0-<5.5 mEq/L

5.5-<6.0 mEq/L

≥6.0 mEq/L

4,612 (3.7)

16,293 (13.0)

34,019 (27.2)

37,182 (29.7)

22,286 (17.8)

8,087 (6.5)

2,787 (2.2)

264 (3.4)

802 (4.9)

1,473 (4.3)

1,272 (3.4)

685 (3.1)

288 (3.6)

330 (11.8)

1.34 (1.16-1.55)
1.24 (1.08-1.44)
1.15 (0.98-1.35)
1.15 (0.99-1.35)
1.20 (1.03-1.39)
1.20 (1.03-1.40)

1.14 (1.05-1.25)
1.11 (1.02-1.22)
1.07 (0.98-1.17)
1.07 (0.98-1.18)
1.08 (0.98-1.19)
1.08 (0.98-1.18)

1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]

0.78 (0.72-0.85)
0.79 (0.73-0.86)
0.83 (0.76-0.89)
0.83 (0.76-0.89)
0.82 (0.76-0.89)
0.83 (0.76-0.90)

0.70 (0.63-0.77)
0.71 (0.65-0.79)
0.75 (0.68-0.83)
0.75 (0.68-0.83)
0.75 (0.68-0.83)
0.76 (0.69-0.84)

0.82 (0.71-0.94)
0.82 (0.71-0.94)
0.87 (0.76-1.00)
0.87 (0.76-0.99)
0.87 (0.76-1.01)
0.88 (0.77-1.02)

2.96 (2.59-3.39)
2.89 (2.53-3.32)
3.02 (2.62-3.47)
3.02 (2.62-3.48)
3.01 (2.59-3.49)
3.04 (2.61-3.54)

Data reported as odds ratio (95% confidence interval). Models 1-6 conducted as described in section 4.2.6. ER: emergency room; oK+ : outpatient
potassium; N: number.

(vs oK+ 4.0-<4.5 mEq/L) associated with oK+ <3.5 mEq/L (OR, 95% CI: 1.20, 1.03-1.40) and
oK+ ≥6.0 mEq/L (OR, 95% CI: 3.04, 2.61-3.54) (Table 4.7 [Model 6]).
The association of dyskalemias with ER visits was similar using multiple imputation
and complete case analyses (Table 4.8 [Model 6]).
In the subgroup analysis, significant differences were observed by region of residence
(South vs other US regions) (Figure 4.6). The odds of an ER visit following a hypokalemia
event was significantly higher amongst those residing in the US South.

4.4

Discussion

In a nationally representative cohort of US Veterans with advanced CKD who transitioned
to dialysis, dyskalemias were associated with higher risk of short-term hospital and ER
visits in the pre-dialysis period. Overall, the risk for short-term hospital/ER visits was
higher following a hyperkalemia event as compared to a hypokalemia event. Additionally,
the risk for a hospital visit was higher as compared to ER visit, with higher risk associated
with hyperkalemia than hypokalemia. When oK+ levels were categorized into granular categories, the risk for short-term visits was the highest at the extreme oK+ levels. Dyskalemias
were associated with higher risk of hospital visits due to “diseases of the circulatory system”
and “endocrine, nutritional, and metabolic diseases and immunity disorders”, especially
the latter. Further, for hospital visits due to “arrhythmias” there was a nonsignificant higher
risk associated with dyskalemias. Also, hypo- and hyperkalemia were associated with a 4.4and 11.9-fold higher risk for hospital visits due to “fluid and electrolyte disorders” (which
includes hypo- and hyperkalemia), respectively. However, caution should be exercised
when interpreting the association of dyskalemias with hospital visits subtypes due to the
low event rates and wide CI.
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Table 4.8: Association of time-updated outpatient potassium with
emergency room visits using multiple imputation and complete case
analyses.
Model

Hypokalemia
(oK+ <3.5 mEq/L)

Referent
(oK+ 3.5-5.5 mEq/L)

Hyperkalemia
(oK+ >5.5 mEq/L)

(A) Multiple imputation (n=21,366)
N (%) of repeated
oK+ measurements
N (%) ER visits
within 2 calendar days
following oK+
1
2
3
4
5
6
N (%) of repeated
oK+ measurements
N (%) ER visits
within 2 calendar days
following oK+
1
2
3
4
5
6

4,612 (3.7)

112,196 (89.6)

8,458 (6.8)

264 (5.7)

4,232 (3.8)

618 (7.3)

2.09 (1.89-2.32)
1 [Reference]
1.96 (1.77-2.17)
1 [Reference]
1.78 (1.60-1.98)
1 [Reference]
1.80 (1.62-2.01)
1 [Reference]
1.66 (1.49-1.86)
1 [Reference]
1.66 (1.48-1.86)
1 [Reference]
(B) Complete case (n=11,239)

2.08 (1.92-2.24)
2.06 (1.91-2.22)
2.11 (1.95-2.28)
2.09 (1.94-2.26)
2.15 (1.98-2.33)
2.04 (1.88-2.21)

2,524 (3.9)

59,022 (90.3)

3,821 (5.8)

172 (6.8)

2,769 (4.7)

321 (8.4)

2.06 (1.81-2.36)
1.95 (1.71-2.22)
1.75 (1.52-2.02)
1.77 (1.53-2.04)
1.69 (1.46-1.96)
1.68 (1.44-1.96)

1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]
1 [Reference]

2.17 (1.95-2.42)
2.15 (1.93-2.40)
2.20 (1.97-2.46)
2.17 (1.94-2.43)
2.16 (1.93-2.42)
1.99 (1.76-2.24)

Data reported as odds ratio (95% confidence interval). Models 1-6 conducted as
described in section 4.2.6. ER: emergency room; oK+ : outpatient potassium; N:
number
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Figure 4.6: Association of time-updated outpatient potassium with
emergency room visits by subgroups (n=21,366). Model adjusted for
confounders accounted in model 6 as described in section 4.2.6. CI:
confidence interval; oK+ : outpatient potassium.
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Our results align with existing literature that has assessed the association of dyskalemias (baseline and time-updated exposure) with healthcare utilization (as a distant/shortterm outcome) (Brunelli et al., 2017; Fitch et al., 2017; Kim et al., 2019; Luo et al., 2016;
Polson et al., 2017; Sharma, Alvarez, Woods, Fogli, et al., 2021). Amongst those with eGFR
<30 ml/min/1.73m2 (Luo et al., 2016), time-updated oK+ levels 5.5-5.9 mEq/L, ≥6.0 mEq/L,
and <3.5 mEq/L (vs oK+ 4.5-4.9 mEq/L) were associated with a 1.3-,3.7-, and 1.9-fold
higher risk of a hospital visit, respectively. In a hemodialysis cohort (Brunelli et al., 2017), a
higher risk of hospital and ER visits with increasing levels of oK+ (vs oK+ 4.0-<4.5 mEq/L)
was observed, with a higher risk associated with a hospital visit compared to an ER visit.
Further, similar to results in the hemodialysis cohort (mentioned above), we observed that
hospital visits due to “diseases of the circulatory system” visits were the most common (36%
in our study vs 28.7% in their study) and the number of hospital visits due to “endocrine,
nutritional, and metabolic diseases and immunity disorders” were also similar ( 12% in
our study vs 9% in their study). Finally, similar to their study, we observed a higher risk
associated with higher oK+ levels for hospital visits due to “diseases of the circulatory
system” and “endocrine, nutritional, and metabolic diseases and immunity disorders”,
especially for the latter. Potassium plays an important role in cardiac repolarization, thus,
dyskalemias would induce arrhythmias leading to a higher risk of hospital visits due to
“diseases of the circulatory system” (Kovesdy, Appel, et al., 2017; Weiss, Qu, and Shivkumar,
2017). Similarly, dyskalemias will lead to higher risk of hospital visits due to “endocrine, nutritional, and metabolic diseases and immunity disorders” as both hypo- and hyperkalemia
are a subtype of this visit type and would be recorded as primary reason of hospital visit.
The risk of dyskalemias increases as kidney function worsens and further dyskalemias
are associated with higher risk of cardiovascular events and mortality (Clase et al., 2020;
Collins et al., 2017; Gilligan and Raphael, 2017; Luo et al., 2016; Korgaonkar et al., 2010;
Kovesdy, Appel, et al., 2017; Kovesdy, Matsushita, et al., 2018; Nakhoul et al., 2015). Thus,
patients are at a higher risk of hospital/ER visits due to dyskalemia-induced events such as
arrhythmias, or are simply referred to an ER or hospitalized after detection of a dyskalemia
event for fear of a potential cardiovascular event. In this context, our study has several
clinical implications. Studies in CKD/ESRD population have shown that those experiencing
hyperkalemia incur higher hospital/ER visit costs as compared to those not experiencing
hyperkalemia (Betts et al., 2018; Brunelli et al., 2017; Fitch et al., 2017; Kim et al., 2019; Polson
et al., 2017; Sharma, Alvarez, Woods, Fogli, et al., 2021). Studies quantifying healthcare costs
associated with hypokalemia are currently lacking, but it can be assumed that hypokalemia
represents a substantial economic burden.
We can hypothesize that correcting and especially preventing dyskalemias could
improve clinical outcomes and reduce hospital/ER visits and associated costs. A study
by Toto et al. (RD et al., 2019) amongst patients experiencing hyperkalemia, found that
risk of hospital visits was lower (vs no medication use) with the use of SPS and patiromer
(especially the latter) and the risk of ER visits was lower with patiromer use. This finding further emphasizes that correcting/preventing hyperkalemia (and potentially even
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hypokalemia) can indeed reduce healthcare burden and associated costs. While the management of hypokalemia is straightforward (K+ supplementation, diuretic dose reduction,
changing anti-hypertensive from diuretics to RAAS inhibitors or K+ sparing diuretics),
the management of hyperkalemia is more complex (including acute interventions such as
administration of insulin, glucose, β2 agonists, and intravenous HCO3 - , or chronic interventions such as the use of K+ binding agents or discontinuation of RAAS inhibitors) (Kovesdy,
Appel, et al., 2017; Palmer and Clegg, 2019). The advent of newer K+ binding agents such
as patiromer calcium and sodium zirconium cyclosilicate for chronic hyperkalemia, might
help reduce the incidence of hyperkalemia with progressive decline in kidney function and
could allow uninterrupted use of cardio- and renoprotective agents such as RAAS inhibitors
(Kidney Disease Outcomes Quality, 2004), ultimately leading to improved clinical outcomes
and reduced healthcare burden. The prevalence (Dashputre, Sumida, Potukuchi, et al., 2021;
Gilligan and Raphael, 2017) of hypokalemia is comparatively lower than hyperkalemia
and the treatment is less complex; however, the healthcare burden and costs need to be
considered when managing patients experiencing hypokalemia.
Our study results need to be interpreted in light of several limitations. First, we
used observational data, hence, we cannot infer causality but only associations. Second,
the cohort consisted of predominantly male US Veterans (98%), and thus the results may
not be generalizable to women or broader general population. Third, all patients survive
until dialysis initiation due to the nature of the cohort and we studied exposure-outcome
relationship in the pre-dialysis period. However, our results align with previous literature,
thus validating the generalizability of our results. Finally, due to the nature of the study, we
cannot eliminate the possibility of unmeasured confounders such as a lack of data about
dietary K+ intake and other nutritional markers.

4.5

Conclusion

In conclusion, in patients with advanced CKD transitioning to dialysis, dyskalemias are
associated with a higher risk of hospital and ER visits in the pre-dialysis period. Close
monitoring of K+ levels and the advent of newer K+ binding agents (in the context of
hyperkalemia) might help in reducing healthcare utilization and eventual economic burden.
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Chapter 5
Conclusion

5.1

Summary of Findings

In this current study using retrospective longitudinal data of US veterans with advanced
CKD (stages 4 and 5, not yet on dialysis) who had K+ measurements prior to dialysis
initiation, we studied the following research aims in the pre-dialysis period:
• Development and validation of a risk score for predicting hyperkalemia (Chapter 2)
• Association of dyskalemias (chronic and acute exposure) with time to first ischemic
stroke (Chapter 3)
• Association of dyskalemias with short-term hospital/ER visits (Chapter 4)
In Chapter 2, we compared the performance (AUROC) of different ML methods (LR,
RF, XGBoost, and SVM) for predicting the outcome of hyperkalemia and observed that LR
method performed the best. Further, using LR as our primary method, we developed and
validated a patient-level risk score to predict the risk of hyperkalemia amongst advanced
CKD patients using the top 10 predictors identified by the LR method.
In Chapter 3, we assessed the association of dyskalemias with time to first ischemic
stroke event. We treated dyskalemia as a chronic exposure using baseline time-averaged
levels of K+ as well as an acute exposure using time-updated levels of K+ . Hypokalemia
as a chronic exposure was associated with a higher risk of ischemic stroke. Conversely,
hyperkalemia as an acute exposure was associated with a lower risk of ischemic stroke.
Finally, in Chapter 4, we assessed the association of dyskalemias with short-term
(within 2 calendar days of measured oK+ ) hospital/ER visits as separate outcome events.
Both hyperkalemia and hypokalemia were associated with a higher risk of short-term
hospital and ER visits. Hyperkalemia had a higher risk for hospital/ER visits compared
to hypokalemia. Further, dyskalemias were associated with a higher risk of hospital visits
than ER visits. Finally, dyskalemias were associated with a high risk of hospital visits due
to “diseases of the circulatory system” and “endocrine, nutritional, and metabolic diseases
and immunity disorders”.
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Implications for Practice, Policy, and Future Research

CKD is of public health concern in the US and is estimated to affect 15% of the adult
population, most of whom are unaware of their condition (Centers for Disease Control and
Prevention. Chronic Kidney Disease Initiative, 2021). Potassium levels are regulated by
the kidneys, thus predisposing patients with CKD to a higher risk of dyskalemia events
(especially hyperkalemia) (Kovesdy, Appel, et al., 2017; Palmer and Clegg, 2019). Further,
dyskalemias are associated with adverse outcomes including higher mortality, cardiovascular events, and healthcare burden (Collins et al., 2017; Fitch et al., 2017; Korgaonkar
et al., 2010; Kovesdy, Matsushita, et al., 2018; Luo et al., 2016). In our study, we assessed
outcomes in the pre-dialysis period amongst patients with advanced CKD transitioning
to dialysis, which represents a unique population with high comorbidity burden (e.g.,
hypertension and CVD) and in frequent need of pharmacotherapeutic interventions (e.g.,
RAAS inhibitors and diuretics) (Johansen et al., 2021). This patient population is at a higher
risk of experiencing dyskalemia events due to the declining kidney function and the overall
disease burden and hence at a higher risk of dyskalemia associated adverse outcomes. Thus,
the research aims undertaken as a part of this dissertation have important implications for
practice, policy, and future research.
We developed and validated a risk score to predict the risk of hyperkalemia. Our
hyperkalemia prediction risk score can be implemented in clinical practice for early identification of patients who are at higher risk of hyperkalemia based on their clinical profile.
Hyperkalemia has a substantial clinical and economic burden on the patient and the healthcare system. Patients with advanced CKD are at a higher risk of experiencing hyperkalemia
events due to multitude of factors discussed earlier. Hence, early prediction of hyperkalemia can help physicians to manage their patients better and identify patients at risk
for future risk of hyperkalemia. Risk prediction models using readily available clinical
information from EMR on a patient can help in early prediction of hyperkalemia. In our
study, we compared different ML techniques in prediction of hyperkalemia and using the
one that afforded the best prediction performance, we developed a prediction model to
predict hyperkalemia amongst patients with advanced CKD transitioning to dialysis. The
hyperkalemia risk prediction model will have good clinical applicability as it includes
patient clinical characteristics (e.g., K+ levels, history of hyperkalemia, age, SBP etc.) that
are easily available in EMR. With the increased use of ML/artificial intelligence and the
use of EMR in healthcare practices, implementing our hyperkalemia risk prediction model
can help physicians and healthcare practices in early identification of patients at risk for
hyperkalemia and making clinical decisions to lower the hyperkalemia risk. This might
help in reducing the overall burden on the patient and the healthcare system.
Hypokalemia as a chronic exposure was associated with higher risk of ischemic
stroke, whereas hyperkalemia as an acute exposure was associated with lower risk of ischemic stroke. These findings suggest the need to closely monitor K+ levels and dyskalemia
events as potential risk factors for stroke. Due to the observational nature of our study our
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results cannot yet be used in clinical practice, but provide useful information for future
studies testing the causality of the detected associations. The association of hypokalemia
with higher risk of ischemic stroke in our study was consistent with previous studies in
different populations (Green et al., 2002; Mattsson et al., 2018; Smith et al., 2003). Our
study findings confirm the higher risk of ischemic stroke associated with hypokalemia in
an advanced CKD population transitioning to dialysis. Physicians might need to closely
monitor K+ levels of patients, adjust their medications (e.g. switching from diuretics to
RAAS inhibitors) as necessary and, adjust dietary intake of K+ to reduce the risk of hypokalemia and eventually ischemic stroke. However, implementing such interventions will
need thorough evaluation of the overall patient profile as switching to RAAS inhibitors from
diuretics or increasing dietary intake of K+ might lead to increased risk of hyperkalemia
in patients with advanced CKD. Further, hyperkalemia (acute exposure) was associated
with lower risk of ischemic stroke. This is likely due to short-term vasodilatory effects of
higher K+ levels leading to reduction in BP and eventually lower risk of ischemic stroke.
Hyperkalemia is associated with higher risk of cardiovascular events like arrhythmia and
the inverse association observed with ischemic stroke needs to be interpreted with caution
in terms of implications for practice.
Both hypo- and hyper-kalemia were associated with higher risk of short-term hospital/ER visits, implying that dyskalemias can lead to burdensome healthcare events and
bear important implications for physicians and healthcare systems. Close monitoring of
K+ levels and maintaining the K+ levels in the normal range by managing/adjusting
dyskalemia-inducing medications (e.g., RAAS inhibitors and diuretics) for comorbidity
management and, adjust dietary intake of K+ to reduce the risk of dyskalemias can potentially reduce the risk of dyskalemia-associated hospital/ER visits. A natural next step
would be to design clinical trials aimed at preventing ER visits and hospitalizations through
treatment of hyperkalemia. In the context of hyperkalemia, the approval of novel therapies
like patiromer calcium and sodium zirconium cyclosilicate can help in management of
hyperkalemia without affecting co-administration of cardio-renoprotective medications like
RAAS inhibitors. Healthcare systems can design policies and practice guidelines focused
on managing dyskalemias amongst patients with CKD, which can focus on multiple interventions that can reduce the overall risk of experiencing a dyskalemia event and eventual
healthcare burden.
Our study findings have several implications for future research. Further studies
are needed to validate and confirm our results in a more representative population and
amongst those who have CKD but do not transition to dialysis. Further studies are required
to validate the hyperkalemia risk prediction model due to the limitations addressed above.
Though, we used various methods (geographical splitting, split-sample splitting, crossvalidation) to assess the performance of our risk prediction model, we did not have an
external dataset for external validation. Hence, it is important to validate our hyperkalemia
model in other populations. The inverse association of hyperkalemia with ischemic stroke
was novel and further studies are required to understand the mechanisms driving this
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association. Finally, in our study, we looked at the association of dyskalemias with shortterm hospital/ER visits. Further studies including short-term hospital/ER visits costs as
an outcome are required to further enhance and shed light upon not only the short-term
healthcare burden but also the economic burden associated with dyskalemias.

5.3

Overall Limitations

Two important limitations of our studies are generalizability to broader population due to a
majority male VA cohort and use of an advanced cohort transitioning to dialysis. As noted
earlier, the research aims for this study were assessed in the pre-dialysis period of a unique
cohort of patients with advanced CKD who transitioned to dialysis. Due to this unique
design, all deaths in the cohort occurred after the initiation of dialysis. Our overall study
findings/implications can be applied to the pre-dialysis period of patients with advanced
CKD transitioning to dialysis. Dyskalemias are associated with higher risk of short-term
mortality (Einhorn et al., 2009; Gilligan and Raphael, 2017). Thus, our findings may not
apply to CKD patients who do not transition to dialysis or die prior to dialysis initiation.
Further, based on the retrospective study design, we cannot infer causality between the
exposure-outcome relationship. Finally, we cannot eliminate the possibility of unmeasured
confounding due to lack of access to dietary intake of K+ .

5.4

Overall Conclusions

In summary, amongst US veterans with advanced CKD (stages 4 and 5 not yet on dialysis)
who transitioned to dialysis, in the pre-dialysis period:
• An internally valid risk score was developed to predict the risk of hyperkalemia
• Hypokalemia (chronic exposure) is associated with higher risk of ischemic stroke,
whereas hyperkalemia (acute exposure) is associated with lower risk of ischemic
stroke
• Dyskalemias are associated with higher risk of short-term hospital/ER visits
Findings from this study add to existing literature on the association of dyskalemias
with outcomes in CKD and further expand on outcomes associated with dyskalemias in
patients with advanced CKD transitioning to dialysis. Further studies in different CKD
populations are required to shed more light on the results observed in our study.
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